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abbreviations and symbols 
 
ABC    accelerated blood clearance 
ACUPA    S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-pentanedioic acid 
ADC    antibody-drug conjugate 
AF488    alexa fluor 488 
AIBN    2, 2′-azoisobutyronitrile 
APB    aspartic acid modified with 4-phenyl-butanol 
API    active pharmaceutical ingredient 
ARho    acryloxyethyl thiocarbamoyl rhodamine B 
Asp    aspartate 
ATRP    atom transfer radical polymerization 
BBB    blood brain barrier 
BSA    bovine serum albumin 
Bz    benzyl 
C    carbon 
CAC    critical aggregation concentration 
CRADA    cooperative research and development agreement 
cRGD    cyclic arginine-glycine-aspartate peptide 
CSA    camphor-10-sulfonic acid 
CTA    chain transfer agent 
Cy5-N3    cyanine5-azide 
Ð    dispersity 
Da    dalton 
DAD    diode array detector 
DAPI    4',6-diamidino-2-phenylindole 
DAR    drug-antibody-ratio 
abbreviations and symbols 
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DCM    dichloromethane 
DEGA    di(ethylene glycol) acetal 
DEGVE    di(ethylene glycol) vinyl ether 
DHP    3,4-dihydro-2H-pyran-2-methanol 
DIC (1)    differential interference contrast (1) 
DIC (2)    N,N′-diisopropylcarbodiimide (2) 
DLS    dynamic light scattering 
DMA    N,N-dimethylacrylamide 
DMAc    N,N-dimethylacetamide 
DMAP    4-(dimethylamino)pyridine 
DMDMA    2,2-dimethyl-1,3-dioxolane-4-yl)methyl acrylate 
DMEM    Dulbecco’s Modified Eagle Medium 
DMF    N,N-dimethylformamide 
DMSO    dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
DOX    doxorubicin 
DP    degree of polymerization 
DPA    2-(diisopropylamino)ethyl methacrylate 
DTX    docetaxel 
EE    encapsulation efficiency 
EGFR    epidermal growth factor receptor 
EPR    enhanced permeability and retention effect 
ESI    electron spray ionization 
EtOH    ethanol 
FA    folic acid 
FACS    flow cytometry 
FBS    fetal bovine serum 
FDA    Food and Drug Administration 
FR    folate receptor 
GC    gas chromatography 
abbreviations and symbols 
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GEM    genetically engineered mouse 
Glu    glutamate 
gp60    glycoprotein 60 
H2O    water 
HA    hyaluronic acid 
HEA    hydroxyethyl acrylate 
HMW    high molecular weight 
HPMA    N-(2-hydroxypropyl)methacrylamide 
HSA    human serum albumin 
HTS    high-throughput screening 
IC50    half maximal inhibitory concentration 
IFP    interstitial fluid pressure 
LA    lactic acid 
Lac    lactate 
LC (1)    liquid chromatography (1) 
LC (2)    loading capacity (2) 
LCST    lower critical solution temperature 
LMW    low molecular weight 
LRP1    low-density lipoprotein receptor-related protein 1 
mAb    monoclonal antibody 
MDR    multiple drug resistance 
MeOH    methanol 
MHA    6-maleimidohexanoic acid 
MIP    maximum intensity projection 
MMAE    monomethyl auristatin E 
MMP    matrix metalloproteinase 
Mn    number average molecular weight 
MPC    2-(methacryloyloxy)ethyl phosphorylcholine 
MPS    mononuclear phagocytic system 
MRM    multiple reaction monitoring 
abbreviations and symbols 
 
4 
MS    mass spectrometry 
MTD    maximum tolerated dose 
mTEGA    methoxy tri(ethylene glycol) acrylate 
MTT    thiazolyl blue tetrazolium bromide 
MW    molecular weight 
MWCO    molecular weight cut off 
N2    nitrogen gas 
NaCl    sodium chloride 
NCI    National Cancer Institute 
NIPAM    N-isopropyl acrylamide 
NMP    nitroxide-mediated polymerization 
NMR    nuclear magnetic resonance 
NSCLC    non-small cell lung cancer 
OEG(M)A   oligo(ethylene glycol) (meth)acrylate 
OH    hydroxyl 
P2O5    phosphorus pentoxide 
PABTC    2-(butylthiocarbonothioylthio)propanoic acid 
PBS    phosphate buffered saline 
Pd    palladium 
PDI    polydispersity 
PDT    photodynamic therapy 
PDX    patient-derived xenograft 
PEG    poly(ethylene glycol) 
PFP    pentafluorophenol 
PFS    progression free survival 
P-gp    P-glycoprotein 
PGS    poly(glycerol sebacate) 
PLA    poly(lactic acid) 
PLGA    poly(lactic-co-glycolic acid) 
PMMA    poly(methyl methacrylate) 
abbreviations and symbols 
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POx    poly(2-oxazoline) 
psi    pound-force per square inch 
PSMA    prostate specific membrane antigen 
PTX    paclitaxel 
PVA    poly(vinyl alcohol) 
QoL    quality of life 
R18    octadecyl rhodamine B chloride 
RAFT    reversible addition-fragmentation chain transfer 
RES    reticulo-endothelial system 
RGD    arginine-glycine-aspartate peptide 
Rho    rhodamine 
RID    refractive index detector 
ROP    ring-opening polymerization 
RP    reversed phase 
RPMI    Roswell Park Memorial Institute 
SEC    size exclusion chromatography 
SIP    small immune protein 
SMDC    small molecule-drug conjugate 
SPARC    secreted protein acidic and rich in cysteine 
SPPS    solid phase peptide synthesis 
TCEP    tris(2-carboxyethyl)phosphine 
TEA    triethylamine 
TFA    trifluoroacetic acid 
THP    tetrahydropyran 
TIC    total ion chromatogram 
TLC    thin layer chromatography 
TMP    trimethyl phosphite 
TOF    time-of-flight 
UPLC    ultra performance liquid chromatography 
UV-VIS    ultraviolet-visible spectroscopy 
abbreviations and symbols 
 
6 
VEGF(R)    vascular endothelial growth factor (receptor) 
XRD    X-ray diffraction 
Z-Ave    Z-Average hydrodynamic diameter 
 
 
7 
aims and outline 
of thesis 
 
aims of thesis 
Today toxic side-reactions of taxane chemotherapy still severely affect patient quality of life (QoL). 
Abraxane and Genexol-PM have been able to significantly lower or even exclude side-effects caused by the toxic 
surfactants such as Cremophor EL and polysorbate 80 used in Taxol and Taxotere, respectively. However, the 
manifested intrinsic systemic toxicity of taxanes (e.g. neutropenia and neuropathy) remains a major issue and 
shows that further exploration of alternative formulations is required for pursuing more efficient and safer taxane 
administration. Polymer-based drug formulations are attractive systems due to the chemical versatility and low-
cost of polymeric carrier material compared to biotechnological carriers such as solubilizing proteins (e.g. albumin) 
and monoclonal antibodies (mAbs). As physical entrapment and chemical conjugation have already shown great 
promise in the development of advanced polymeric drug formulations, the overall aim of this thesis was to design, 
synthesize and evaluate new taxane platforms based on these two formulation strategies. 
With respect to physical encapsulation, two types of polymeric carriers will be evaluated. As a first system 
we aimed to explore the potential of poly(glycerol sebacate) (PGS). This polymer has established biodegradable 
and biocompatible properties which can be an important asset for future regulatory approval. As this polymer is 
insoluble in water, the aim is to devise a formulation strategy based on solvent displacement. The second system, a 
block copolymer micelle system with stimuli-responsive behavior, was aimed for physical drug encapsulation. The 
goal was for the latter polymer to degrade and disassemble into fully water-soluble derivatives under acidic 
conditions as encountered in the tumor-microenvironment, endosomes and lysosomes. In this way, entrapped drug 
could be released in a more selective fashion and the corresponding polymer degradation products cleared more 
swiftly from the body (i.e. by renal excretion). The strategy for achieving this objective involved introduction of 
aims and outline of thesis 
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acid-sensitive ketal-moieties pending on the amphiphilic block copolymer backbone. Subsequently, an extensive in 
vitro analysis of both platforms should allow to assess whether or not the suggested systems have potential as 
hydrophobic drug delivery vehicles. 
Literature reports that, in the bloodstream, physically encapsulated drugs can diffuse out of the carrier 
vehicle. This could still induce systemic toxicity, irrespective of bioresponsive behavior and/or low critical 
aggregation concentration (CAC) of the carrier system. Though this cannot be generalized and should be evaluated 
for each system separately, this dissertation also wanted to provide an alternative taxane formulation platform 
which could allow for less susceptibility to systemic burst release. Chemical conjugation of drug to a polymer is a 
fitting rationale in this regard. Taxane-polymer conjugates currently in clinical trial are typically synthesized 
through post-modification of high molecular weight polymer with taxanes. However, the relatively high dispersity 
of these polymers (i.e. poly(glutamic acid), polyHPMA) does not allow for obtaining well-defined drug-polymer 
conjugates and might also put challenges in acquiring high drug loadings with minimal batch-to-batch variation. 
The latter however can be of crucial importance when aiming for regulatory approval and might be resolved when 
a polymer chain is grafted onto taxanes. The goal was to investigate whether this reversed approach is feasible 
with advanced polymerization techniques, to examine the chemical versatility of this approach and to evaluate the 
overall drug delivery performance. 
 
outline of thesis 
PART I – Chapter 1 provides a concise overview of the current issues of conventional chemotherapy and 
describes the opportunities for nanomedicine strategies to improve the efficacy of anti-cancer drugs. A description 
of the different assets of nanomedicines for altering pharmacokinetics and biodistribution by passive/active 
targeting and bioresponsive drug release is provided. 
Chapter 2 describes the history and early development of taxanes (i.e. paclitaxel (Taxol) and docetaxel 
(Taxotere)). Both the discovery and the historic evolution in manufacturing strategies of taxanes are covered. 
Additionally, the biological mechanism of action of taxanes is described. Next, the physicochemical background of 
the commercial formulations Taxol and Taxotere is described, along with their clinical translation and related 
toxicity issues. 
  
aims and outline of thesis 
 
9 
PART II – Chapter 3 reports on the formulation of polymeric nanoparticles based on PGS. A straightforward 
solvent displacement method was developed and key physicochemical properties in aqueous medium were 
evaluated including nanoparticle size, dispersity, colloidal stability and CAC. Next, nanoprecipitation of an organic 
phase containing both PGS and hydrophobic dye/paclitaxel (PTX) was investigated to obtain loaded nanoparticles 
by solvent displacement. Fluorescent dye- and PTX-loaded PGS nanoparticles were subsequently used for in vitro 
uptake and cytotoxicity studies, respectively. 
Chapter 4 describes the synthesis of acid-degradable block copolymers based on hydroxyethyl acrylate 
(HEA) and ketal-based (2,2-dimethyl-1,3-dioxolane-4-yl)methyl acrylate (DMDMA) by reversible addition-
fragmentation chain transfer (RAFT) polymerization. Using a macroCTA (macro chain transfer agent) approach, the 
main focus of this study was to systematically examine the influence of hydrophobic block design on self-assembly 
behavior (i.e. CAC, colloidal stability and degradation), drug loading and in vitro biological performance by varying 
the DMDMA content in the hydrophobic block. Solvent displacement was applied to physically encapsulate a 
hydrophobic fluorescent dye and PTX. In this way, we systematically evaluated the potential of these block 
copolymers for their use as nanocarrier for hydrophobic anti-cancer drugs. 
PART III – Chapter 5 investigates a novel design approach for paclitaxel-polymer prodrug conjugates by 
conjugation of PTX to a CTA and subsequent RAFT polymerization of hydrophilic N,N-dimethylacrylamide (DMA). As 
PTX and pDMA can serve as hydrophobic and hydrophilic segment respectively, amphiphilic properties (self-
assembly, CAC and aqueous stability) were examined. Furthermore, the possibility for post-polymerization 
modification of the opposite polymer chain end was explored with a fluorescent dye. Finally, uptake of the PTX-
polymer prodrug conjugate and effective delivery of PTX to cancer cells was evaluated in vitro. 
Chapter 6 reports on “second-generation” PTX-polymer conjugates, by implementing two types of acid-
sensitive acetal-linkers in the synthesis strategy reported in Chapter 5. Both the first- and second-generation PTX-
polymer conjugates were compared in terms of polymer composition and characteristics, self-assembly behavior, 
in vitro drug release and cytotoxicity. 
Chapter 7 describes the synthesis of a polymeric prodrug conjugate of docetaxel (DTX), inspired by the 
synthetic approach described for PTX in Chapter 5. Additionally, a high-affinity small molecule ligand for prostate-
specific membrane antigen (PSMA) was synthesized and modified with a maleimide moiety to be further used for 
post-modification of the DTX-polymer prodrug conjugate. In vitro cellular uptake of the PSMA-targeted DTX-
polymer prodrug conjugate was evaluated by flow cytometry (FACS) using a human, PSMA-positive prostate cancer 
cell line and compared to a non-targeted DTX-polymer prodrug control conjugate.  
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PART IV - Chapter 8 positions this doctoral dissertation within a broader international context by providing 
an up-to-date overview of the taxane formulations which are either approved or currently residing in clinical trial. 
First, the two approved PTX formulations alternative to Taxol (i.e. Abraxane and Genexol-PM) are described in 
detail in terms of synthesis, formulation and clinical evaluation. Next, a series of pioneering advanced taxane 
formulations are highlighted which are currently being evaluated in clinical trials. Additionally, two other 
platforms are described which are considered somewhat outside the nanomedicine field (i.e. antibody-drug 
conjugates (ADCs) and small molecule-drug conjugates (SMDCs)), as the latter have also been explored for 
improving the delivery of taxanes and other chemotherapeutic drugs. Finally, a critical view on the current limited 
clinical availability of nanomedicines including taxane formulations is described, along with important 
considerations and suggestions for future improvement of clinical translation of not only advanced taxane 
formulations, but anti-cancer medicines in general. 
Chapter 9 provides a summary of the aforementioned topics, along with general conclusions that can been 
drawn from the obtained results of this doctoral dissertation. In addition, suggestions are brought forward for 
future exploration, evaluation and optimization of the developed systems, in particular for the grafting-from-drug 
approach. 
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1 chemotherapy 
Cancer is a major cause of death worldwide, only exceeded by cardiovascular diseases.[1,2] Surgery and 
radiotherapy are effective and valuable treatment modalities for solid, well-localized tumors, but less suitable for 
treatment of metastatic cancer.[1] For the latter, small molecule chemotherapy is the current choice of treatment, 
as systemic circulation upon intravenous administration allows for drugs to distribute throughout the body and 
thus the likeliness of reaching metastatic sites is enhanced.[3,4] 
Several small molecule anti-neoplastic compounds targeting highly proliferative cells have already been 
identified half a century ago. Today however, the use of these compounds is often hampered by a low therapeutic 
index.[5] Table 1 summarizes the most common types of antineoplastic agents used in clinical setting. Although 
chemotherapeutic drugs exhibit substantial toxicity towards cancer cells as the latter exhibit high proliferation 
rates, healthy tissues featured by fast cell proliferation (e.g. hair follicles, bone marrow, gastrointestinal tract) are 
equally affected, thereby causing uncomfortable and sometimes life threatening side-effects.[6] These side-effects 
often have to be addressed by additional (pre)medication.[7] Due to the aspecific distribution of chemotherapeutic 
drugs throughout the body, relatively high doses need to be administered (e.g. 175 mg/m2 Taxol in combination 
with carboplatin for treatment of advanced non-small cell lung cancer (NSCLC)) in order to achieve sufficient drug 
levels at the tumor site.[8] However, increasing dose is limited to a certain extent, as high systemic exposure further 
increases toxicity and severely reduces the quality of life (QoL) of patients.[9] 
Another issue arises from a pharmaceutical point of view. It is estimated that approximately one third of 
potent small molecule anti-cancer drugs are rather hydrophobic and thus have limited solubility in aqueous 
medium.[10] This in particular holds true for the taxanes paclitaxel (PTX) and docetaxel (DTX) (Figure 1) and hence 
poses major challenges towards pharmaceutical formulation of these drugs.[11,12] This issue prompted the 
pharmaceutical industry to identify effective solubilizing excipients and concurrently triggered intensive research 
towards more advanced anti-cancer formulations capable of delivering drugs in a more effective, safer and 
patient-friendly fashion.[13,14] 
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Table 1. Classification of commonly used antineoplastic agents.[15–18] 
drug class mechanism of action examples indications 
alkylating agents impair cell function by forming 
covalent bonds on important 
molecules (e.g. proteins, DNA, RNA) 
cisplatin, carboplatin, 
chlorambucil, 
cyclophosphamide 
ovarian, breast, testicular and 
bladder cancer,  
(non)-hodgkin lymphoma, 
leukemia 
anti-metabolites structural analogues of naturally 
occurring metabolites involved in 
DNA and RNA synthesis 
5-fluorouracil, 
methotrexate, 
gemcitabine, 
mercaptopurine 
gastric, colorectal, head, neck, 
lung, breast, ovarian and 
pancreatic cancer, 
osteosarcoma, leukemia, non-
hodgkin lymphoma 
antitumor antibiotics intercalate DNA at specific 
sequences, creating free radicals 
which cause strand breakage 
bleomycin, 
anthracyclines 
(doxorubicin, epirubicin) 
breast, gastric, testicular, 
ovarian and thyroid cancer, 
(non)-hodgkin lymphoma, 
leukemia, neuroblastoma, 
squamous cell carcinoma 
topoisomerase inhibitors interfere with enzymes 
responsible for uncoiling of DNA 
during replication 
irinotecan, etoposide, 
camptothecin, SN-38 
colorectal and testicular 
cancer, small cell lung cancer 
tubulin-binding drugs taxanes block microtubule 
disassembly 
vinca alkaloids prevent 
microtubule formation 
taxanes (PTX, DTX) 
vinca alkaloids 
(vincristine, vinorelbine) 
breast, prostate, ovarian, and 
pancreatic cancer, NSCLC, 
leukemia, adenocarcinoma, 
AIDS-related Kaposi sarcoma 
mechanistic target of 
rapamycin (mTOR) 
inhibitors 
interfere with mTOR, a protein 
kinase involved in cellular 
metabolism, growth and 
proliferation  
everolimus, temsirolimus breast, pancreatic and lung 
cancer, renal cell carcinoma 
Abbreviations: DNA, deoxyribonucleic acid; RNA, ribonucleic acid; SN-38, 7-ethyl-10-hydroxycamptothecin; PTX, paclitaxel; DTX, 
docetaxel; AIDS, acquired immune deficiency syndrome.  
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Figure 1. Chemical structures of PTX and DTX. 
 
2 nanomedicine 
The knowledge of cancer biology and etiology has expanded substantially over the past few decades.[19,20] 
Not only has this led to novel classes of small molecule anti-cancer therapeutics (e.g. molecularly targeted drugs), 
this improved understanding also provided a means to optimize the efficacy of conventional anti-cancer drugs. In 
view of increasing the therapeutic index of conventional, FDA-approved chemotherapeutics, great efforts have 
been put in the field of nanomedicine.[21–23] Initially investigated by merely liposomal formulations (e.g. Doxil, an 
FDA-approved liposomal formulation of doxorubicin),[24] similar endeavors have now also been developed using 
various other types of versatile, biocompatible polymeric nanomaterials such as dendrimers, polymerosomes, block 
copolymer micelles, polymer-drug conjugates and antibody-drug conjugates (Figure 2).[25–31] 
 
2.1 assets 
Several arguments are in favor of nanomedicines for enhancing the therapeutic efficacy of extremely 
hydrophobic chemotherapeutics such as taxanes. First of all, physical encapsulation or chemical conjugation of 
taxanes into amphiphilic nanostructures can significantly enhance drug solubility and the carrier vehicle can serve 
as a protective shield against chemical and biochemical degradation.[32,33] Second, hydrophobic compounds, 
solubilized by conventional surfactants (e.g. PTX is solubilized with Cremophor EL in Taxol and DTX is solubilized 
with Tween 80 in Taxotere) are susceptible to premature burst release into the bloodstream by supramolecular 
dissociation of the surfactant and/or by fast passive drug diffusion and subsequent interaction with plasma 
proteins.[34] Chemical conjugation or strong non-covalent interaction between drug and polymeric carrier can be 
crucial techniques for circumventing systemic drug release and hence side-effects.[35–37] Third, fast renal clearance 
chemotherapy and nanomedicine 
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of small molecule anti-cancer drugs can be avoided as drug-associated nanocarriers with size ≥ 5 nm do not easily 
pass the small fenestrae in renal vasculature.[38–40] The latter can drastically prolong drug half-life. Numerous in 
vivo studies indeed report on altered pharmacokinetic profiling of physically encapsulated and chemically 
conjugated nanomedicine drugs, compared to the corresponding free drugs.[41–43] Fourth, it is known that 
nanocarriers passively distribute throughout the body in a heterogeneous manner. Nanomaterials tend to 
accumulate in tissues with highly fenestrated vasculature.[44–47] This phenomenon can be exploited to provide a 
more selective delivery of drugs into tumors whether or not in combination with additional active targeting 
strategies. Passive and active targeting will be discussed into more detail in section 2.2. Fifth, polymeric carriers 
can be chemically designed to trigger a response towards specific internal or external stimuli (e.g. change in pH, 
enzymes, redox, ultrasound, light). These bio- or stimuli-responsive properties can further enhance the selectivity 
and control in delivering anti-cancer agents and hence increase their therapeutic index.[48–50] Finally, 
nanomedicines can significantly alter the route of cellular drug uptake and hence limit drug resistance. 
Hydrophobic small molecule drugs typically enter (tumor) cells by passive diffusion. Nanoparticles on the other 
hand are predominantly taken up by endocytosis, a mechanism which can be stimulated even more by active 
targeting strategies (section 2.2.2).[51,52] Altering the route of uptake can inherently change intracellular drug 
localization and concentration. While gradual uptake by passive diffusion only leads to modest cellular drug 
concentrations, endocytosis of nanocarriers allows for delivering a high amount of drug cargo within a short period 
of time.[53] The resulting high intracellular drug concentrations can hence saturate efflux, mediated by cytosolic 
multiple drug resistance (MDR) proteins such as to P-glycoproteins (P-gp).[54] This can be of great importance for 
improving the efficacy of chemotherapeutic agents for which drug resistance has been reported. 
 
2.2 altering pharmacokinetics and biodistribution 
2.2.1 passive targeting 
On a cellular level, cancer can be characterized by several aberrations in normal processes (e.g. 
proliferation, metabolism, …).[19,20] These malfunctions translate into tumors with physiological properties 
significantly different from healthy tissue. Nanomedicines enable the exploitation of these anomalies for tumor 
targeting by the so called enhanced permeability and retention effect (EPR).[46,55,56] Blood vessels in solid tumors 
are often highly fenestrated due to aberrant angiogenesis. This results in endothelial gaps between 100 – 780 nm 
in size through which nanocarriers can easily extravasate into the interstitial fluid.[4,57,58] The lymphatic drainage of 
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the latter is often impaired in tumors. This allows nanocarriers to reside longer in proximity of malignant tissues 
(Figure 3). The FDA-approved formulation Doxil and the majority of the nanomedicines currently in clinical trials 
(e.g. Table 2 for taxane-based nanomedicines) rely on this passive targeting, mediated by the EPR effect.[59] 
 
Figure 2. Overview of prominent nanomedicines. 
 
In order to achieve significant passive targeting, it is crucial for nanomaterials to possess long blood 
circulation half-lives.[60] This sets up challenges as the latter is a very complex biological matrix, containing several 
substances (e.g. enzymes, antibodies) which can induce systemic drug clearance. A key player in causing these 
phenomena is the reticulo-endothelial system (RES), also called the mononuclear phagocytic system (MPS).[61] 
Certain plasma proteins, called opsonins, interact with non-endogenous materials. This renders them immunogenic 
and allows recognition by macrophages in liver (Kupffer cells), lymph nodes and spleen. This accelerated clearance 
can be avoided by decorating the surface of the nanocarriers with a hydrophilic corona (e.g. poly(ethylene glycol) 
(PEG)).[62] It is also known that larger materials (> 200 nm) are more likely to be affected by MPS, irrespective of 
surface chemistry.[63,64] The optimal size to benefit from the EPR effect should be evaluated for each system, as it 
involves finding the right balance between prolonging circulation time (increased size) and tumor penetrating 
capacity (decreased size).[65,66]   
antibody / hydrophilic carrier 
linker / hydrophobic moiety 
targeting ligand 
drug 
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Figure 3. Illustration of passive (EPR-mediated) and active targeting. 
 
2.2.2 active targeting 
Active targeting is a promising tool to further enhance the delivery of nanomedicines and hence broaden 
the therapeutic window. As mentioned before, MDR can be overcome as active targeted anti-cancer nanomedicines 
are known to be taken up by receptor-mediated endocytosis. The resulting high intracellular drug concentrations 
are less susceptible to P-gp-mediated cytosolic efflux.[67] Additionally, in many cases active targeting results in 
internalization and subcellular trafficking of drug loaded nanoparticles close to the target site. The latter can be 
exploited for drugs which cannot spontaneously pass cellular membranes (e.g. nucleic acid-based drugs).[68] 
Active targeting involves decoration of the carrier vehicle with high-affinity ligands which can be 
recognized by receptors or antigens, specifically overexpressed in the targeted tissues (Figure 3).[69] A wide range 
of receptors have been evaluated, either for direct targeting of tumor cells (e.g. CD44 receptor,[70–76] folate 
receptors (FRs),[77–79] transferrin receptors,[80,81] prostate specific membrane antigen (PSMA),[82,83] epidermal growth 
factor receptors (EGFRs))[84,85] and/or targeting of tumor-associated vasculature (e.g. αVβ3 integrins,[86] PSMA,[87] 
glycoprotein 60 (gp60)).[88] Several types of targeting ligands have been used including proteins (e.g. transferrin 
and albumin for targeting transferrin receptors and gp60, respectively),[88,89] monoclonal antibodies and their 
fragments (e.g. for EGFRs targeting),[69,90] polysaccharides (e.g. hyaluronic acid (HA) for CD44 receptor targeting),[91–
94] peptides (e.g. cyclic arginine-glycine-aspartate peptide (cRGD) for αVβ3 integrin targeting),[95–98] aptamers (e.g. 
A10 for PSMA targeting)[99,100] and small molecules (e.g. folic acid (FA) for FRs targeting).[77,101–103] 
However, active targeting is not without risk. Additional functionalization can alter the physicochemical 
properties of the carrier vehicle.[104] This can in turn significantly influence the in vivo behavior. As these ligands are 
not always hydrophilic (e.g. FA), high densities onto the surface of the vehicle can result in colloidal instability and 
aggregation. Furthermore, stealth properties can be jeopardized when the hydrophilic domains of the carrier are 
covered up to a high extent by more hydrophobic ligands which can lead to higher RES-mediated clearance.[105,106] 
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Indeed, preclinical evaluation of PSMA-targeted, DTX-loaded nanoparticles, developed by Langer and co-workers, 
demonstrated that an average 200 PSMA-ligands per nanoparticle resulted in the best in vivo outcome, even 
though up to 1000 molecules could be decorated per nanoparticle.[82] Finding this optimal degree of 
functionalization to obtain active targeting and to maintain in vivo stability has proven to be challenging and 
partly explains the lacking clinical translation of active targeted nanomedicines (Chapter 8).[69,107] Recent literature 
also reports that active targeting can be both time- and dose-dependent. Effective active targeting has been 
demonstrated shortly after intravenous injection, whilst over longer periods of time, passive targeting can 
predominate.[108] Additionally, active targeting has shown to be more efficient at lower doses. When nanomedicines 
are administered at high doses, passive targeting can prevail.[109] These findings should be taken into account for 
future evaluation of active targeted nanomedicines. 
 
2.2.3 stimuli-responsive release 
Systemic drug exposure and side-effects can be further restricted by triggering a release under specific 
conditions. These triggers can be either external or internal.[110] Examples of external stimuli include ultraviolet or 
near-infrared light which are often used within the field of photodynamic therapy (PDT).[111] Other examples are 
ultrasound and magnetic forces which will not be further discussed. This dissertation focuses on the use of internal 
triggers. For instance, various nanocarrier systems reported in literature rely on change in pH for inducing drug 
release.[112–117] Due to the high metabolic rate of tumors, the tumor microenvironment is slightly more acidic (i.e. pH 
6.5) than the physiological level (i.e. pH 7.4). Additionally, endo- and lysosomal vesicles are characterized by higher 
acidity (i.e. pH 5.5 - 5).[118,119] Furthermore, the expression of certain enzymes is often upregulated in cancerous 
tissue (e.g. matrix metalloproteinases (MMPs), cathepsin B).[120,121] Also, certain tumors which are low in oxygen and 
nutrient levels are often rich in reductive agents.[122] All these features can be exploited for bio-responsive release 
of anti-cancer drugs by designing acid-sensitive, enzyme-sensitive and redox-sensitive carrier systems, 
respectively. 
A variety of acid-sensitive (e.g. ketals, acetals, hydrazones, oximes, orthoesters), enzyme-sensitive (e.g. 
peptide sequences, esters), base (esters, carbonate esters) and redox-sensitive (e.g. disulfides) functionalities have 
been exploited to design responsive nanomedicines (Figure 4).[123–132] With regard to stimuli-responsive polymeric 
micelles, these functionalities can be introduced inside the hydrophobic core either by using functionalized 
monomers or by post-modification.[133–135] The stimulus will trigger degradation of the hydrophobic core into 
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hydrophilic moieties, resulting in complete disassembly and release of encapsulated drug.[136] Additionally, for 
cross-linked systems (e.g. cross-linked block copolymer micelles, nanogels) stimuli-responsive cross-linkers can be 
used, allowing full degradation of the nanovehicle into hydrophilic degradation products which can be cleared 
from the body by renal filtration.[137,138] For polymer-drug conjugates, the goal is to covalently bind drug and 
polymer through a responsive linker, allowing for tumor-specific, oxidative/reductive, enzyme- or pH-triggered 
cleavage and avoiding systemic premature burst release.[139] Importantly, as several stimuli are not highly tumor-
specific (e.g. low pH in endo- and lysosomes, enzymes such as esterases, …), combinations with active targeting 
should be considered to maximize the therapeutic benefit.[140] 
 
 
Figure 4. Overview of bio-responsive linker chemistries. 
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1 history 
In 1962, a plant screening operation was organized by the US National Cancer Institute. It was found that 
an extract of the bark of Taxus brevifolia (or Pacific yew) exerted cytotoxicity in vitro against the human KB cancer 
cell line. Initially, only modest anti-cancer activity was detected in vivo, therefore the discovery initially did not 
receive overall positive response. In the 1970s, the complete structure elucidation of the active compound (i.e. 
paclitaxel (PTX)) was performed along with more extensive in vivo studies. Contrarily, the latter showed very 
promising results. The subsequent discovery of the mechanism of action (section 3) fueled the scientific interest 
even further which eventually led to clinical translation of PTX.[1] Phase I and II trials started in 1984 and 1985, 
respectively. The first report on clinical anti-cancer activity against ovarian cancer was published in 1989. Few 
years later, similar positive results were obtained for breast cancer treatment with PTX and in 1992, Bristol-Myers 
Squibb got FDA-approval for Taxol (formulation details are described in section 4) for treatment of ovarian, breast 
and NSCLC.[2,3] 
The scarcity of PTX triggered the exploration towards alternative, renewable sources (section 2). In 1981, a 
collaboration started between the pharmaceutical company Rhône-Poulenc Rorer Inc. and the Institut de Chemie 
des Substances Naturelles. In 1986, this collaboration resulted in the discovery of the semisynthetic analogue 
docetaxel (DTX).[4] DTX exhibited widespread in vitro and in vivo activity with at least similar potency compared to 
PTX.[5] Due to the regenerative capacity of the source (i.e. needles), DTX experienced swift clinical development.[6] In 
1992, Rhône-Poulenc Rorer Inc. and the National Cancer Institute (NCI) signed a cooperative research and 
development agreement (CRADA) to seek approval for Taxotere (formulation details are described in section 4).[7] 
Phase I and II trials started in 1992 and 1993, respectively.[8,9] Substantial single agent activity was observed in 
treatment of breast, ovarian and NSCLC.[10] In 1996, DTX was granted accelerated approval for second-line 
treatment of breast cancer.[11] 
 
2 production 
PTX can be extracted from the bark of Pacific yew trees, but only in very low yields (i.e. 0.01 %). 
Approximately 2500 trees need to be harvested to obtain 1 kg of PTX.[12] Additionally, these trees are characterized 
by a very slow growth rate, impeding large scale cultivation. This led to a supply crisis for clinical phase III trials of 
Taxol in the 1990s and urged the pharmaceutical industry to search for alternative production methods.[13] 
Extensive research was conducted in finding protocols for the total synthesis of PTX.[14–18] Even though methods 
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have been developed and described in literature, none of these, however, appeared to be viable on an industrial 
scale. The most successful strategy which eventually resolved the PTX supply crisis involved a semisynthetic 
approach out of 10-deacetyl baccatin III.[2] The latter is a precursor which can be extracted out of renewable 
sources (i.e. needles) of a broader spectrum of yew tree varieties with faster growth rates (e.g. European yew 
(Taxus baccata)).[19,20] This approach also led to the discovery and development of DTX (section.1). Novel 
biotechnological approaches including production from fungal endophytes and plant cell cultures are currently 
gaining interest as well. Semisynthesis of DTX and PTX from 10-deacetyl baccatin III, obtained from either yew 
trees or plant cell cultures, are the most commonly applied strategies for the commercial supply of taxanes. 
Extensive efforts are currently being devoted to achieving higher yields, lowering the production costs and 
improving the environmental sustainability.[21] 
 
 
Figure 1. (a) composition, size and structural organization of microtubules, (b) microtubule binding site of PTX (DTX shares the 
same binding site).[22] 
 
3 mechanism of action 
Taxanes are known for their interaction with microtubules.[22] These hollow cylindrical macromolecular 
structures are built out of 13 longitudinal protofilaments composed of tubulin, a dimeric protein containing an α- 
and a β-subunit (Figure 1a).[23] Microtubules are important building blocks of the cytoskeleton and play pivotal roles 
in various dynamic processes including cell migration, organelle movement and spindle formation during mitosis. 
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The latter renders microtubules an attractive drugable target, as the proportion of cells in active cell cycle phase is 
substantially higher in tumor tissue than in normal tissues. Taxanes bind to the inner surface of microtubules, 
specifically through interaction with the β-tubulin subunit and thereby promote both their formation and their 
stabilization (Figure 1b).[24] DTX possesses a 2-fold higher microtubule binding affinity compared to PTX.[25] The 
latter partly explains the lower dose of DTX required for obtaining similar in vitro and in vivo anti-cancer effects 
(section 4). This stabilization thus prevents depolymerization of microtubules from occurring as during normal 
mitosis, but instead arrests cells in the late G2/M-phase which eventually leads to apoptotic cell death. 
 
4 taxane solubilization: Taxol and Taxotere 
Despite their high potency in cancer treatment, taxanes are used only to a modest extent in clinic today. 
The hydrophobic structure of PTX, discovered in the 1970s, already highlighted that taxanes possess extremely low 
water-solubility. For example, it was found that the solubility of PTX in water is below 0.3 μg/mL. Thus, finding a 
suitable pharmaceutical formulation was challenging for Bristol-Myers Squibb. The company developed a 
formulation of PTX composed of a 50:50 ethanol:Cremophor EL mixture and commercialized it under the brand 
name Taxol.[26] In clinic, often 175 mg/m2 of PTX is administered by intravenous infusion every 3 weeks.[27] This 
formulation is diluted into an iso-osmotic solution (e.g. 5 % dextrose) which is subsequently administered by 
intravenous infusion over a time course of several hours.[28] Taxol has been FDA-approved for treatment of several 
cancers including NSCLC, AIDS-related Kaposi sarcoma, ovarian and breast cancer.[29] 
Even though slightly more hydrophilic, DTX also exhibits very limited water-solubility. For this reason, 
Rhône-Poulenc Rorer Inc. (now Sanofi) formulated DTX in a 50:50 ethanol:polysorbate 80 mixture and 
commercialized it under the brand name Taxotere.[5] A DTX dose of 100 mg/m2 is often administered upon dilution, 
every 3 weeks within 1 - 2 hours of intravenous infusion.[27] In phase III trials, Taxotere has shown both similar and 
superior efficacy compared to Taxol (e.g. in platinum combination therapy for treatment of ovarian cancer and as 
single agent for treatment of anthracycline-resistant metastatic breast cancer, respectively).[30–33] Neutropenia was 
often more abundant in DTX treatment but generally, less neuropathy was observed than with PTX.[30] Taxotere is 
currently FDA-approved for treatment of adenocarcinoma, squamous cell carcinoma of head and neck, NSCLC, 
breast and prostate cancer.[34]   
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However, the surfactants of both Taxol (i.e. Cremophor EL, a pegylated derivative of castor oil) and 
Taxotere (i.e. polysorbate 80, an ester of pegylated sorbitan with oleic acid) cause serious hypersensitivity 
reactions in patients, even within minutes during infusion.[35–41] Therefore, patients undergoing therapy with Taxol 
or Taxotere have to be pretreated with antihistamines and/or corticosteroids to temper severe, possibly fatal 
allergic reaction. Polysorbate 80 in particular can also induce fluid retention and often requires additional 
treatment with diuretics.[37] This has somewhat hampered extensive use of Taxol and Taxotere in clinic, but also 
instigated scientific interest for developing alternative taxane formulations using more biocompatible excipients 
in order to administer taxanes in a safer fashion. 
  
chapter 2 
 
32 
5 references 
[1] D. G. Kingston, J. Nat. Prod. 2000, 63, 726–734. 
[2] D. G. I. Kingston, Phytochemistry 2007, 68, 1844–1854. 
[3] “Taxol® (NSC 125973),” can be found under https://dtp.cancer.gov/timeline/flash/success_stories/S2_taxol.htm, 2016. 
[4] F. Lavelle, F. Gueritte-Voegelein, D. Guenard, Bull. Cancer 1993, 80, 326–338. 
[5] M. C. Bissery, G. Nohynek, G. J. Sanderink, F. Lavelle, Anticancer Drugs 1995, 6, 339-355-368. 
[6] J. Verweij, M. Clavel, B. Chevalier, Ann. Oncol. 1994, 5, 495–505. 
[7] E. Blume, J. Natl. Cancer Inst. 1992, 84, 673. 
[8] R. Pazdur, R. A. Newman, B. M. Newman, A. Fuentes, J. Benvenuto, B. Bready, D. Moore Jr., I. Jaiyesimi, F. Vreeland, M. M. 
Bayssas, et al., J. Natl. Cancer Inst. 1992, 84, 1781–1788. 
[9] A. D. Seidman, C. Hudis, J. P. A. Crown, C. Balmaceda, D. Lebwohl, V. Currie, T. Gilewski, T. Hakes, M. Robles, K. Klem, in 
Proc. Am. Soc. Clin. Oncol., 1993, p. 63. 
[10] A. T. van Oosterom, D. Schrijvers, Anticancer Drugs 1995, 6, 356–368. 
[11] R. Dagher, J. Johnson, G. Williams, P. Keegan, R. Pazdur, J. Natl. Cancer Inst. 2004, 96, 1500–1509. 
[12] G. M. Cragg, K. M. Snader, Cancer Cells 1991, 3, 233–235. 
[13] D. Guenard, F. Gueritte-Voegelein, P. Potier, Acc. Chem. Res. 1993, 26, 160–167. 
[14] R. A. Holton, R. R. Juo, H. B. Kim, A. D. Williams, S. Harusawa, R. E. Lowenthal, S. Yogai, J. Am. Chem. Soc. 1988, 110, 6558–
6560. 
[15] W. F. Berkowitz, A. S. Amarasekara, J. J. Perumattam, J. Org. Chem. 1987, 52, 1119–1124. 
[16] J. Lin, M. M. Nikaido, G. Clark, J. Org. Chem. 1987, 52, 3745–3752. 
[17] P. A. Wender, D. B. Rawlins, Tetrahedron 1992, 48, 7033–7048. 
[18] L. Ettouati, A. Ahond, C. Poupat, P. Potier, Tetrahedron 1991, 47, 9823–9838. 
[19] D. G. Kingston, Pharmacol. Ther. 1991, 52, 1–34. 
[20] V. Senilh, S. Blechert, M. Colin, D. Guenard, F. Picot, P. Potier, P. Varenne, J. Nat. Prod. 1984, 47, 131–137. 
[21] S. Soliman, Y. Tang, Biotechnol. Bioeng. 2015, 112, 229–235. 
[22] C. Dumontet, M. A. Jordan, Nat. Rev. Drug Discov. 2010, 9, 790–803. 
[23] I. Arnal, R. H. Wade, Curr. Biol. 1995, 5, 900–908. 
[24] S. Rao, L. He, S. Chakravarty, I. Ojima, G. A. Orr, S. B. Horwitz, J. Biol. Chem. 1999, 274, 37990–37994. 
[25] J. F. Diaz, J. M. Andreu, Biochemistry 1993, 32, 2747–2755. 
[26] A. Sparreboom, O. VanTellingen, W. J. Nooijen, J. H. Beijnen, Cancer Res. 1996, 56, 2112–2115. 
[27] S. E. Jones, J. Erban, B. Overmoyer, G. T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W. J. Urba, K. I. Pritchard, 
et al., J. Clin. Oncol. 2005, 23, 5542–5551. 
[28] P. H. Wiernik, E. L. Schwartz, J. J. Strauman, J. P. Dutcher, R. B. Lipton, E. Paietta, Cancer Res. 1987, 47, 2486–2493. 
[29] “Paclitaxel,” can be found under https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel, 2016. 
[30] P. A. Vasey, G. C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, D. Parkin, J. Paul, A. Hay, S. B. Kaye, J. Natl. Cancer 
Inst. 2004, 96, 1682–1691. 
[31] S. B. Kaye, M. Piccart, M. Aapro, P. Francis, J. Kavanagh, Eur. J. Cancer 1997, 33, 2167–2170. 
[32] E. Saloustros, D. Mavroudis, V. Georgoulias, Expert Opin. Pharmacother. 2008, 9, 2603–2616. 
[33] T. Vu, S. Ellard, C. H. Speers, S. C. Taylor, M. L. de Lemos, F. Hu, K. Kuik, I. A. Olivotto, Ann. Oncol. 2008, 19, 461–464. 
[34] “Docetaxel,” can be found under https://www.cancer.gov/about-cancer/treatment/drugs/docetaxel, 2016. 
[35] H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Eur. J. Cancer 2001, 37, 1590–1598. 
[36] E. K. Rowinsky, E. A. Eisenhauer, V. Chaudry, S. G. Arbuck, R. C. Donehower, Semin. Oncol. 1993, 20, 1–15. 
[37] A. J. ten Tije, J. Verweij, W. J. Loos, A. Sparreboom, Clin. Pharmacokinet. 2003, 42, 665–685. 
[38] L. B. Norris, Z. P. Qureshi, P. B. Bookstaver, D. W. Raisch, O. Sartor, H. Chen, F. Chen, C. L. Bennett, Community Oncol. 2010, 
7, 425–428. 
  
taxanes 
 
33 
[39] Z. Weiszhar, J. Czucz, C. Revesz, L. Rosivall, J. Szebeni, Z. Rozsnyay, Eur. J. Pharm. Sci. 2012, 45, 492–498. 
[40] M. J. Hawkins, P. Soon-Shiong, N. Desai, Adv. Drug Deliv. Rev. 2008, 60, 876–885. 
[41] J. Wanders, D. Schrijvers, U. Bruntsch, M. Gore, J. Verweij, A. Hanauske, H. Franklin, M. Roelvink, M. Bayssas, S. B. Kaye, in 
Proc. Am. Soc. Clin. Oncol., 1993, p. 73. 
  
 
  
35 
 
 
PART II 
 
DESIGN OF ADVANCED 
TAXANE NANOFORMULATIONS BASED ON 
PHYSICAL ENCAPSULATION 
  
  
 
 
37 
chapter 3 
 
poly(glycerol sebacate) nanoparticles for 
encapsulation of hydrophobic 
anti-cancer drugs 
 
Benoit Louage,a Liesa Tack,a Yadong Wang,b Bruno G. De Geesta 
 
a Laboratory of Pharmaceutical Technology, Department of Pharmaceutics,  
Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium 
b Departments of Bioengineering, Chemical and Petroleum Engineering, Surgery, Mechanical Engineering and 
Materials Science, and the McGowan Institute for Regenerative Medicine,  
3700 O’Hara Street, 411 Benedum Hall, Pittsburgh, PA 15261, USA 
 
Polymer Chemistry 2017, DOI: 10.1039/C6PY02192A 
  
chapter 3 
 
38 
 
 
 
 
 
 
 
abstract 
Physical encapsulation of hydrophobic compounds into nanocarriers which are stable in aqueous medium 
is of high interest as it can increase solubilization of the drug, lower its toxicity, control its pharmacokinetic profile 
and thus overall improve the therapeutic efficacy. To increase solubilization of a drug in aqueous medium, the 
carrier should contain hydrophobic domains which can form non-covalent interactions with hydrophobic drug 
molecules. Besides liposomes, polymers have been widely acknowledged as promising nanocarriers. In this paper, 
we report on the formulation of poly(glycerol sebacate) (PGS), an inexpensive, water insoluble but biodegradable 
and biocompatible polymer, into nanocarriers for hydrophobic drugs. Mixing of alcoholic PGS solutions with water 
(i.e. solvent displacement) produced a fine and highly stable dispersion with a size which can be controlled by the 
PGS concentration and solvent to water ratio. These dispersions were used for the encapsulation of hydrophobic 
compounds such as a fluorescent dye and two drugs known for their anti-mitotic activity (i.e. paclitaxel (PTX) and 
flubendazole (FLU)). These formulations were then evaluated in vitro.  
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1 introduction 
Up to now, patients receiving chemotherapy still experience aggravating side-effects (i.e. hypersensitivity, 
hair loss, nausea, higher susceptibility for diseases due to impaired immune function, etc.).[1] Non-specific drug 
activity and toxic solubilizing agents present in the anti-cancer drug formulations can cause these adverse 
effects.[2–5] These issues have triggered research over the past 20 years towards advanced delivery systems for 
chemotherapeutic drugs to minimize these side-effects of chemotherapy. Nanomedicine is considered to be one of 
the most promising strategies to achieve this goal.[6–8] One key feature of nanocarriers is the possibility of 
improving drug selectivity by the so-called enhanced permeability and retention (EPR) effect.[9–11] This passive 
targeting mechanism involves accumulation of nanoparticles in tumor tissue due to poor endothelial connections 
in neoplastic blood vessels and impaired lymphatic drainage. Secondly, aqueous solubility of hydrophobic anti-
cancer drugs (e.g. paclitaxel (PTX) and flubendazole (FLU)) can be significantly improved by physical or chemical 
incorporation into a nanoparticle.[12,13] 
 
 
Figure 1. Synthesis of poly(glycerol sebacate) by polycondensation between glycerol and sebacic acid under heating and 
reduced pressure. The structure is an idealized form as branching occurs involving the middle hydroxyl group of glycerol in 
the polycondensation reaction. 
 
Polymers are a critical player in the field of nanomedicines.[14–23] Besides affording drug encapsulation, 
another crucial requirement for the polymer is to be biocompatible, as excipients are known to cause severe side-
effects (i.e. Cremophor EL). Poly(glycerol sebacate) (PGS) is a polyester formed by polycondensation of glycerol and 
sebacic acid (Figure 1), resulting in a viscous polymer with moderate molecular weight. So far, PGS has been used 
for subsequent treatment under high vacuum and heating to produce a crosslinked elastomeric material.[24] 
Attractive aspects of PGS are its biodegradability owing to the abundant presence of esters bonds and the fact that 
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both glycerol and sebacic acid are inexpensive and endogenous components present in the human body.[25] 
Moreover, materials made from glycerol and sebacic acid have been approved by FDA for use in medical 
applications.[26] Literature shows that PGS elastomers show excellent biocompatibility in vitro and in vivo.[27] Due to 
its established biocompatibility and interesting mechanical properties, PGS elastomers have already proven to be a 
useful biomaterial, especially in the field of regenerative medicine.[27–29] Despite these attractive properties the use 
of non-crosslinked PGS as drug nanocarrier has been overlooked, to the best of our knowledge. 
Though the pending hydroxyl groups contribute to a hydrophilic nature on the polymer surface, PGS is not 
water-soluble, suggesting that the polymer also exhibits hydrophobic behaviour in aqueous medium which can be 
suitable for both self-assembly behaviour and physical encapsulation of hydrophobic drugs. These features raise 
the potential of PGS to produce nanoparticles for hydrophobic anti-cancer drugs. 
 
2 results and discussion 
Unlike the widespread poly(lactic-co-glycolic acid) (PLGA) which is still regarded as one of the gold 
standards for hydrophobic drug encapsulation, PGS can be readily dissolved in ethanol (EtOH) up to a fairly high 
concentration (at least 100 mg/mL). Figure S1 shows the size exclusion chromatography (SEC) elugram of PGS, 
along with its average molecular weight (Mn) and polydispersity (Ð). Stable PGS nanoparticle suspensions were 
obtained using a straightforward solvent displacement method (pictures of PGS nanoparticles formulated in H20 
and physiological glucose solution (i.e. dextrose 5 %) are shown in Figure S2 - S3, respectively). Briefly, a 
concentrated PGS solution in EtOH was diluted into deionized water (H2O) under simple stirring, without the need 
for high shear homogenization or ultrasonication. Instantaneously, a fine dispersion was formed which is ascribed 
to the so-called ouzo effect.[30] This effect involves a series of interfacial phenomena and recently, Couvreur and co-
workers proposed for PLGA-based particles that organic solvents with high water affinity lead to smaller 
nanoparticles than solvents with a lower water affinity.[31] As PLGA is not soluble in ethanol, this solvent was not 
included in their study. Here the use of ethanol for PGS nanoparticles formulation is a strong asset as it avoids 
work up of the nanoparticles by dialysis to remove organic solvent due to the biocompatible nature of ethanol. 
Importantly, we also noticed that stable dispersions could be obtained in the absence of any surfactant.  
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Figure 2. Particle size distribution (A), PDI and Z-average after 0 h and 96 h (B) of PGS nanoparticles formulated by solvent 
displacement from EtOH into deionized H2O (n = 4). 
 
Dynamic light scattering (DLS) was used to determine nanoparticle size, polydispersity (PDI) and colloidal 
stability over time under static conditions. PGS stock solutions in EtOH (10, 20 and 50 mg/mL) were prepared and 1 
mL stock solution was subsequently formulated into 10 mL of H2O. The DLS data in Figure 2A show that particle size 
depends on PGS concentration. Indeed, increasing PGS concentrations leads to larger nanoparticles with Z-average 
diameters of 111.6 ± 0.9, 144.4 ± 0.3 and 208.6 ± 2.4 nm (n = 4), for a PGS concentration of 1, 2 and 5 mg/mL, 
respectively. Overall, PDIs were found to be low (i.e. < 0.2). Furthermore, all the nanoparticles suspensions 
exhibited excellent stability over time with no detectable alteration in nanoparticle size and PDI within a 
timeframe of 96 hours (Figure 2B). 
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Figure 3. Excitation intensity ratio of pyrene at 338 nm (Iex338) and 333 nm (Iex333) as function of PGS or PVA concentration (n = 
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To test if hydrophobic interaction was the main driving force for the formation of nanoparticles, we 
measured the critical aggregation concentration (CAC) of PGS by plotting the ratio of the excitation intensity at 338 
and 333 nm of the hydrophobic dye pyrene versus the concentration of PGS in aqueous medium. These experiments 
show that pyrene becomes accommodated within the hydrophobic environment at PGS concentrations as low as 
0.4 ± 0.1 μg/mL (n = 3) (Figure 3). This value is roughly 500-fold lower as compared to the measured CAC of 
poly(vinyl alcohol) (PVA) (i.e. 200 ± 8 μg/mL (n = 3), a commonly used emulsion stabilizer in several 
pharmaceutical formulations such as PLGA.[32] 
The low CAC of PGS motivated us at exploring the potential of these nanoparticles for encapsulation of 
hydrophobic drugs and subsequent intracellular drug delivery. For this purpose, we loaded the PGS nanoparticles 
with a hydrophobic fluorescent dye (i.e. Cy5-N3) by co-dissolution of Cy5-N3 and PGS in EtOH prior to solvent 
displacement in H2O. Note that nanoparticles were prepared at a PGS concentration of 5 mg/mL as this appeared to 
be optimal for drug encapsulation (vide infra). Precipitated, non-encapsulated dye was removed by filtration 
(0.450 μm). SKOV-3 human ovarian carcinoma cells were pulsed with different concentrations of Cy5-N3-labelled 
PGS nanoparticles and their cellular uptake was analysed by flow cytometry (FACS). As a control, we prepared an 
equally concentrated Cy5-N3 solution in EtOH in the absence of PGS, followed by solvent displacement in H2O and 
membrane filtration. The flow cytometry histograms, shown in Figure 4A, clearly indicate a dose-dependent uptake 
of both encapsulated and freely soluble dye. However, the mean fluorescence values of cells pulsed with Cy5-N3-
labelled PGS nanoparticles are dramatically higher than those of cells pulsed with non-encapsulated dye. These 
findings demonstrate that formulation of a hydrophobic dye in PGS nanoparticles increases its aqueous 
compatibility and hence leads to much higher cellular association. We attribute this to the ability of the 
hydrophobic interior of the PGS nanoparticles to accommodate hydrophobic compounds which otherwise 
precipitate from solution. Confocal microscopy was subsequently used to investigate the intracellular fate of the 
nanoparticles. Figure 4B shows that the Cy5-N3-labelled PGS nanoparticles are inside the SKOV-3 cells and not 
merely adhering to the cell membrane. Counterstaining of the intracellular acidic vesicles (i.e. endosomes and 
lysosomes) with LysoTracker (Figure 4C) yields significant co-localization between the LysoTracker channel and the 
Cy5-N3 channel, suggesting that PGS nanoparticles are predominantly internalized by endocytosis, as would be 
expected for particles within this size range. 
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Figure 4. (A) Flow cytometry histograms obtained from SKOV-3 cells pulsed with different concentrations of Cy5-N3 
formulated in PGS nanoparticles or in H2O. (B) Confocal microscopy image (maximum intensity projection (MIP) + orthogonal 
planes) of SKOV-3 cells pulsed with Cy5-N3-labelled PGS nanoparticles (red fluorescence). Cell membrane was stained in 
green with phalloidin-AlexaFluor488 (note that when not permeabilizing the cell membrane with Triton-X, phalloidin 
behaves as a membrane staining rather than an actin staining). Cell nuclei were stained in blue with Hoechst. (C) Confocal 
and differential interference contrast (DIC) images of SKOV-3 cells pulsed with Cy5-N3-labelled PGS nanoparticles (red) and 
counter-stained with LysoTracker (green). Co-localization is observed as a yellow/orange signal. Note that the dark/bright 
dots on the DIC image are not lysosomes/endosomes by lipid bodies. 
 
Next, we aimed at exploiting the capacity of the PGS nanoparticles to accommodate hydrophobic drugs. 
For this purpose, PTX was formulated using a similar protocol as for the formulation of Cy5-N3-labelled PGS 
nanoparticles. Paclitaxel has a very low solubility in water and will therefore be largely distributed within the PGS 
phase. We measured by LC-MS the solubility of PTX in a 10% ethanol in water solution to be only 4.5 μg/mL. By 
altering the concentrations of PGS and PTX in EtOH, the solvent displacement procedure was optimized for 
formulation in both H2O and dextrose 5 %. When the formulation contained 5 mg/mL PGS and 0.5 mg/mL PTX, drug 
precipitation was not observed neither macroscopically (i.e. by visual inspection: Figure S2 - S3), nor microscopically 
(i.e. by optical microscopy: Figure 5A1 or by DLS: Figure 6 and Figure S4). By contrast, PTX similarly diluted from EtOH 
into deionized H2O resulted in macroscopic precipitation as confirmed by both optical microscopy (Figure S2 – S3) 
and DLS (Figure 5A2 - 5B). DLS of the PGS/PTX nanoparticles yielded a similar Z-average diameter and low PDI as 
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compared to the unloaded 5 mg/mL PGS nanoparticles both in H2O (Figure 2A and Figure 6) and in dextrose 5 % 
(Figure S4). Additionally, Z-average diameter and PDI remained constant for at least 2 days. This implies that no 
further work-up would be required. Additionally, when formulated in dextrose 5 %, the obtained formulation could 
directly be added to an infusion bag as the presence of 10 % of ethanol is not hampering the medical use of the 
formulation. 
To investigate whether indeed PTX is encapsulated within the PGS nanoparticles in amorphous form and 
not present as PTX nanocrystals stabilized by PGS polymers, we performed X-ray diffraction (XRD). The 
diffractograms shown in Figure 7 give clear proof of the highly crystalline nature of PTX and the semi-crystalline 
nature of PGS as bulk gel material. Upon nanoparticle formation, the crystallinity of PGS is reduced as the peak 
intensity at 20 is strongly reduced and the peak intensity at 5 is almost fully abolished. The diffractogram of the 
PGS/PTX nanoparticles on its turn also shows reduced peak intensity of the PGS-related peaks but also does not 
show any PTX-related peaks. This suggests that PTX is present in amorphous state, likely being molecularly 
dissolved within the matrix of the PGS nanoparticles. To further explore the potential of the PGS nanoparticles we 
also attempted the formulation of flubendazole (FLU, Figure S5). FLU is an anti-helminthic drug with extremely 
poor solubility in aqueous medium and with moderate solubility in DMSO and formic acid. Interestingly, FLU has 
recently been found to exhibit an anti-mitotic effect which suggests its potential use as anti-cancer drug. [13] 
Contrary to PTX, FLU-loaded nanoparticles were formulated by solvent displacement from DMSO into water, which 
required a dialysis period of 3 days to remove the DMSO. This procedure yielded nanoparticles with similar size as 
PTX/PGS nanoparticles. 
 
 
Figure 5. Optical microscopy images of PTX formulated in PGS (A1) and diluted from EtOH into H2O (A2). (B) Size distribution 
measured by DLS of PTX diluted from EtOH into H2O.   
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Figure 6. DLS size distribution (A), Z-average diameter and PDI over 3 days (B) of PGS/PTX nanoparticles in H2O. 
 
 
Figure 7. X-ray diffractograms of PTX, PGS and PGS/PTX formulations. 
 
Finally, in vitro cytotoxicity of the developed PTX/PGS and FLU/PGS formulations were evaluated on SKOV-
3 cells by MTT assay, along with the cytocompatibility of unloaded PGS nanoparticles. Two commercial PTX 
formulations (i.e. Abraxane and Genexol-PM) were included for comparison. Abraxane is a PTX formulation 
solubilized and stabilized by albumin, whilst Genexol-PM consists of PTX-loaded polymeric micelles based on 
monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-b-PDLLA). SKOV-3 cells were incubated for 72 
hours to evaluate the in vitro cytotoxic effect of PTX. Figure 8 shows that the PTX/PGS formulation induces similar 
in vitro cytotoxicity compared to Abraxane and Genexol-PM at equal PTX dosing, whilst PGS itself does not exert 
intrinsic cytotoxic effects, as expected. Even a lower IC50-value was observed for the PTX/PGS formulation (Table 1). 
Cell viability can be decreased to less than 20%, indicating that PTX can be released out of the PGS nanoparticles 
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and can exert its anti-mitotic effect. The release of PTX could occur both in the cell culture medium and after 
cellular uptake. Release of PTX in culture medium would most probably be due to passive diffusion out of the 
nanoparticles and not because of particle disintegration, considering even at a PTX dose of 0.1 μg/mL, the 
corresponding PGS concentration (i.e. 1 μg/mL) is still above the CAC of PGS (i.e. 0.4 ± 0.1 μg/mL PGS). Additionally, a 
significant drop in cell viability was induced by the FLU/PGS formulation as. The lower IC50-value is most likely 
attributed to the lower intrinsic potency of FLU compared to PTX. 
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Figure 8. Cell viability measured by MTT assay of SKOV-3 cell treated with unloaded PGS nanoparticles, PTX/PGS and FLU/PGS 
nanoparticles, Abraxane and Genexol-PM. *The PGS data points refer to the concentration of PGS present at the respective 
PTX/FLU concentrations (i.e. in the developed PTX/PGS and FLU/PGS formulation, the PGS concentration (in μg/mL) is 10-fold 
higher than the PTX and FLU concentration) (n = 6). 
 
Table 1. IC50-values of PGS and PTX formulations. (n = 6) 
formulation IC50 [nM] 
PGS / 
PTX/PGS 13 
Abraxane 67 
Genexol-PM 35 
FLU/PGS 433 
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3 conclusions 
We have shown that PGS is capable of forming well-defined nanoparticles by a very simple solvent 
displacement method. The produced PGS nanoparticle dispersion is colloidally stable in aqueous medium for 
prolonged periods of time and a low CAC implies that the formed nanoparticles are unlikely to rapidly disassemble 
upon dilution. We demonstrated in vitro that a hydrophobic fluorescent dye is efficiently endocytosed by cells 
when loaded into PGS nanoparticles. Finally, a sufficient amount of PTX and FLU could be physically encapsulated 
into the PGS nanoparticles. MTT assay confirmed the expected intrinsic cytocompatibility of PGS nanoparticle itself, 
whilst high cytotoxicity was observed for PTX- and FLU-loaded PGS nanoparticles. These data stimulate further 
exploration to assess whether PGS nanoparticles could serve as a nanomedicine platform for physical 
encapsulation of hydrophobic drugs. 
 
4 experimental 
4.1 materials 
Chemicals were purchased from Sigma-Aldrich unless mentioned otherwise. PGS was synthesized as 
previously reported.27 SEC analysis in dimethylacetamide (DMAc) revealed a Mn of 4.6 kDa Da and a D of 3.7. Cy5-N3 
was obtained from Lumiprobe. Enzyme-free cell dissociation buffer, Dulbecco’s modified Eagle medium (DMEM), 
foetal bovine serum (FBS), L-glutamine, sodium pyruvate, penicillin, streptomycin, Hoechst, Alexa Fluor 488 
Phalloidin and LysoTracker Red were obtained from Thermofisher. SKOV-3 cells were supplied by ATCC. Paclitaxel 
(PTX) was purchased from LC Laboratories. 
 
4.2 nanoparticle formulation 
Formulation of the PGS nanoparticles was carried out by a solvent displacement technique. Briefly, 1 mL of 
PGS stock solution in EtOH (10, 20 or 50 mg/mL) was added dropwise to 10 mL of H2O under stirring. Nanoparticle 
size, polydispersity and colloidal stability was analysed by dynamic light scattering (DLS). Measurements were 
performed at 37 °C on a Zetasizer Nano S (Malvern). 
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4.3 critical aggregation concentration (CAC) 
Following a described protocol, the CAC of PGS nanoparticles was determined by fluorescence 
spectrometry using pyrene as a fluorescent probe.[23] First, 2.5 mL serial dilutions of PGS nanoparticles in H2O were 
prepared with PGS concentrations ranging from 1 x 10-6  to 1 mg/mL. Second, a 3.6 mg/mL (1.8 × 10−2 M) stock 
solution of pyrene in acetone was prepared and kept on ice to prevent evaporation of the acetone. Next, 10 μL of 
this solution was diluted to 1 mL acetone and kept on ice. To each dilution, 8.3 μL of the latter pyrene solution was 
added under stirring leading to a pyrene concentration of 6.0 × 10-7 M. Similarly, the CAC of poly(vinyl alcohol) (PVA) 
was determined for comparison. Fluorescence excitation spectra were recorded at 20 °C on a Cary Eclipse 
fluorescence spectrophotometer (Agilent Technologies) equipped with a Varian Cary Temperature Controller. The 
CAC was quantified based on the change in excitation intensity ratio at 338 and 333 nm with varying concentration. 
 
4.4 x-ray diffraction 
X-ray diffractograms were recorded on a Bruker D8 diffractometer. 
 
4.5 cell culture 
SKOV-3 (human ovarian cancer cell line) cells were cultured in DMEM, supplemented with 10% FBS, 2 mM 
L-glutamine, 1 mM sodium pyruvate, and antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin). Cells were 
incubated at 37 °C in a controlled, sterile environment of 95 % relative humidity and 5 % CO2. SKOV-3 cells were 
used for all cell experiments. 
 
4.6 hydrophobic dye encapsulation 
Cy5-N3-loaded PGS nanoparticles were prepared by co-dissolution in EtOH of Cy5-N3 (0.2 mg/mL) and PGS 
(50 mg/mL), followed by solvent displacement in H2O as described above. Using a similar protocol, a Cy5-N3 
solution in EtOH (0.2 mg/mL) was formulated in 10 mL of H2O and used as control for further in vitro cellular 
uptake experiments. All samples were filtered (0.450 μm) before use to remove precipitated dye. 
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4.7 FACS 
SKOV-3 cells were seeded into 24-well titer plates (250 000 cells per well, suspended in 1 mL of culture 
medium) and incubated overnight. Next 10, 20 or 40 μL of Cy5-N3-labelled PGS nanoparticle/control was added to 
the cells followed by 24 hours of incubation to allow cellular uptake. After incubation, wells were aspirated and 
detached. Cell suspensions were centrifuged (350 g, 7 min, 4 °C). Finally, supernatant was aspirated and the cell 
pellets were suspended into 350 μL of PBS and kept on ice to maintain cell integrity. FACS was performed on a BD 
Accuri C6 (BD Biosciences). Data were processed by FlowJo software. 
 
4.8 confocal microscopy 
First, a Hoechst stock solution of 1 mg/mL was prepared in dimethyl sulfoxide (DMSO). Alexa Fluor 488 
Phalloidin was dissolved in 1.5 mL of methanol to obtain a stock concentration of 6.6 μM. Of these stock solutions, 6 
and 35 μL were added to 1.4 mL of PBS supplemented with 1% bovine serum albumin (BSA), respectively. The 
commercial LysoTracker Red 1 mM stock solution was diluted in culture medium to a working concentration of 60 
nM. SKOV-3 cells were plated out on Willco-Dish glass bottom dishes (5 000 cells, suspended in 200 μL of culture 
medium) and incubated overnight. Next, 5 μL of Cy5-N3-labelled PGS nanoparticle was added, followed by 24 hours 
of incubation. Hoechst and Alexa Fluor 488 Phalloidin staining was carried out on fixed cells. In summary, culture 
medium was aspirated and cells were washed with PBS. Next, 200 μL of 2 % paraformaldehyde was added and 
allowed to fixate for 15 min. After aspiration and washing, 200 μL of Hoechst-Alexa Fluor 488 Phalloidin working 
solution was added and incubated for 40 min at room temperature. Finally, the samples were washed with PBS. 
Further, staining with LysoTracker Red was performed on live cells. Briefly, culture medium was aspirated and cells 
were washed twice with PBS. Next, 200 μL of LysoTracker Red working solution was added and allowed to incubate 
for 1.5 h before performing confocal microscopy. Confocal microscopy was carried out on a Leica DMI6000 B 
inverted microscope equipped with an oil immersion objective (Leica, 63×, NA 1.40) and attached to an Andor DSD2 
confocal scanner. Images were processed with the ImageJ software package.  
  
chapter 3 
 
50 
4.9 hydrophobic drug encapsulation 
PTX/PGS nanoparticles were prepared by co-dissolution of PTX (5 mg/mL) and PGS (50 mg/mL) in EtOH, 
followed by solvent displacement in H2O as described earlier. 
FLU/PGS nanoparticles were prepared by co-dissolution of FLU (5 mg/mL) and PGS (50 mg/mL) in DMSO, 
followed by solvent displacement in H2O as described earlier. The formulation was subsequently dialyzed against 
H2O for 3 days (MWCO 3.5 kDa) to remove organic solvent. 
 
4.10 in vitro cytotoxicity 
MTT assay was performed as previously described.[23] Dilution series of unloaded PGS nanoparticles were 
prepared (concentrations ranging from 5 × 10-3 to 5 mg/mL). PTX/PGS and FLU/PGS nanoparticles were diluted 
(concentrations ranging from 5 × 10-5 to 50 μg/mL) along with two control nanoparticle formulations: Abraxane 
(Celgene) and Genexol-PM (Samyang Biopharmaceuticals). The MTT stock solution was prepared by dissolving 100 
mg MTT in 20 mL of PBS and subsequent membrane filtration (0.220 μm). Before use, MTT stock solution was 5-fold 
diluted with culture medium. Briefly, SKOV-3 cells were seeded into 96-well titer plates (10 000 cells per well, 
suspended in 200 μL of culture medium) and incubated overnight. Next, 50 μL of sample, DMSO (positive control = 
0% viability) or H2O (negative control = 100% viability) was added to the cells followed by 72 hours of incubation. 
Cells were washed with PBS, 100 μL MTT working solution was added and incubated for 2.5 hours. Finally, the 
formed purple formazan crystals were dissolved in 50 μL of DMSO. Absorbance was determined at 590 nm using an 
EnVision Multilabel plate reader. The absorbance of the positive control was used as blank and therefore 
subtracted from all values. 
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Figure S1. Size exclusion chromatography (SEC)-elugram of PGS. 
 
 
Figure S2. Digital photographs PGS nanoparticles (B), PTX/PGS nanoparticles (C) and pure PTX formulated in H2O (D), compared 
with pure H2O (A).   
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Figure S3. Digital photographs PGS nanoparticles (B), PTX/PGS nanoparticles (C) and pure PTX formulated in physiological 
glucose solution (i.e. dextrose 5 %) (D), compared with pure dextrose 5 % (A). 
 
 
Figure S4. Size (A) and 48-hour stability (B) of PGS and PGS/PTX nanoparticles in dextrose 5 %, measured by DLS at 25 °C. 
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Figure S5. Size distribution (intensity) of PGS/FLU nanoparticles measured by DLS. 
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abstract 
Low solubility of potent (anti-cancer) drugs is a major driving force for the development of non-cytotoxic, 
stimuli-responsive nanocarriers, including systems based on amphiphilic block copolymers. In this regard, we 
investigated the potential of block copolymers based on 2-hydroxyethyl acrylate (HEA) and the acid-sensitive 
ketal-containing monomer (2,2-dimethyl-1,3-dioxolane-4-yl)methyl acrylate (DMDMA) to form responsive drug 
nanocarriers. Block copolymers were successfully synthesized by sequential reversible addition-fragmentation 
chain transfer (RAFT) polymerization, in which we combined a hydrophilic poly(HEA)x block with a (responsive) 
hydrophobic poly(HEAm-co-DMDMAn)y copolymer block. The DMDMA content of the hydrophobic block was 
systematically varied to investigate the influence of polymer design on physico-chemical properties and in vitro 
biological performance. We found that a DMDMA content higher than 11 mol% is required for self-assembly 
behavior in aqueous medium. All particles showed colloidal stability in PBS at 37 °C for at least 4 days, with sizes 
ranging from 23 to 338 nm, proportional to the block copolymer DMDMA content. Under acidic conditions, the 
nanoparticles decomposed into soluble unimers, of which the decomposition rate was inversely proportional to the 
block copolymer DMDMA content. Flow cytometry and confocal microscopy showed dose-dependent, active in vitro 
cellular uptake of the particles loaded with hydrophobic octadecyl rhodamine B chloride (R18). The block 
copolymers showed no intrinsic in vitro cytotoxicity whilst loaded with paclitaxel (PTX) a significant decrease in 
cell viability was observed comparable or better than the two commercial PTX nanoformulations Abraxane and 
Genexol-PM at equal PTX dose. This systematic approach evaluated and showed the potential of these block 
copolymers as nanocarriers for hydrophobic drugs.   
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1 introduction 
Even though anti-neoplastic compounds with remarkable potential were already discovered half a century 
ago, poor solubility in aqueous medium still hampers widespread clinical use.[1],[2] With a solubility of merely 0.3 
μg/mL, paclitaxel (PTX) in particular is considered as extremely hydrophobic.[3] PTX is an important anti-cancer 
drug, known for inhibiting cell replication by blocking microtubuli depolymerization during the late G2/M phase of 
the cell cycle. It has shown activity against several cancer types including ovarian, lung, breast, bladder, neck and 
AIDS-related Kaposi’s sarcoma.[4],[5] The clinically used PTX formulation, i.e. Taxol, involves a 50:50 
ethanol:Cremophor EL co-solvent mixture to enhance PTX solubility and allow systemic administration of a 
therapeutic relevant dose. However, severe side effects including anaphylactoid hypersensitivity reactions, 
hyperlipidaemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy have been 
associated with Cremophor EL upon intravenous administration.[6] To avoid hypersensitivity, patients are pretreated 
with corticosteroids and antihistamines which in turn further complicates therapy and quality of life.[7] 
Poor solubility and non-specific pharmacodynamics of conventional chemotherapeutics have strongly 
contributed to an exponentially growing interest for advanced chemotherapy through nanoscale drug delivery 
systems.[8],[9] Important assets have been ascribed to nanomedicines.[10],[11] First, the use of alternative carriers can 
eliminate toxicity of excipients. Second, due to leaky vasculature and impaired lymphatic drainage, solid tumors 
have the tendency to retain nanoparticles especially when their size is between 10 and 200 nm.[12] This so-called 
enhanced permeability and retention (EPR) effect, along with prolonged circulation time, induced by the stealth 
corona on the surface of the nanoparticles as well as by reduced renal clearance, can lower the effective dose.[13],[14] 
Third, drug solubility can dramatically be increased by encapsulation into hydrophobic compartments of 
nanovehicles. These assets have partly been confirmed in the clinic for Abraxane, an FDA-approved 130 nm albumin 
stabilized (crystalline) paclitaxel formulation which is administered intravenously.[15] Compared to Taxol, it has 
reduced systemic toxicity and increased efficacy against several cancer types.[16] However, the manufacturing of 
nanocarriers containing recombinant proteins (i.e. human serum albumin in case of Abraxane) remains a costly 
process.[17] 
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Abbreviations: PDLLA, poly(D,L-lactide); PAPB, poly(aspartic acid) modified with 4-phenyl-butanol; PGlu, poly(glutamic acid); 
PAsp, poly(aspartic acid); PLGA, poly(D,L-lactic-co-glycolic acid); PTX, paclitaxel; SN-83, 7-ethyl-10-hydroxy-camptothecin; 
DOX, doxorubicin 
a Approved in South Korea in 2007. 
 
Fully synthetic supramolecular polymeric nanostructures form a sound alternative for controlled drug 
delivery.[18] In particular nanoparticles composed of amphiphilic block copolymers (e.g. micelles, nanospheres and 
polymerosomes) have attracted increasing attention owing to their unique features such as small size, high water-
solubility, stability in the blood stream and high drug loading capacity and their general in vitro and in vivo 
tolerance.[19],[20],[21] In addition, amphiphilic block copolymers can be tailored in terms of responsiveness to stimuli 
such as temperature, pH, enzymes, oxidation/reduction etc… , allowing straightforward formulation strategies, 
selective drug release upon cellular uptake and degradation in a biological medium.[22],[23],[24],[25],[26] Finally, the 
opportunity to engineer drug nanocarriers with targeting moieties enables active tumor targeting which can be 
crucial in treating metastatic cancer.[27],[28] 
Amphiphilic block copolymers can be solid candidates for anti-cancer drug delivery, as several types 
already made it into clinical trials (Table 1).[29],[30],[31],[32],[33] Due to the promising potential of this technology, 
elaborate research has been conducted the last decade to further fine-tune block copolymer properties. In this 
way, various pH- and temperature responsive block copolymer systems have been reported in literature.[34],[35],[36],[37] 
The most widely described temperature-responsive polymeric systems are based on poly(N-isopropyl acrylamide) 
(PNIPAM), poly(oligo(ethylene glycol) (meth)acrylate) (OEG(M)A) or poly(2-oxazoline) (POx) which exhibit a lower 
Table 1. Block copolymer anti-cancer drug delivery systems in clinical trial. 
formulation block polymer type diameter drug progress 
Genexol-PM mPEG-PDLLA < 50 nm PTX phase IIa 
NK-105 PEG-PAPB 85 nm PTX phase II 
NK-012 PEG-PGlu-SN-38 
conjugate 
20 nm SN-38 phase II 
NK-911 PEG-PAsp-DOX 
conjugate 
40 nm DOX phase II 
NC-6004 PEG-PGlu 30 nm cisplatin phase I/II 
NC-4016 PEG-PGlu 40 nm oxaliplatin phase I 
BIND-014 PEG-PDLLA/PEG-PLGA 100 nm docetaxel phase I 
SP-1049C Pluronic L61, F127 30 nm DOX phase III 
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critical solution temperature (LCST) within the physiological relevant range in aqueous medium.[38],[39],[40],[41] 
Reversible pH-sensitive systems have been developed using functional moieties of which the hydrophobicity is 
altered by protonation and deprotonation (e.g. tertiary amino groups).[42] In this way, Armes and co-workers 
reported on pH-sensitive vesicles based on a 2-(methacryloyloxy)ethyl phosphorylcholine (MPC) and 2-
(diisopropylamino)ethyl methacrylate (DPA) diblock copolymer.[42] This system forms vesicles at pH > 6 and 
dissolves at lower pH values due to protonation of DPA, inducing a fast release of payload. A possible risk, however, 
of such reversible systems is bioaccumulation as re-self-assembly can occur when the polymers exit acidic 
organelles (i.e. endosomes and lysosomes). This can be circumvented by using functional groups which irreversibly 
switch into hydrophilic moieties under acidic conditions. Next to imines, hydrazides, hydrazones, orthoesters and 
oximes, ketals are of particular interest due to their non-cytotoxic nature.[43],[44],[45],[46],[47],[48] Several pH-sensitive 
ketal-based polymeric structures have been reported (e.g. micelles and microparticles).[49],[50] The irreversible 
hydrolysis of ketals at pH < 5 allows endosomal (pH 4 – 5.5) degradation and drug release. Furthermore, 
irreversible hydrolysis leads to fully soluble polymeric degradation products which should afford better (renal) 
clearance from the body.[51] 
Reversible addition-fragmentation chain transfer (RAFT) polymerization has proven to be a powerful 
technique for the preparation of well-defined amphiphilic block copolymers.[52],[53],[54] Compared to other controlled 
radical polymerizations (CRP) such as nitroxide-mediated polymerization (NMP) and atom transfer radical 
polymerization (ATRP), RAFT polymerization excels in its versatility.[55],[56],[57] A wide variety of (functional) 
monomers can be prepared by RAFT polymerization in different solvents under mild reaction conditions. Finally, the 
technique’ s high end-group fidelity at reasonably high conversion (80 %) offers the opportunity for pre- and post-
functionalization, e.g. with cell receptor specific targeting ligands and proteins.[58],[59],[60] Recently, we have reported 
on the RAFT copolymerization of (2,2-dimethyl-1,3-dioxolane-4-yl)methyl acrylate (DMDMA), a monomer containing 
a ketal functional group, with either methoxy tri(ethylene glycol) acrylate (mTEGA) or 2-hydroxyethyl acrylate 
(HEA).[61],[62] These copolymers proved to exhibit LCST behavior which can be tailored by varying the DMDMA feed 
ratio. The copolymers degraded into fully soluble unimers under acidic conditions and furthermore showed 
promising in vitro cytocompatibility. When using HEA as co-monomer, a significantly faster degradation rate was 
witnessed. This can be ascribed to the higher exposure of the DMDMA units to the acidic aqueous medium in 
copolymers with HEA, whereas DMDMA units are more shielded from exposure to the aqueous environment in 
copolymers with the more bulky mTEGA monomer. 
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Figure 1. Self-assembly behavior, loading strategy (solvent displacement) and acid-triggered degradation of responsive 
poly(HEA)x-b-poly(HEAm-co-DMDMAn)y block copolymer drug nanocarriers. 
 
In this paper we report on the synthesis of responsive acid-degradable block copolymers based on HEA 
and DMDMA by RAFT polymerization, using a macroCTA (macro chain transfer agent) approach, to exploit the faster 
degradation of these copolymers.[63] The general block copolymer structure consists of a hydrophilic poly(HEA)x 
block and a (responsive) hydrophobic poly(HEAm-co-DMDMAn)y block, as shown in Figure 1. The main focus of this 
study was to systematically examine the influence of polymer design on self-assembly behavior, physico-chemical 
properties (critical aggregation concentration (CAC), colloidal stability and pH-responsive behavior), drug loading 
properties and in vitro biological performance by varying the DMDMA content of the hydrophobic block. The applied 
loading strategy (solvent displacement) is shown in Figure 1, along with the rationale for acidic DMDMA hydrolysis. 
The latter involves the change of the hydrophobic ketal functional group into a hydrophilic glycerol moiety 
inducing supramolecular disassembly and release of payload, as the hydrophobic block gradually turns hydrophilic. 
In this way, we systematically evaluated the potential of these block copolymers for their use as nanocarrier for 
PTX as hydrophobic anti-cancer drug. 
  
degradable ketal-based bock copolymer nanoparticles 
 
61 
2 results and discussion 
2.1 synthesis poly(HEA)x macroCTA 
Amphiphilic block copolymers were prepared by sequential RAFT polymerization, starting with the 
synthesis of poly(2-hydroxyethylacrylate) (poly(HEA)x). This polymer serves as hydrophilic polymer block and is 
subsequently used as macroCTA for chain extension with a second responsive block consisting of both HEA as 
hydrophilic monomer and DMDMA as hydrophobic acid-degradable ketal monomer (Scheme 1A). Synthesis of 
poly(HEA)x was terminated at 70 % conversion as determined by GC. SEC analysis in DMA showed a number average 
molecular weight (Mn) of 12.8 kDa and a dispersity (Ð) of 1.11. No significant low or high molecular weight shoulders 
could be observed on the SEC trace (Figure S1), indicating the formation of a well-defined polymer. The latter is 
necessary for further use as macroCTA for subsequent block copolymerization. 
 
 
Scheme 1. Synthesis of (A) poly(HEA)x macroCTA and (B) poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. HEA and DMDMA are depicted 
in blue and red, respectively.  
 
2.2 synthesis and characterization poly(HEA)x-b-poly(HEAm-co-DMDMAn)y 
To allow for a systematic investigation on how the HEA:DMDMA feed ratio of the second block influences 
the structural block copolymer composition and properties, we used an automated synthesis robot. The advantage 
of this approach is, next to the obviously improved time efficiency, the reduced inter-experiment variability as well 
as the ability to automatically withdraw samples during the polymerizations to study their kinetics. The poly(HEA)x 
macroCTA was used as hydrophilic block to which five different HEA:DMDMA molar feed ratios (40:10, 30:20, 25:25, 
20:30, 10:40) were added to form a hydrophobic, responsive second block (Scheme 1B). In addition to triple 
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precipitation, the polymers were further purified by extensive dialysis to remove any residual solvent and 
monomer, as the latter two can influence in vitro cell culture experiments. Note that we did not synthesize block 
copolymers with a fully DMDMA-based hydrophobic block as preliminary experiments showed such block 
copolymers to form macroscopic aggregates in aqueous medium. 
 
  
Figure 2. First order kinetic plots for the copolymerization of HEA (blue) and DMDMA (red) using the poly(HEA)x macroCTA 
resulting in poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. 
 
Kinetic samples of the copolymerization reactions were analyzed by GC and SEC (SEC traces are shown in 
Figure S2) to determine the evolution of monomer conversion and the resulting polymer molar mass (distribution) 
in time. Initially, a linear increase of Ln([M]0/[M]t) as function of reaction time is observed for both HEA and DMDMA 
(Figure 2). After nearly complete consumption of HEA, the polymerization rate for DMDMA decreases indicating that 
the HEA chain end is more reactive towards DMDMA than the DMDMA chain end. The lower reactivity of DMDMA 
might be related to its bulkier side chain. The copolymerization behavior of HEA and DMDMA was also evaluated by 
determination of the reactivity ratios by non-linear least square fitting of the incorporated HEA mol fraction (fHEA) 
versus the theoretical HEA mol fraction (FHEA) using the Contour software.[71] As the copolymerization with 10:40 
HEA:DMDMA ratio was so fast that only one data point for HEA was obtained at Ln([M]0/[M]t) corresponding to 60% 
conversion, this copolymerization was not included in the fit. Furthermore, to exclude effects of equilibration of the 
RAFT polymerization process, fHEA was determined at ~30 % conversion of HEA based on the GC kinetic data. The 
resulting reactivity ratios are rHEA =1.07 ±0.09 and rDMDMA = 0.62 ± 0.07, whereby it should be noted that these values 
are rough estimates as they are only based on four data points (FHEA = 0.4, 0.5, 0.6 and 0.8 with fHEA = 0.472, 0.557, 
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0.650 and 0.822, respectively). These reactivity ratios imply that the composition of the poly(HEAm-co-DMDMAn)y 
block gradually changes from being HEA rich to being DMDMA rich. This is schematically illustrated based on the 
calculated monomer distributions for the synthesized block copolymers by regression analysis of the GC kinetics 
(Figure 3). Furthermore, SEC analysis shows a linear increase of Mn with conversion and a narrow Ð indicating good 
control over the polymerization (Figure 4). The composition of the different bock copolymers is listed in Table 2. For 
each block copolymer, a clear similarity is observed between the overall DMDMA composition when calculated from 
GC and 1H-NMR spectroscopy data. 1H-NMR spectra with peak integrations are shown in Figure S3 ? S7 for P1 ? 
P5. 
 
Figure 3. Average monomer distributions, calculated by regression analysis of the conversion versus time data, for the 
synthesized poly(HEA)x-b-poly(HEAm-co-DMDMAn)y block copolymers. The blue and red dots represent HEA and DMDMA, 
respectively. 
 
Table 2. Compositional data for the synthesized polymers. 
polymer [HEA]0/ 
[CTA] 
conversion 
HEA (%)a 
 [HEA]0/ 
[mCTA*] 
conversion 
HEA (%)a 
[DMDMA]0/ 
[mCTA*] 
conversion 
DMDMA 
(%)a 
mol% 
DMDMAb 
mol% 
DMDMAc 
Mn 
(kDa)d 
Ðd 
 hydrophilic block  responsive block     
mCTA* 50 70  - - - - - - 12.8 1.11 
P1 50 70  40 100 10 89 11 12 26.6 1.22 
P2 50 70  30 100 20 87 21 24 24.7 1.20 
P3 50 70  25 100 25 90 27 27 26.2 1.21 
P4 50 70  20 100 30 89 33 32 25.7 1.20 
P5 50 70  10 100 40 91 45 39 24.3 1.20 
a Calculated by GC using DMF as internal standard. b Overall DMDMA composition calculated by GC. c Overall DMDMA 
composition determined by 1H-NMR spectroscopy. d Analyzed by SEC. * mCTA = macroCTA  
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Figure 4. Mn and Ð (determined by SEC) plots as function of theoretical Mn (based on GC) for the kinetic study for the synthesis 
of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. 
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2.3 self-assembly and temperature-responsive behavior in aqueous medium 
To investigate the influence of the DMDMA content on the self-assembly behavior and temperature-
responsive properties, the block copolymers were dispersed (concentration 5 mg/mL) in cold phosphate buffered 
saline (PBS, pH 7.4, 150 mM NaCl) and subsequently measured by dynamic light scattering (DLS) at different 
temperatures (5, 20 and 37 °C). Normalized intensity and corresponding volume size distribution histograms of the 
particles, measured at increasing temperatures (5, 20 and 37 °C), are shown in Figure 5A. The corresponding Z-
Average hydrodynamic diameter and polydispersity (PDI) are plotted in Figure 5B as function of temperature and 
the DMDMA content of the poly(HEA)x-b-poly(HEAm-co-DMDMAn)y block copolymers (Table 2). A bimodal intensity 
size distribution is observed for the block copolymer with the lowest DMDMA content (i.e. 11 mol%, P1). The highest 
intensity is observed for a distribution with a size around 4 nm, representing soluble unimers. Furthermore, loose 
aggregates (60 – 300 nm) are detected, as often observed for thermoresponsive polymers.[72],[73],[74] However, the 
fraction of aggregates for P1 is limited, as the latter is not observed in the corresponding the volume size 
distribution of P1 (Figure 5A). The graphs show that the DMDMA content drastically affects the particle size. A larger 
particle diameter is measured with increasing DMDMA content. P2 , P3 and P4 (containing 21, 27 and 33 mol% 
DMDMA, respectively) likely form micelles, whereas P5 (45 mol% DMDMA) forms larger assemblies. This trend is in 
line with the expectations as in aqueous medium, hydrophobic molecules are more likely to interact mutually than 
with water instead, therefore generating larger assemblies. 
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Figure 5. (A) Intensity size 
distribution histograms of 
poly(HEA)x-b-poly(HEAm-co-
DMDMAn)y (left panel), measured 
at different temperatures (5, 20 
and 37 °C) by DLS. * The bimodal 
intensity size distribution of P1 
shows a fraction of large 
particles. However, this fraction 
is very little and most likely 
associated to loose aggregates 
as it is not observed in the 
corresponding volume size 
distribution of the polymer (right 
panel). (B) Z-Average 
hydrodynamic diameter and PDI 
as function of DMDMA content of 
poly(HEA)x-b-poly(HEAm-co-
DMDMAn)y (5 mg/mL), measured 
at 5, 20 and 37 °C by DLS (n = 3). 
Note that, due to the bimodal 
intensity size distribution and 
unimer state of P1, the 
corresponding values for Z-
Average hydrodynamic diameter 
and PDI are of little relevance. 
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The block copolymers with 21, 27 and 33 mol% DMDMA (P2, P3 and P4, respectively) show an increase in 
particle size upon increasing temperature, indicating the temperature-responsive behavior of these polymers. This 
influence of temperature was not unexpected, as our previously reported poly(mTEGAm-co-DMDMAn)y and 
poly(HEAm-co-DMDMAn)y copolymers exhibited similar LCST behavior.[61],[62] On the other hand, temperature exerted 
minimal effect on the block copolymers with the lowest (11 mol%, P1) and highest (45 mol%, P5) DMDMA content 
which form either mainly soluble unimers (P1) or larger aggregates (P5), respectively, with constant size 
irrespective of temperature. Note that the observed trends in particle size are not due to time-dependent 
aggregation as the nanoparticle size remained constant over at least 4 days as shown further on in this paper 
(Figure 7). The values for Z-Average hydrodynamic diameter and PDI against temperature are summarized for all 
block copolymers in Table 3. Note that a relatively low PDI is observed for all samples except for P1, due to its 
bimodal intensity size distribution. 
 
2.4 critical aggregation concentration (CAC) 
To compare the minimally required polymer concentration in aqueous medium for self-assembly of the 
different block copolymers, the excitation intensity ratio of pyrene at 338 nm (I3) and 333 nm (I1) was plotted 
versus the concentration of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y in PBS at 20 °C (Figure 6A). The subsequent 
calculated CACs are shown in Table 3 and Figure 6B (see Figure S8 for CAC fitting parameters of each block 
copolymer individually). The CAC of the block copolymers decreased from 241 to 10 μg/mL with increasing DMDMA 
content from 11 (P1) to 45 (P5) mol%. Increasing hydrophobicity contributes to lowering of CAC because of more 
pronounced hydrophobic interactions. The observation that P1 does show a relatively high CAC although DLS does 
not show extensive particle formation (Figure 5A and 7), indicates that the presence of DMDMA does allow for a 
certain extent of hydrophobic interaction between pyrene and P1, possibly related to hydrophobic interactions 
occurring within the unimers or the loose aggregates. Similar observations were made by others, e.g. Hennink and 
co-workers observed that addition of PTX from ethanol to an aqueous solution containing a temperature-
responsive polymer below its phase transition temperature did not lead to immediate precipitation of PTX.[4] This 
behavior was ascribed to hydrophobic interaction between PTX and hydrophobic repeating units in the polymer 
backbone. 
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Figure 6. (A) Intensity ratio of pyrene at 338 nm (I3) and 333 nm (I1) as function of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y 
concentration, determined by fluorescence spectrophotometry at 20 °C (n = 2). (B) CAC of poly(HEA)x-b-poly(HEAm-co-
DMDMAn)y at 20 °C as function of DMDMA content (n = 2). 
 
Table 3. Supramolecular characteristics of synthesized block copolymers. 
polymer mol% DMDMAa Z-Average 
(nm)b 
PDIb Z-Average 
(nm)b 
PDIb Z-Average 
(nm)b 
PDIb CAC (μg/mL)c 
  5 °C 20 °C 37 °C  
P1 11 8.9 ± 0.4 
0.61 ± 
0.02 
11.4 ± 1.8 
0.56 ± 
0.09 
13.4 ± 1.0 
0.49 ± 
0.04 
241 ± 15 
P2 21 14.4 ± 0.1 
0.22 ± 
0.01 
21.7 ± 3.4 
0.13 ± 
0.08 
23.3 ± 0.5 
0.05 ± 
0.01 
84 ± 4 
P3 27 19.6 ± 0.6 
0.10 ± 
0.03 
24.4 ± 1.2 
0.07 ± 
0.04 
52.7 ± 0.1 
0.16 ± 
0.01 
31 ± 1 
P4 33 27.0 ± 0.8 
0.20 ± 
0.01 
35.8 ± 5.0 
0.12 ± 
0.01 
100.4 ± 0.6 
0.24 ± 
0.01 
14 ± 1 
P5 45 276.5 ± 5.3 
0.32 ± 
0.03 
283.6 ± 
68.2 
0.26 ± 
0.03 
337.7 ± 6.1 
0.23 ± 
0.05 
10 ± 1 
a Overall DMDMA composition based on GC data. b Numeric values for Z-Average hydrodynamic diameter and PDI of 
poly(HEA)x-b-poly(HEAm-co-DMDMAn)y, measured at 5, 20 and 37 °C (n = 3) by DLS. c CAC at 20 °C (n = 2). 
  
0.1 1 10 100 1000 10000
0.0
0.5
1.0
1.5
11 mol% - P1
21 mol% - P2
27 mol% - P3
33 mol% - P4
45 mol% - P5
DMDMA content:
Conc (μg/mL)
I ex
 3
38
nm
 / 
I ex
 3
33
nm
5 15 25 35 45
0
100
200
300
DMDMA content (mol%)
C
AC
 (μ
g/
m
L)
degradable ketal-based bock copolymer nanoparticles 
 
69 
2.5 in vitro stability and pH-responsive behavior 
At first, we aimed at investigating the colloidal stability of the block copolymer assemblies at pH 7.4 and 
gaining proof-of-concept for the acidic hydrolysis of the DMDMA repeating units (Figure 1). To examine whether the 
poly(HEA)x-b-poly(HEAm-co-DMDMAn)y nanoparticles are stable when dispersed in PBS or show aggregation over 
time, the block copolymer assemblies in PBS (see section 2.3) were measured over 4 days at 37 °C by DLS. 
Measurements were performed in triplicate. As shown in Figure 7, all nanoparticles remained stable at pH 7.4 for at 
least 4 days. Particle stability at physiological pH is essential to avoid premature drug release before the 
nanoparticles are internalized by cells. 
On day 4, HCl was added to obtain a HCl concentration of 100 mM (pH 1). To examine the effect on the 
potential acidic hydrolysis of the ketal groups in the block copolymer side chains, the Z-Average hydrodynamic 
diameter, light scattering intensity and size volume distribution profiles were monitored by DLS. As shown in Figure 
7, all block copolymer dispersions, except the block copolymer with 11 mol% DMDMA (P1), exhibit a gradual decrease 
in Z-Average diameter, light scattering intensity and volume size distribution. The reason that this is not observed 
for P1 can be ascribed to the unimer state of this polymer which won’t be affected by hydrolysis of its ketal 
moieties. The reason that often a bimodal distribution emerges during degradation is likely to be attributed to the 
inherent dynamic nature of block copolymer micelles, especially when their thermodynamic equilibrium is shifting 
due to hydrolysis of the DMDMA repeating units. The general decrease in size and scattering intensity suggests that 
in acidic medium, hydrolysis of the ketal groups effectively leads to decomposition of the block copolymer 
nanoparticles into soluble unimers. The latter is confirmed by 1H-NMR spectroscopy (Figure 8) showing complete 
absence of the ketal groups for the block copolymer with 21 mol% DMDMA (P2) after hydrolysis. Similar 
observations were done for the block copolymer with 45 mol% DMDMA (P5) (Figure S9). Interestingly, from the 
evolution of the Z-average diameter and the scattering intensity as function of time, one can observe that the rate 
of hydrolysis depends on the DMDMA content, with hydrolysis being significantly slower as the hydrophobic 
poly(HEAm-co-DMDMAn)y copolymer block contains more DMDMA repeating units and gradient structure. This slower 
hydrolysis can be ascribed to the stronger hydrophobic interactions within the polymers with higher DMDMA 
content, leading to stronger dehydration of the hydrophobic core domains and thereby decreased contact with HCl. 
Furthermore, a larger extent of DMDMA units needs to be hydrolyzed for the more hydrophobic block copolymers to 
render them hydrophilic enough for disassembly of the self-assembled structures. 
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2.6 in vitro cellular uptake 
Next, we investigated the potential of the block copolymers for intracellular delivery of a hydrophobic 
payload. For this purpose we used the SKOV-3 human ovarian cancer cell line. Block copolymer nanoparticles were 
loaded with octadecyl rhodamine B chloride (R18), a fluorescent dye suitable for staining embedded hydrophobic 
moieties (Figure S10).[75] The encapsulation was performed by adding a R18 stock solution in ethanol to a block 
copolymer dispersion (10 mg/mL) in PBS at a 1:10 volume ratio under stirring. R18 in pure PBS was used as a control. 
Subsequently, cellular uptake of the samples was assessed by flow cytometry (FACS) and confocal microscopy. 
Flow cytometry shows a dose-dependent increase in fluorescence (Figure 9A) and percentage of 
rhodamine positive cells (Figure 9B) for all poly(HEA)x-b-poly(HEAm-co-DMDMAn)y nanoparticles, whereas no 
difference is observed between blank cells and cells pulsed with R18 in PBS. The latter indicates that the 
hydrophobic dye needs to be encapsulated in order to be internalized by cells. Earlier in this paper it was already 
shown that a 5 mg/mL dispersion in PBS of the block copolymer with 11 mol% DMDMA (P1) mainly consisted out of 
soluble unimers. This in turn explains why the R18-labeled formulation of P1 shows significantly lower cellular 
uptake compared to the other block copolymer formulations at the same concentration. 
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Figure 7. (Left panels) Z-Average diameter and light scattering intensity of the block copolymers as function of time, 
measured at 37 °C by DLS. The block copolymers were measured over 4 days in PBS (n = 3) after which HCl was added to 
obtain a HCl concentration of 100 mM (pH 1). (Right panels) Corresponding volume distribution histograms. 
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Figure 8. 1H-NMR spectrum of P2 (21 mol% DMDMA) before (red) and after (blue) hydrolysis. Note the absence of the ketal 
functional group after hydrolysis. 
 
Confocal microscopy was used to investigate the intracellular fate of the block copolymer nanoparticles in 
more detail. In particular confocal microscopy allows distinguishing between internalized and cell membrane 
bound nanoparticles. Fixed SKOV-3 cells were pulsed with Hoechst and Alexa Fluor 647 Phalloidin to stain the cell 
nuclei and the actin filaments, respectively. As shown in maximized intensity projections (MIPs) (Figure 10), cellular 
uptake of R18-loaded particles (depicted in red) is observed for all block copolymers except P1. The latter was 
similar to the blank which is in line with previous experiments showing absence of particle formation for this block 
copolymer. To further elucidate the intracellular fate of the observed nanoparticles, live SKOV-3 cells were stained 
with LysoTracker Deep Red. This is a fluorescent acidotropic probe, selectively accumulating in acidic organelles of 
live cells, e.g. endosomes and lysosomes. Presence of fluorescent nanoparticles in these organelles is confirmed by 
colocalization between red and green fluorescence (Figure 11), suggesting active intracellular uptake of the 
nanoparticles.[76] 
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Figure 9. (A) Histograms of SKOV-3 cells, incubated for 24 hours with 0.01, 0.1 and 1 mg/mL of R18-loaded poly(HEA)x-b-
poly(HEAm-co-DMDMAn)y. (B) Corresponding percentage rhodamine + cells (n = 2). 
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Figure 10. Maximized intensity projections (MIPs) of SKOV-3 cells, incubated for 24 hours with R18-loaded poly(HEA)x-b-
poly(HEAm-co-DMDMAn)y (red). Cell nuclei and actin filaments are depicted in blue and green, respectively. Note that the Alexa 
Fluor 647 Phalloidin staining was performed without permeabilizing the cells to obtain a more selective staining of actin 
neighboring the cell membrane. 
 
2.7 drug loading 
To further explore the potential of the poly(HEA)x-b-poly(HEAm-co-DMDMAn)y block copolymers for 
intracellular delivery of hydrophobic drugs, we used PTX as hydrophobic anti-cancer drug. Similar to R18 
encapsulation, PTX-loading was performed by addition of a PTX solution in ethanol (5 mg/mL) to a block copolymer 
dispersion (10 mg/mL) with a 1:10 volume ratio. Unloaded drug can easily be eliminated by membrane filtration as 
PTX precipitates in aqueous medium due to its limited solubility (0.3 μg/mL). 
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Figure 11. Confocal microscopy images of SKOV-3 cells, incubated for 24 hours with R18-loaded poly(HEA)x-b-poly(HEAm-co-
DMDMAn)y (red). LysoTracker Deep Red was used for acidic organelle staining (green; note that this color was assigned for the 
sake of clarity and to allow rhodamine being assigned the red color). Colocalization of nanoparticles with these organelles 
(white) was analyzed using the colocalization function in the Imaris software package. Right panel: overlay of R18-loaded 
nanoparticles and acidic organelles with the corresponding differential interference contrast (DIC) image. The observed 
yellow color in the overlay panel also indicates colocalization. 
 
The concentration of PTX in the samples after filtration was measured by LC-MS. As shown in Figure 12A, 4 
out of 5 block copolymers solubilized significantly higher amounts of PTX than pure water. The block copolymer 
with 11 mol% DMDMA (P1) was not able to encapsulate PTX, fully in line with the observations of the previous DLS, 
CAC and FACS experiments. The almost identical structural composition of the block copolymers with 27 (P3) and 33 
(P4) mol% DMDMA (Figure 3) probably results in comparable interaction with PTX and therefore similar PTX 
solubility. Nanoparticles of the block copolymer with 45 mol% DMDMA (P5) did not encapsulate higher 
concentrations of PTX compared to block copolymers with 27 (P3) or 33 (P4) mol% DMDMA. This can be explained 
based on the size distribution histograms of the block copolymer at 20 °C (Figure 5A). This shows that a significant 
amount of particles is larger than 450 nm which could have been removed during membrane filtration (0.450 μm). 
A similar trend is observed in Figure 12B for the calculated encapsulation efficiencies (EE) and loading capacities 
(LC), defined in section 4.9. DLS analysis of the PTX-loaded block copolymer nanoparticles showed no significant 
change in size compared to empty nanoparticles (data not shown). 
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Figure 12. (A) Concentration of PTX, encapsulated by poly(HEA)x-b-poly(HEAm-co-DMDMAn)y, measured by LC-MS (n = 5). (B) 
Calculated encapsulation efficiency (EE) and loading capacity (LC) of PTX-loaded poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. *** 
Student’s t-test: p < 0.001. 
 
2.8 in vitro cytotoxicity 
The in vitro cytotoxicity of empty and paclitaxel loaded poly(HEA)x-b-poly(HEAm-co-DMDMAn)y 
nanoparticles was evaluated on SKOV-3 cells via MTT assay. Abraxane and Genexol-PM were included for 
comparison. Abraxane is a formulation of albumin stabilized PTX nanocrystals, whilst Genexol-PM consists of PTX-
loaded polymeric micelles based on monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-b-
PDLLA).[77] An incubation period of 72 hours was used to evaluate the known inhibitory effect of PTX on (cancer) cell 
proliferation. According to ISO 10993-5, cell viability below 70 % in comparison to negative control indicates 
cytotoxicity. 
As shown in Figure 13A, no significant intrinsic cytotoxic effect can be ascribed to any of the block 
copolymers at concentrations up to 1 mg/mL. The formation of acetone (Figure 1) upon hydrolysis of the ketal 
moieties does not seem to affect the cell viability. This suggests that the synthesized block copolymers are 
cytocompatible, at least within the presently applied experimental setting. Significant in vitro cytotoxicity was 
observed for block copolymer formulations with PTX concentrations ranging from 0.01 to 10 μg/mL (Figure 13B). The 
cytotoxic effect was comparable or, in the case of PTX concentrations of 0.1 and 0.01 μg/mL, more potent than 
Abraxane and Genexol-PM. Based on the determined CACs, the PTX formulations prepared from the block polymers 
with a DMDMA content > 11 mol% (section 2.4) were below their CAC at a PTX concentration of 0.1 μg/mL. The 
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formulation prepared from the 11 mol% DMDMA block copolymer (P1) was below CAC at a PTX concentration of 0.01 
μg/mL. Note that for the latter formulation, PTX concentrations of 10 and 1 μg/mL could not be obtained. Taking CAC 
into account, along with the in vitro stability of the nanoparticles (section 2.5), the cytotoxic effect will likely be 
due to a combination of PTX which is efficiently solubilized in culture medium and PTX which is released after 
endocytosis by degradation of the DMDMA units. Future research will aim at elucidating the pH-induced release of 
the drug inside the complex intracellular medium and its relative contribution on PTX-induced cytotoxicity. 
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Figure 13. (A) In vitro cytotoxicity of unloaded poly(HEA)x-b-poly(HEAm-co-DMDMAn)y on SKOV-3 cells after 72 hours of 
incubation (n = 3). (B) In vitro cytotoxicity of PTX-loaded poly(HEA)x-b-poly(HEAm-co-DMDMAn)y on SKOV-3 cells after 72 hours 
of incubation (n = 3). Abraxane and Genexol-PM were used as control. * PTX well concentrations of 10 and 1 μg/mL could not be 
obtained for P1. *** Student’s t-test: p < 0.001.   
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3 conclusions 
Well-defined responsive poly(HEA)x-b-poly(HEAm-co-DMDMAn)y block copolymers were synthesized with 
good control by sequential RAFT polymerization. Kinetic studies revealed that the reactivity ratios for the 
HEA:DMDMA copolymerization of the second block are rHEA = 1.07 ± 0.09 and rDMDMA = 0.62 ± 0.07. We have shown 
that the DMDMA content strongly influences aqueous self-assembly behavior, CAC and stimuli-responsive 
properties. A content of > 11 mol% DMDMA is required to afford the formation of nanoparticles in aqueous medium. 
All particles proved to be stable in PBS at 37 °C for at least 4 days and turned fully water-soluble upon acid-
triggered hydrolysis. This should allow the polymers to be cleared from the body by renal filtration. Active cellular 
uptake was observed in vitro by flow cytometry and confocal microscopy. PTX could be loaded into the 
nanoparticles by solvent displacement, increasing PTX solubility in water by a factor of up to 650. Of these 
formulations, in vitro cytotoxicity comparable or better than 2 commercial PTX nanoformulations was observed, 
whilst empty particles did not induce any significant cytotoxic effect. 
Due to these promising preliminary in vitro results, our current investigations aim at further exploring 
ketal-based systems for the design of anti-cancer drug nanocarriers which could, owing to their small size (i.e. the 
most promising systems in this paper had a Z-Average hydrodynamic diameter around 20, 50 and 100 nm, 
respectively), penetrate deep into poorly vascularized metastatic tumor tissue. We will for example consider cross-
linking strategies to further lower the CAC. Additionally, we aim in the future at engineering the nanoparticle 
surface with ligands which afford active targeting of receptors which are overexpressed by ovarian cancer cells, 
such as the folate receptor alpha (FRα) and CD44 receptor.[78],[79],[80],[81] 
 
4 experimental 
4.1 materials 
All chemicals were purchased from Sigma Aldrich unless mentioned otherwise. The RAFT agent 2-
(butylthiocarbonothioylthio)propanoic acid (PABTC) and monomer (2,2-dimethyl-1,3-dioxolane-4-yl)methyl 
acrylate (DMDMA) were synthesized according to literature.[64],[65] Octadecyl Rhodamine B Chloride (R18), enzyme-
free Cell Dissociation Buffer, Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), L-glutamine, 
sodium pyruvate, penicillin, streptomycin, Hoechst, Alexa Fluor 647 Phalloidin and LysoTracker Deep Red were 
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obtained from Invitrogen. SKOV-3 cells were supplied by ATCC. Paclitaxel (PTX) was purchased from LC 
Laboratories. 
 
4.2 synthesis poly(HEA)x macroCTA 
The macroCTA was synthesized by RAFT homopolymerization of 2-hydroxyethyl acrylate (HEA). PABTC (2 
mmol, 0.476 g), 2, 2′-azoisobutyronitrile (AIBN) (0.2 mmol, 0.033 g) and HEA (100 mmol, 11.612 g) were dissolved in 
N,N-dimethylformamide (DMF) to obtain a monomer concentration of 2 M and a monomer:CTA:initiator molar ratio 
of 50:1:0.1. The solution was bubbled with argon for 15 minutes. The reaction was performed at 70 °C under inert 
atmosphere and the monomer conversion was monitored by gas chromatography (GC). The homopolymer was 
isolated by triple precipitation in cold (5 °C) diethyl ether and subsequently dried under high vacuum at room 
temperature. The homopolymer was analyzed by size exclusion chromatography (SEC). 
GC-samples were prepared by diluting 20 μL of polymerization mixture with 980 μL of methanol. GC was 
conducted on a 7890A system from Agilent Technologies equipped with an Agilent J&W Advanced Capillary GC 
column (30 m, 0.320 mm, and 0.25 μm). Injector and detector temperatures were kept constant at 250 and 280 °C, 
respectively. The column was initially set at 50 °C, followed by two heating stages: from 50 °C to 100 °C with a rate 
of 20 °C /min and from 100 °C to 300 °C with a rate of 40 °C /min, and then held at this temperature for 0.5 
minutes. Injections were performed with an Agilent Technologies 7693 auto sampler. Detection was done with a 
flame ionization detector. Conversion was determined based on the integration of monomer peaks using DMF as 
internal standard. 
SEC was carried out on an Agilent 1260 system, equipped with a 1260 ISO-pump, a 1260 diode array 
detector (DAD) and a 1260 refractive index detector (RID). Measurements were performed in DMA containing 50 
mM LiCl at 50°C, using a flow rate of 0.593 mL/min. A guard column and two PL gel 5 μm mixed-D columns were 
used in series, calibrated with poly(methyl methacrylate) standards. 
 
4.3 synthesis and characterization poly(HEA)x-b-poly(HEAm-co-DMDMAn)y 
The block copolymers were synthesized by RAFT copolymerization of HEA and DMDMA using the poly(HEA)x 
macroCTA described in section 4.2. A total of five block copolymers were synthesized for which the HEA:DMDMA 
molar feed ratio was 40:10, 30:20, 25:25, 20:30 and 10:40, respectively. All polymerizations were conducted within 
the same experimental setup using a Chemspeed ASW2000 automated synthesizer equipped with 16 parallel 
chapter 4 
 
80 
reactors of 13 mL, a Huber Petite Fleur thermostat for heating/cooling, a Huber Ministat 125 for reflux and a 
Vacuubrand PC 3000 vacuum pump.[66] 
Stock solutions (336.5 mg/mL macroCTA in DMF and 4.7 mg/mL AIBN in DMF) and monomers (HEA and 
DMDMA, neat) were bubbled with argon for 30 minutes before being introduced into the robot system and then 
kept under argon atmosphere. The hood of the automated synthesizer was continuously flushed with nitrogen and 
the reactors were flushed with argon to ensure an inert atmosphere. Prior to the polymerizations, the reactors 
were deoxygenated through ten vacuum-argon cycles. Stock solutions and monomers were transferred into the 
reactors using the liquid handling robot of the automated synthesizer. Each reactor eventually contained 
poly(HEA)x macroCTA (0.12 mmol, 0.514 g), AIBN (0.012 mmol, 2 mg) and 6 mmol of total monomer, dissolved in 
DMF to obtain a total monomer concentration of 1.8 M. The molar monomertotal:CTA:initiator ratio was 50:1:0.1. The 
reactions were run simultaneously at 70 °C. During the polymerizations, 50 μL samples were taken at preset time 
intervals for GC- and SEC-analysis. After the reactions, the block copolymers were purified by triple precipitation in 
cold diethyl ether and subsequent vacuum drying. Finally, all block copolymers were dialyzed (MWCO 3.5 kDa) for 4 
days against water at 5 °C and recollected after freeze-drying. 
The block copolymers were analyzed by SEC and 1H-NMR spectroscopy. 1H-NMR spectra were recorded on a 
Bruker 300 MHz FT-NMR spectrometer using chloroform-d or methanol-d4 as solvent. 
 
4.4 self-assembly and temperature-responsive behavior in aqueous medium 
Supramolecular and temperature-responsive self-assembly behavior in PBS was evaluated by dynamic 
light scattering (DLS). The block copolymers of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y (5 mg/mL) were sonicated for 
15 minutes in cold (5 °C) PBS to induce faster dispersion compared to sonication at room temperature. After 
sonication, the samples were kept on ice overnight to allow complete dispersion. Next, the samples were filtered 
(0.450 μm) and measured at different temperatures (5, 20 and 37 °C). Measurements were carried out on a 
Zetasizer Nano S (Malvern). 
  
degradable ketal-based bock copolymer nanoparticles 
 
81 
4.5 critical aggregation concentration (CAC) 
Similar to a described protocol, the CACs of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y were determined by 
fluorescence microscopy using pyrene as a fluorescent probe.[67],[68] First, 2.5 mL polymer dispersions in PBS were 
made according to section 4.4 with concentrations ranging from 0.001 to 1 mg/mL. Secondly, a 3.6 mg/mL (1.8 x 10-2 
M) stock solution of pyrene in acetone was prepared and kept on ice to prevent evaporation of the acetone. Next, 
10 μL of this solution was diluted to 1 mL acetone and kept on ice. To each polymer dispersion, 8.3 μL of the latter 
pyrene solution was added under stirring leading to a pyrene concentration of 6.0 x 10-7 M. Fluorescence excitation 
spectra were collected at 20 °C on a Cary Eclipse fluorescence spectrophotometer (Agilent Technologies) equipped 
with a Varian Cary Temperature Controller. The CAC was quantified based on the change in excitation intensity ratio 
at 338 and 333 nm with varying concentration. 
 
4.6 in vitro stability and pH-responsive behavior 
Dispersions (5 mg/mL) of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y were prepared as described in section 4.4. 
DLS measurements were conducted over 4 days at 37 °C. On day 4, HCl was added under vigorous stirring to obtain 
a HCl concentration of 100 mM (pH 1). Subsequently, size and light scattering intensity was monitored by DLS. After 
7 hours incubation at 37 °C, a sample was taken from the acidic polymer dispersion and subsequently freeze-dried. 
The freeze-dried product was analyzed by 1H-NMR spectroscopy, using methanol-d4 as solvent. 
 
4.7 cell culture 
SKOV-3 (human ovarian cancer cell line) cells were cultured in DMEM, supplemented with 10% FBS, 2 mM 
L-glutamine, 1 mM sodium pyruvate and antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin). Cells were 
incubated at 37 °C in an controlled, sterile environment of 95% relative humidity and 5% CO2. SKOV-3 cells were 
used for all cell experiments. 
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4.8 in vitro cellular uptake 
4.8.1 encapsulation octadecyl rhodamine B chloride (R18) 
A hydrophobic fluorescent dye (R18) was loaded into the nanoparticles using a solvent displacement 
technique. First, a 10 mg/mL stock solution of R18 in ethanol was prepared and kept on ice. Subsequently, 5 μL of 
this solution was diluted to 1 mL ethanol and kept on ice. Next, 1 mL of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y 
dispersions (10 mg/mL) were prepared in cold PBS according to section 4.4. Under stirring, 100 μL of the R18 
working solution was added to 1 mL of block copolymer dispersion. Formulations were stabilized overnight at room 
temperature with open lid to allow evaporation of the ethanol. Finally, excess dye was removed by membrane 
filtration (0.450 μm). Dilutions of 1 and 0.1 mg/mL block copolymer were prepared in PBS. In a similar way a PBS 
control sample was prepared by adding 100 μL of R18 working solution to 1 ml of pure PBS under stirring, followed 
by overnight incubation at room temperature. Precipitated dye was removed by filtration. 
 
4.8.2 FACS 
SKOV-3 cells were seeded into 24-well titer plates (250 000 cells per well, suspended in 0.9 mL of culture 
medium) and incubated overnight to allow cell sedimentation and subsequent adhesion to the bottom of the wells. 
Next, 100 μL of R18-labeled poly(HEA)x-b-poly(HEAm-co-DMDMAn)y (0.1, 1 or 10 mg/mL)/PBS control (section 4.8.1) 
was added to the cells (polymer concentration in well: 0.01, 0.1 or 1 mg/mL), followed by 24 hours of incubation to 
allow cellular uptake. After incubation, the wells were aspirated and washed with 1 mL of PBS. After subsequent 
aspiration of the wells, 500 μL of Cell Dissociation Buffer was added to the cells. The cells were completely 
detached from the wells after 15 minutes of incubation. The cell suspensions were transferred into Eppendorf 
tubes and immediately centrifuged (350 g, 15 minutes, 5 °C). Finally, the supernatant was aspirated and the cell 
pellets were suspended into 300 μL of PBS and kept on ice to maintain cell integrity. FACS was performed on a BD 
Accuri C6 (BD Biosciences). The data were processed by FlowJo software. 
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4.8.3 confocal microscopy 
First, a Hoechst stock solution of 1 mg/mL was prepared in dimethyl sulfoxide (DMSO). Alexa Fluor 647 
Phalloidin was dissolved in 1.5 mL of methanol to obtain a stock concentration of 6.6 μM. Of these stock solutions 6 
and 35 μL were added to 1.4 mL of PBS supplemented with 1 % bovine serum albumin (BSA), respectively. The 
commercial LysoTracker Deep Red 1 mM stock solution was diluted in culture medium to a working concentration 
of 60 nM. SKOV-3 cells were plated out on Willco-Dish glass bottom dishes (50 000 cells, suspended in 200 μL of 
culture medium) and incubated overnight. Next, 5 μL of 10 mg/mL R18-labeled poly(HEA)x-b-poly(HEAm-co-
DMDMAn)y (section 4.8.1) was added, followed by 24 hours of incubation. R18 in pure PBS, described in section 4.8.1, 
was used as blank. 
Simultaneous Hoechst and Alexa Fluor 647 Phalloidin staining was carried out on fixed cells. In summary, 
culture medium was aspirated and cells were washed with PBS. Next, 200 μL of 4 % paraformaldehyde was added 
and allowed to fixate for 15 minutes. After aspiration and washing, 200 μL of Hoechst-Alexa Fluor 647 Phalloidin 
working solution was added and incubated for 40 minutes at room temperature. Finally, the samples were washed 
with PBS. 
Further, staining with LysoTracker Deep Red was performed on live cells. Briefly, culture medium was 
aspirated and cells were washed twice with PBS. Next, 200 μL of LysoTracker Deep Red working solution was 
added and allowed to incubate for 1.5 hours before performing confocal microscopy. Confocal microscopy was 
carried out on a Leica DMI6000 B inverted microscope equipped with an oil immersion objective (Zeiss, 63x, NA 
1.40) and attached to an Andor DSD2 confocal scanner. Images were processed with Imaris software. 
 
4.9 drug loading 
Paclitaxel (PTX) loaded poly(HEA)x-b-poly(HEAm-co-DMDMAn)y nanoparticles were formulated based on the 
protocol described in section 4.8.1. A 5 mg/mL solution of PTX in ethanol was prepared and sealed to prevent 
solvent evaporation. Next, 1 mL of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y dispersions (10 mg/mL) were prepared in 
PBS as described in section 4.4. To these polymer dispersions 100 μL of PTX solution was added under vigorous 
stirring. The polymeric nanoparticles were allowed to stabilize overnight at room temperature with the lid kept 
open to enable evaporation of the ethanol. Finally, precipitated PTX was removed by membrane filtration (0.450 
μm). 
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To determine the concentration of loaded paclitaxel by LC-MS the following sample preparation was 
performed. Briefly, 50 μL of PTX loaded nanoparticle dispersion was diluted into 950 μL of methanol. Of this 
solution 500 μL was 2-fold diluted in 500 μL methanol. Finally, 100 μL of the latter dilution was added to 100 μL of 
MilliQ water. Of the sample 2 μL was injected into an Agilent 1200 series HPLC system equipped with a 
Phenomenex Luna C18 (2) (100 A, 50 x 2.00 mm, 3 μm) preceded by a Grace Alltima C18 (7.5 x 2.1 mm, 5 μm) guard 
column. The column temperature was 40 °C and the sample compartment was maintained at room temperature. A 
binary solvent system was used in gradient mode with an initial flow rate of 0.2 ml/min. To allow shorter runtimes, 
this flow rate was increased to 0.3 ml/min after 5.6 minutes, maintained for 6 minutes and then switched back to 
the initial flow rate to be maintained up to the end of the run (12.5 min). The solvents used were as follows: solvent 
A (90/10 % v/v H2O/MeOH) and solvent B (100 % v/v MeOH). The runs started with a 36/64 volume ratio of solvent A 
and B which switched to 10/90 after 1.5 minutes. The latter ratio was maintained for 2.6 minutes and subsequently 
switched back to the initial ratio to be maintained up to the end of the run. The drug was detected by mass 
spectrometry using an API 3000 (AB Sciex) triple quadrupole mass spectrometer operated in the multiple reaction 
monitoring (MRM) mode. From the determined PTX concentration, encapsulation efficiency (EE) and loading 
capacity (LC) can be calculated. These parameters are defined by the formulas below: 
 
EE = 
????????????????
????????????????
 x 100 % 
 
 
LC = 
?????????????????????????
????????????????? ?????????????????????
 x 100 % 
 
4.10 in vitro cytotoxicity 
The MTT assay was inspired on previously described methods in literature.[69],[70] Dispersions of poly(HEA)x-
b-poly(HEAm-co-DMDMAn)y (10 mg/mL) were prepared in cold PBS as described in section 4.4. Of these dispersions, 
dilution series were made (concentrations ranging from 5 x 10-3 to 5 mg/mL). The PTX loaded nanoparticles, 
prepared as described in section 4.9, were diluted (concentrations ranging from 5 x 10-5 to 50 μg/mL) along with 
two control nanoparticle formulations: Abraxane (Celgene) and Genexol-PM (Samyang Biopharmaceuticals). The 
MTT stock solution was prepared by dissolving 100 mg MTT in 20 mL of PBS and subsequent membrane filtration 
(0.220 μm). Before use, the MTT stock solution was 5-fold diluted with culture medium. 
degradable ketal-based bock copolymer nanoparticles 
 
85 
Briefly, SKOV-3 cells were seeded into 96-well titer plates (10 000 cells per well, suspended in 200 μL of 
culture medium) and incubated overnight. Next, 50 μL of sample, DMSO (positive control = 0 % viability) or PBS 
(negative control = 100 % viability) was added to the cells, followed by 72 hours of incubation. Subsequently, the 
medium was aspirated and the cells were washed with 250 μL of PBS. After aspiration, 100 μL of MTT working 
solution was added and the cells were incubated for 2.5 hours. Finally, the MTT working solution was aspirated and 
the formed purple formazan crystals were dissolved in 50 μL of DMSO. Absorbance was determined at 590 nm 
using an EnVision Multilabel plate reader. The absorbance of the positive control was used as blank and therefore 
subtracted from all values. Cell viability (%) was defined as follows: 
 
Cell Viability = 
???????????? ? ?????????????
??????????????? ? ????????????
 x 100 % 
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6 supporting info 
 
 
Figure S1. SEC-trace of poly(HEA)x macroCTA. 
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Figure S2. Kinetic SEC-traces for the synthesis of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. 
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Figure S3. 1H-NMR spectrum of P1 in methanol-d4. 
  
degradable ketal-based bock copolymer nanoparticles 
 
91 
 
Figure S4. 1H-NMR spectrum of P2 in methanol-d4. 
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Figure S5. 1H-NMR spectrum of P3 in chloroform-d. 
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Figure S6. 1H-NMR spectrum of P4 in chloroform-d. 
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Figure S7. 1H-NMR spectrum of P5 in chloroform-d. 
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Figure S8. CAC fitting parameters (n = 2) of poly(HEA)x-b-poly(HEAm-co-DMDMAn)y. 
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Figure S9. 1H-NMR spectrum of P5 (45 mol% DMDMA) before (red, solvent: chloroform-d) and after (blue, solvent: methanol-
d4) hydrolysis. 
 
 
Figure S10. Molecular structure of octadecyl rhodamine B chloride (R18). 
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abstract 
We report on the polymeric prodrug design of the anti-cancer agent paclitaxel via a grafting-from-drug 
approach. A chain transfer agent for Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization was 
efficiently and regioselectively linked to the C2’ position of paclitaxel which is crucial for its bioactivity. Subsequent 
RAFT polymerization of a hydrophilic monomer yielded well-defined paclitaxel-polymer conjugates with high drug 
loading, water-solubility and stability. The versatility of our approach was further demonstrated by ω-end post-
functionalization with a fluorescent tracer. In vitro experiments showed that these conjugates are readily taken up 
into endosomes from where native PTX can efficiently be cleaved off and reach its subcellular target, as observed 
by the cytotoxicity profile matching those of commercial PTX formulations based on mere physical encapsulation. 
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1 introduction 
The high incidence of side-effects caused by conventional chemotherapeutics urges the development of 
novel, more efficient, formulations of this class of drug molecules. Taxanes rank amongst the most potent and 
widely available drugs for anti-cancer treatment. However, taxanes (i.e. paclitaxel (PTX) and docetaxel (DTX)) have 
very limited water-solubility and their respective first clinically approved formulations Taxol and Taxotere, contain 
surfactants (i.e. Cremophor EL and polysorbate 80, respectively) which by itself are prone to cause severe side 
effects. Extensive research endeavors have been devoted to taxane formulation into alternative, non-toxic 
surfactant-based nanoparticulate formulations based on albumin (e.g. Abraxane) or amphiphilic block copolymers 
(e.g. Genexol-PM).[1–4] The latter two commercial PTX formulations have proven to reduce surfactant-related side-
effects and allow higher PTX dosing.[5,6] Though considered as nanoformulations, both do not show significant 
differences in pharmacokinetics as compared to free PTX.[7] Literature suggests that this is due to fast systemic 
release of taxanes from nanoparticles by passive diffusion and subsequent binding to plasma proteins such as 
endogenous human serum albumin (HSA), thereby annihilating controlled drug release.[8] Chemical conjugation of 
taxanes might offer a promising solution to limit burst release effects. Not only does this allow prevention of 
abrupt systemic toxicity, this strategy can also confer longer blood circulation and tumor accumulation by the EPR 
effect. 
In this regard, drug-polymer conjugates have witnessed intensive development since they were 
introduced by Ringsdorf in the 1970s.[9] A popular ligation strategy involves linking a hydrophilic polymer to 
taxanes through esterification of the hydroxyl moieties of the drug. In particular for PTX, drug-polymer conjugates 
have been developed based on post-polymerization modification with PTX of pre-formed polymers at their 
backbone or chain end.[10] Such grafting-onto approach however suffers from similar limitations as witnessed in the 
polymer-protein conjugation field,[11,12] including steric hindrance to achieve high conjugation efficiency, difficulties 
to control and assess site-specificity and cumbersome purification challenges to remove non-reacted polymer and 
drug. With respect to the use of drug-linked monomers, issues can arise concerning very hydrophobic pocket 
formation at high drug loading and hence very slow drug release kinetics due to limited access of water. 
Furthermore, as drug conjugation is typically done via ester, hydrazone or ketal formation, the resulting polymeric 
degradation products are polyanionic, polycationic or contain polyhydrazine/polyhydrazides or 
polyaldehydes/polyketones. These polymeric species hold toxicity risks, including long term accumulation in the 
body.   
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Therefore, alternative synthetic techniques are required for designing well-defined polymeric taxane 
prodrugs with reduced heterogeneity, combining high drug loading with high water-solubility and the possibility to 
introduce additional functionalities. An emerging strategy to address these issues is by applying grafting-from-
drug polymerization, an approach which also gained interest in the polymer-protein conjugation field.[13–18] With the 
advent of controlled polymerization, this strategy yields access to well-defined drug-polymer conjugates with 
good control over polymer length, bearing one drug per polymer chain and importantly, allows for simple 
purification, i.e. removal of residual monomer. Ring-opening polymerization of lactide from PTX towards 
poly(lactide) has been reported,[19] to yield well-defined, but hydrophobic, polymeric prodrugs which require 
additional surfactants to obtain a stable formulation in aqueous medium. The Nicolas group has reported on the 
preparation of hydrophobic nanoparticles by RAFT- and NMP-mediated polymerization of squalene-methacrylate 
from another drug molecule (i.e. gemcitabine) which was covalently modified with a RAFT chain transfer agent or 
NMP initiator.[20] 
 
2 results and discussion 
Here we report on the design of regioselective amphiphilic PTX-polymer conjugates prepared via RAFT 
polymerization using a PTX-ligated chain transfer agent (CTA) in which PTX and polymer chain serve as 
hydrophobic and hydrophilic segment, respectively. To highlight the versatility of this approach we also 
demonstrate the possibility for post-polymerization modification of the opposite polymer chain end. This is 
exemplified for the attachment of a fluorescent tracer molecule, but also small molecule cancer cell targeting 
ligands could be used. Our synthesis strategy is depicted in Scheme 1 and comprises in a first step direct ligation of 
a RAFT CTA (i.e. 2-(butylthiocarbonothioylthio)propanoic acid (PABTC)) to the C2’ hydroxyl group of PTX which 
possesses the highest reactivity for esterification.[21] After purification via flash chromatography, PTX RAFT CTA 
(PTX-PABTC) was obtained in high yield (93 %) and high purity as shown by detailed NMR spectroscopy and mass 
spectrometry (ESI-MS) (Figure 1 and Figures S10-S15 in Supporting Information) showing proton signals from PTX 
and PATBC being in excellent agreement. Regioselective modification at the C2’ position of PTX is clearly proven by 
the disappearance of C2’ OH proton at 3.85 ppm (d, J = 5.5 Hz, 1H) in addition to a shift of the adjacent C2’ proton 
from 4.77 ppm (dd, J = 5.5, 2.8 Hz, 1H) to 5.45 ppm (dd, J = 12.9, 2.6 Hz, 1H). As the C2’ hydroxyl is crucial for the 
bioactivity of PTX,[22] an inactive polymeric prodrug is obtained. Subsequently, PTX-PABTC was used for RAFT 
polymerization of N,N-dimethylacrylamide (DMA). PolyDMA is a hydrophilic and biocompatible polymer,[23] but also 
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other vinyl monomers can be used as long as they are compatible with an organic solvent in which a PTX-
functionalized RAFT CTA can be dissolved. A moderate degree of polymerization (DP) of 30 DMA repeating units 
was targeted to obtain a conjugate with both high water-solubility and PTX loading. In addition, a PTX-polyDMA 
conjugate with a DP of 15 was prepared with PTX-PABTC and a non-PTX containing polymer with a DP of 30 with 
PABTC. Triple precipitation from ether in which both CTA´s as well as free PTX are soluble but polyDMA and PTX-
polyDMA are not, allowed isolation of pure PTX-polymer conjugate. Size exclusion chromatography (SEC; Figure 2A) 
revealed narrowly distributed polymers with no significant low or high molecular weight shoulders. 1H-NMR 
analysis (Figure 1A and Figure S17-S20 in Supporting Information) proved high chain end fidelity from the excellent 
agreement between proton signals from PTX and PATBC. Absence of free PTX and PTX-PABTC was further confirmed 
by DOSY NMR (Figure 1B) which showed polyDMA and PTX signals exhibiting similar diffusional behavior in the 
spectra of both PTX-polyDMA15 and PTX-polyDMA30. Table 1 summarizes the properties of the respective polymers 
after purification. 
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Scheme 1. (A) Conceptual illustration of the functionalized PTX-polymer prodrug design and (concentration-dependent) 
aqueous self-assembly into nanoparticles. (B) Corresponding reaction scheme based on esterification of PTX with a RAFT CTA, 
followed by polymerization of N,N-dimethylacrylamide and post-polymerization modification of the trithiocarbonate 
endgroup with a maleimide-functional fluorescent dye. 
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Figure 1. 1H-NMR (A) and DOSY NMR (B) spectra of PTX, PTX-PABTC and PTX-polyDMA15/30. 
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Figure 2. (A) SEC elugrams of PTX, PTX-PABTC, PTX-polyDMA15/30 and polyDMA30. (B) CAC of PTX-polyDMA30 in PBS measured by 
pyrene assay (n = 2). (C) Size distribution of PTX-polyDMA30 and polyDMA30 (30 mg/mL in PBS) measured by DLS (n = 4). (D) 
Colloidal stability of PTX-polyDMA30 measured by DLS (30 mg/mL in PBS, 37 °C) (n = 4). 
 
In a next series of experiments, we investigated the behavior of the PTX-polymer conjugates in aqueous 
medium. PTX-polyDMA30 afforded a transparent formulation, both in H2O and PBS at concentrations up to at least 
30 mg/mL. At a drug loading of around 21 %, PTX-solubility in aqueous medium is increased by more than 2 x 104-
fold.[24] By contrast, the PTX-polymer conjugate with a DP of 15 (i.e. PTX-polyDMA15) could not be solubilized nor 
properly dispersed in aqueous medium (i.e. PBS), even after extensive sonication or decrease in concentration. This 
highlights the importance of the hydrophilic polymer chain length on the resulting solution behavior, but also 
opens avenues to prepare solid hydrophobic nanoparticles using this approach, e.g. via solvent displacement in 
surfactant solution. We subsequently characterized the supramolecular behavior of the PTX-polyDMA30 in aqueous 
medium. At a concentration of 30 mg/mL in PBS, dynamic light scattering (DLS; Figure 2C) indicated the presence of 
self-assembled nanostructures, with a Z-average hydrodynamic diameter of 27.9 nm ± 0.8 and a narrow dispersity 
(PDI) of 0.100 ± 0.038 (Figure 2D). Note that the control polymer polyDMA30 formed soluble unimers in PBS at 
equal concentration (i.e. 30 mg/mL). Importantly, over a time course of at least 5 days, neither a change in size and 
PDI nor crystallization of released PTX was observed in PBS. These findings highlight the potential of this strategy 
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to obtain stable aqueous PTX formulations and avoid burst drug release. The critical aggregation concentration 
(CAC) of PTX-polyDMA30 was determined by fluorescence spectrophotometry (Figure 2B; pyrene assay) to be 102 
μg/mL ± 12. This is relatively high, compared to typical amphiphilic block copolymers and can be explained by the 
relative small hydrophobic proportion of the PTX-polyDMA30 conjugate. The CAC implies that under physiological 
conditions, the polymer will likely be present as soluble unimer and is also likely to bind serum proteins. However, 
in case a stable nanoparticulate formulation is desired, the versatility of RAFT polymerization also offers the 
possibility to introduce reactive co-monomers which could be used for crosslinking, or to use degradable 
monomers with transient solubility.[19] 
 
Table 1. Compositional data of the synthesized polymers. 
polymer [DMA]0/ 
[CTA] 
conversion 
DMA
 
(%)
a
 
DPconv,b DPendgroup,c Mn 
(Da)
d
 
Ð
d
 PTX 
loading capacity 
(%)
e
 
PTX-polyDMA15 15 90 14 16 2648 1.09 35 
PTX-polyDMA30 30 99 30 31 4356 1.07 21 
polyDMA30 30 91 27 29 3477 1.09 - 
a
 Determined by 
1
H-NMR spectroscopy. 
b
 Determined by 
1
H-NMR spectroscopy based on monomer conversion. 
c
 
Determined by 
1
H-NMR spectroscopy based on endgroup analysis. 
d
 Analyzed by SEC in DMAc, calibrated with PMMA 
standards. 
e
 Calculated based on conversion by 
1
H-NMR spectroscopy: MWPTX/MWPTX-polyDMA x 100 %. 
 
  
chapter 5 
 
108 
Figure 3. (A) Confocal microscopy images of SKOV-3 human ovarian cancer cells pulsed with PTX-polyDMA30-Rho conjugate. 
Counterstaining was performed with Hoechst and Phalloidin to stain cell nuclei and plasma membrane, respectively (A1). The 
conjugate was co-incubated with Dextran-AF488 to stain (early) endosomes (A2). Lysosomal vesicles were stained with 
LysoTracker (A3). For guidance, in panels A2 and A3, a co-localization event is marked with a yellow arrow and two non-co-
localization events are marked with a red, respectively green arrow. Scale bars (white, bottom right in each panel) correspond 
to a length of 15 μm. (B) In vitro cytotoxicity of PTX-polyDMA30 versus commercial PTX nanoformulations Abraxane and 
Genexol-PM. Non-PTX-conjugated polyDMA30 was used as a control (n = 6). 
 
As mentioned earlier, one of the major advantages of RAFT over other polymerization techniques is the 
direct access towards α,ω-telechelic polymers.[25] PTX-polyDMA30 has PTX at the α-end, thereby offering an 
opportunity for post-polymerization modification of the ω-endgroup.[26] We demonstrate this by attachment of a 
fluorescent dye tetramethyl rhodamine maleimide. First, the trithiocarbonate moiety at the ω-end was converted 
into a thiol by aminolysis (confirmed by UV-VIS spectroscopy Figure S21 in Supporting Information) and 
subsequently reacted with tetramethyl rhodamine (Rho) maleimide to form a stable thioether bond between 
polymer and dye. A similar strategy however could also be used to introduce radiotracers or targeting ligands. 
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After dialysis, absence of free dye was observed by reversed phase TLC (Figure S22 in Supporting Information). DLS 
further proved that conjugation of the rhodamine dye, thereby obtaining PTX-polyDMA30-Rho, did not significantly 
alter the supramolecular behavior of the conjugate (Figure S23 in Supporting Information). 
Subsequently, we evaluated the in vitro behavior of the PTX-polyDMA30-Rho conjugate on SKOV-3 human 
ovarian cancer cells. After 2 h of incubation, intracellular localization of the PTX-polyDMA30-Rho was investigated 
by confocal microscopy. As shown in Figure 3A1, a punctuated fluorescence pattern is observed inside the cells 
which proofs the polymeric prodrug is efficiently internalized. To shed light on the uptake mechanism, PTX-
polyDMA30-Rho was co-incubated with Alexa Fluor 488 (AF488) labeled dextran (Figure 3A2) or counterstained 
with LysoTracker (Figure 3A3). Dextran conjugates are known to be taken up by pinocytosis,[27] thereby staining 
endosomes, whereas Lysotracker is known to stain lysosomal vesicles. The strong co-localization of PTX-
polyDMA30-Rho with Dextran-AF488 and partial co-localization with LysoTracker, indicates active endocytosis into 
intracellular acidic vesicles. When the experiment was repeated at 4 °C where energy-dependent endocytosis is 
blocked, no uptake of the conjugate was observed (data not shown). These findings show that, in contrast to PTX 
which is a membrane-permeable molecule,[28] the polymeric prodrug is actively taken up by endocytosis (i.e. 
pinocytosis) but not yet abundantly present in lysosomal vesicles within 2 h. As PTX is known to exit cancer cells 
through P-glycoprotein efflux, altering the route through which PTX enters the cell might prolong its intracellular 
residence and might hold potential to overcome multidrug resistance.[29] 
Next, the effect of PTX-polyDMA30 on the in vitro viability of SKOV-3 cells was investigated. Cells were 
incubated for 72 h with PTX-polyDMA30, polyDMA30 control polymer and 2 commercial PTX nanoformulations 
Abraxane and Genexol-PM. Cell viability was assessed by MTT assay. As shown in Figure 3B, no cytotoxicity was 
observed for control polyDMA30, suggesting that polyDMA is cytocompatible within the experimental window. 
Interestingly, PTX-polyDMA30 exhibits an IC50 of 79 nM ± 7, comparable to both Abraxane and Genexol-PM (IC50 of 
56 nM ± 11 and 65 nM ± 13, respectively). These findings demonstrate that despite covalent polymer ligation to a 
position on PTX crucial for its bioactivity (i.e. the C2´ OH), a similar in vitro cytotoxicity effect is exerted as for 
formulations which rely on mere physical encapsulation. In other words, upon storage in endosomal/lysosomal 
vesicles, where esterases like cathepsin B[30] are present, native PTX is released from an inactive polymeric prodrug 
and can subsequently still reach its subcellular target and exert its cytotoxic activity. 
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3 conclusions 
Summarizing, we demonstrated the synthesis of well-defined polymeric prodrugs of the anti-cancer drug 
PTX via a grafting-from-drug RAFT approach. PolyDMA grown from a regioselectively modified PTX-ester CTA 
affords a dramatic increase in drug aqueous solubility upon formation of stable nanoparticles or unimers 
depending on the concentration. We further demonstrated the introduction a fluorophore at the ω-end of the 
polymer chain via post-polymerization modification which allowed for tracking the intracellular fate of the 
prodrug. Importantly, the PTX-polymer conjugate showed no loss in activity in vitro. 
We believe the attractiveness of our approach lies in its versatility as it allows for the synthesis of a 
library of polymer-PTX conjugates starting from a single well-characterized PTX-CTA. Such library could encompass 
different polymer chain lengths, monomers and side chain or end group functionalities, and could offer a valuable 
tool to investigate structure-property relationships to alter the pharmacokinetic profile of PTX towards optimal 
tumour targeting. Furthermore, as the PTX-polymer conjugate is an inactive prodrug, our strategy also holds 
promise to enhance the maximum tolerable dose (MTD) and thus further improve the therapeutic effect by 
increasing the administered dose. These investigations, along with exploring active targeting strategies, the use of 
transiently soluble monomers and assessing the potential to overcome multidrug resistance are currently ongoing. 
 
4 experimental 
4.1 materials 
All chemicals were purchased from Sigma Aldrich unless mentioned otherwise. The RAFT CTA 2-
(butylthiocarbonothioylthio)propanoic acid (PABTC) was synthesized according to literature.[31] TLC plates were 
purchased from Macherey Nagel. Dulbecco’s phosphate buffered saline (PBS), Dulbecco’s modified Eagle medium 
(DMEM), fetal bovine serum (FBS), L-glutamine, sodium pyruvate, penicillin, streptomycin, Hoechst, Alexa Fluor 488 
Phalloidin, Dextran Alexa Fluor 488 (10 000 Da) and LysoTracker Green were obtained from Thermo Fisher 
Scientific. SKOV-3 cells were supplied by ATCC. Tetramethyl rhodamine (Rho) maleimide was purchased from 
Anaspec. 
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4.2 analysis 
NMR spectra were recorded on a Bruker 300 and 400 MHz FT-NMR spectrometer. Chemical shifts (δ) are 
given in ppm relative to TMS. Samples were prepared in given deuterated solvents and their signals referenced to 
residual non-deuterated signals of the solvent. 
Electron spray ionization-mass spectroscopy (ESI-MS) measurements were performed on a Waters 
(Milford, Mass, USA) LCT Premier XE TOF equipped with an electrospray ionization interface. Samples were infused 
in an acetonitrile:formic acid (1000:1) mixture at 0.1 mL/min. 
Size exclusion chromatography (SEC) was carried out on an Agilent 1260 system, equipped with a 1260 
ISO-pump, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). Measurements were 
performed in N,N-dimethylacetamide (DMAc) containing 50 mM LiCl at 50 °C, using a flow rate of 0.593 mL/min. A 
guard column and two PL gel 5 μm mixed-D columns were used in series, calibrated with poly(methyl 
methacrylate) (PMMA) standards obtained from PSS (Mainz, Germany). 
Dynamic light scattering (DLS). DLS measurements were carried out on a Zetasizer Nano S (Malvern) with a 
HeNe laser (λ = 633 nm) at a scattering angle of 173°. 
Fluorescence excitation spectra were collected at room temperature on a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) equipped with a Varian Cary Temperature Controller. 
 
4.3 synthesis PTX RAFT CTA 
In a 10 mL round-bottom flask, PABTC (0.386 mmol, 0.092 g), 4-(dimethylamino)pyridine (DMAP) (0.039 
mmol, 0.005 g) and PTX (0.351 mmol, 0.300 g) were dissolved in 3.865 mL anhydrous dichloromethane (DCM). 
Next, N,N′-diisopropylcarbodiimide (DIC) (0.386 mmol, 0.049 g) was added dropwise and reaction was stirred for 1 
hour at room temperature and monitored by TLC. Subsequently, mixture was filtered and concentrated in vacuo. 
The crude product was purified by silica gel chromatography (eluent 6:4 hexane:ethyl acetate v/v). After 
concentration and subsequent drying under high vacuum, the obtained yellow solid (0.326 mmol, 0.350 g, 93 %) 
was analyzed by NMR spectroscopy and ESI-MS. 
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4.4 RAFT polymerization 
PTX-PABTC (0.186 mmol, 0.200 g), 2,2′-azobis(2-methylpropionitrile) (AIBN) (0.037 mmol, 0.006 g) and 
N,N-dimethylacrylamide (DMA) (5.592 mmol, 0.554 g or 2.796 mmol, 0.277 g; for targeted degree of polymerization 
(DP) of 30 and 15, respectively) were dissolved in a Schlenk tube in N,N-dimethylformamide (DMF) to obtain a 
monomer concentration of 2 M and a CTA:initiator molar ratio of 5:1. The solutions were subjected to 5 freeze-
pump-thaw cycles before polymerization was initiated at 70 °C for 3 h under vacuum. Monomer conversion was 
determined by 1H-NMR spectroscopy. Polymers were collected by triple precipitation from cold (4 °C) diethyl ether 
and the obtained light yellow solids were subsequently dried under high vacuum (PTX-polyDMA30 (0.158 mmol, 
0.635 g, 85 %) and PTX-polyDMA15 (0.117 mmol, 0.282 g, 63 %)). 
A similar protocol was used for the synthesis of polyDMA30 control polymer by dissolving PABTC (0.210 
mmol, 0.050 g), DMA (6.303 mmol, 0.625 g) and AIBN (0.042 mmol, 0.007 g) in 2.364 mL dry DMF and subsequent 
RAFT polymerization and purification described above (0.166 mmol, 0.488 g, 79 %). 
 
4.5 critical aggregation concentration (CAC) 
CAC of PTX-polyDMA30 was determined by fluorescence spectroscopy using pyrene as a fluorescent probe 
based on a described protocol.[4] First, a dilution series of polymeric prodrug was prepared in PBS with 
concentrations ranging from 10-2 to 103 μg/mL. Secondly, a 3.6 mg/mL (1.8 x 10-2 M) stock solution of pyrene in 
acetone was prepared and kept on ice to prevent evaporation of the acetone. Next, 10 μL of this solution was 
diluted to 1 mL acetone and kept on ice. To 6 mL of each conjugate dilution, 20 μL of the latter pyrene solution was 
added under stirring leading to a pyrene concentration of 6.0 x 10-7 M. The CAC was quantified by fluorescence 
spectrophotometry at room temperature based on the change in excitation intensity ratio at 338 and 333 nm with 
varying concentration. 
 
4.6 rhodamine post-functionalization 
PTX-polyDMA30 was fluorescently labeled by post-functionalization of the ω-end group. First, 
trithiocarbonate ω-end group was removed by aminolysis. In a Schlenk tube, PTX-polyDMA30 (0.007 mmol, 0.030 g) 
was dissolved in 1 mL dry DMF. To this yellow colored solution, 1-propylamine (0.297 mmol, 0.018 g) was added 
dropwise and reaction was stirred at room temperature for 30 minutes until the solution turned colorless. PTX-
polymer-paclitaxel prodrugs by a grafting-from-drug approach 
 
113 
polyDMA30SH (´SH´ refers to the free thiol which was unmasked at the polymer chain end upon aminolysis of the 
trithiocarbonate) was collected by triple precipitation from cold (4 °C) diethyl ether and obtained white solid was 
subsequently dried under high vacuum. UV-VIS spectroscopy was performed to confirm removal of trithiocarbonate 
ω-end group. 
In a next step, the obtained PTX-polyDMA30SH was dissolved in 3 mL 50 mM phosphate buffer containing 10 
mM TCEP (tris(2-carboxyethyl)phosphine). To another Schlenk tube, tetramethyl rhodamine (Rho) maleimide 
(0.009 mmol, 0.005 g) was dissolved in 1 mL dimethyl sulfoxide (DMSO). Both Schlenk tubes were subjected to 3 
freeze-pump-thaw cycles. Next, the rhodamine solution was added dropwise to polymer. After overnight stirring at 
room temperature, reaction was quenched for 5 h with N-hydroxyethyl acrylamide (0.370 mmol, 0.043 g) and 
dialyzed against 1 : 1 methanol : distilled water for 1 day and finally against distilled water for 4 days (MWCO 1 kDa). 
The sample was subsequently freeze-dried and analyzed by SEC in DMAc, reversed-phase (RP)-TLC and DLS (0.003 
mmol, 0.015 g, 45 %). 
 
4.7 cell culture 
SKOV-3 human ovarian cancer cells were cultured in DMEM, supplemented with 10 % FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate and antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin). Cells were 
incubated at 37 °C in a controlled, sterile environment of 95 % relative humidity and 5 % CO2. 
 
4.8 confocal microscopy 
Hoechst stock solution of 1 mg/mL was prepared in DMSO. Alexa Fluor 488 Phalloidin stock solution of 6.6 
μM was prepared in methanol. Of both stock solutions 6 and 35 μL were added to 1.4 mL of PBS supplemented with 
1 % bovine serum albumin (BSA), respectively. LysoTracker Green 1 mM stock solution in DMSO was diluted in culture 
medium to obtain a working concentration of 60 nM. SKOV-3 cells were plated out on Willco-Dish glass bottom 
dishes (5 000 cells, suspended in 200 μL of culture medium) and incubated overnight at 37 °C. Next, 20 μL of a 5 
mg/mL PTX-polyDMA30-Rho solution in PBS was added to obtain a well concentration of 455 μg/mL. The labeled 
PTX-polymer conjugate was subsequently incubated for 2 h either at 4 °C or 37 °C. 
Hoechst-Phalloidin co-staining was carried out on fixed cells. In summary, culture medium was aspirated 
and cells were washed three times with PBS. Next, 200 μL of 4 % paraformaldehyde was added and allowed to 
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fixate for 15 minutes. After aspiration and washing, 200 μL of Hoechst-Phalloidin working solution was added and 
incubated for 30 minutes at 37 °C. Samples were washed with PBS prior to imaging. 
LysoTracker staining was performed on live cells. Briefly, culture medium was aspirated and cells were 
washed with PBS. Next, 200 μL of LysoTracker working solution was added and allowed to incubate 1 h at 37 °C 
before performing confocal microscopy. 
In an additional experiment, 5 000 SKOV-3 cells were incubated for 2 h in culture medium supplemented 
with 455 μg/mL PTX-polyDMA30-RHO and 2 mg/mL Dextran Alexa Fluor 488. After incubation, cells were washed 
with PBS and fixed with 4 % paraformaldehyde as described earlier. Confocal microscopy was carried out on a Leica 
DMI6000 B inverted microscope equipped with an oil immersion objective (Leica, 63×, NA 1.40) and attached to an 
Andor DSD2 confocal scanner. Images were processed with the ImageJ software package. 
 
4.9 in vitro cytotoxicity 
In vitro cytotoxicity was assessed by MTT assay. Dilution series of polyDMA30 control polymer and PTX-
polyDMA30 conjugate were prepared in PBS with concentrations ranging from 5 x 10-5 to 50 μM. Two control 
nanoparticle PTX formulations Abraxane (Celgene) and Genexol-PM (Samyang Biopharmaceuticals) were diluted in 
PBS to obtain PTX concentrations ranging from 5 x 10-5 to 50 μM. MTT stock solution was prepared by dissolving 100 
mg MTT in 20 mL PBS and subsequent membrane filtration (0.220 μm). Before use, the MTT stock solution was 5-
fold diluted in culture medium. 
Briefly, SKOV-3 cells were seeded into 96-well plates (10 000 cells per well, suspended in 200 μL of 
culture medium) and incubated overnight. Next, 50 μL of sample, DMSO (positive control = 0 % viability) or PBS 
(negative control = 100 % viability) was added, followed by 72 h of incubation. Subsequently, medium was 
aspirated and cells were washed with 250 μL of PBS. After aspiration, 100 μL of MTT working solution was added 
and cells were incubated for 2 h. Finally, MTT working solution was aspirated and the formed purple formazan 
crystals were dissolved in 50 μL of DMSO. Absorbance was determined at 590 nm using an EnVision Multilabel 
plate reader. The absorbance of the positive control was used as blank and therefore subtracted from all values. 
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6 supporting info 
6.1 paclitaxel 
PTX was purchased from LC Laboratories and its purity was confirmed by NMR spectroscopy and ESI-MS. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 8.11 (d, J = 7.1 Hz, 2H, o-2O-ArH); 7.72 (d, J = 7.1 Hz, 2H, o-3’NH-ArH); 7.60 (t, J = 
7.4 Hz, 1H, p-2O-ArH); 7.53 – 7.30 (m, 10H, 3’-ArH and 2O-ArH and 3’NH-ArH); 7.12 (d, J = 8.9 Hz, 1H, 3’-NH-); 6.27 (s, 
1H, 10-H); 6.20 (t, J = 8.6 Hz, 1H, 13-H); 5.76 (dd, J = 8.9, 2.8 Hz, 1H, 3’-H); 5.66 (d, J = 7.1 Hz, 1H, 2-H); 4.92 (dd, J = 9.7, 
2.2 Hz, 1H, 5-H); 4.77 (dd, J = 5.5, 2.8 Hz, 1H, 2’-H); 4.38 (ddd, J = 11.0, 6.6, 4.4 Hz, 1H, 7-H); 4.24 (dd, J = 29.7, 8.4 Hz, 
2H, 20-HH); 3.85 (d, J = 5.5 Hz, 1H, 2’-OH); 3.78 (d, J = 7.0 Hz, 1H, 3-H); 2.58 (d, J = 4.3 Hz, 1H, 7’-OH); 2.55 – 2.42 (m, 
1H, 6-HH); 2.36 (s, 3H, 4O-Ac-H); 2.34 – 2.22 (m, 2H, 14-H2); 2.21 (s, 3H, 10O-Ac-H); 2.03 (s, 1H, 1-OH); 1.85 (ddd, J = 
14.0, 11.0, 2.4 Hz, 1H, 6-HH); 1.78 (d, J = 1.4 Hz, 3H, 18-H3); 1.67 (s, 3H, 19-H3); 1.22 (s, 3H, 16-H3); 1.13 (s, 3H, 17-H3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 209.73 (9-CO); 172.81 (1’-CO); 171.35 (10-O-CO); 170.49 (4-O-CO); 167.33 (3’-NH-
CO); 167.02 (2-O-CO); 142.03 (12-C); 133.81 (12-C); 138.10, 133.73, 133.25, 132.06, 130.29, 129.29, 129.09, 128.82, 128.78, 
128.42, 127.18 and 127.14 (2O-ArH, 3’-NH-ArH and 3’-ArH); 84.50 (5-C); 81.22 (4-C); 79.03 (1-C); 76.60 (20-C); 75.69 
(10-C); 75.06 (2-C); 73.32 (2’-C); 72.35 (13-C); 72.22 (7-C); 58.65 (8-C); 55.23 (3’-C); 45.78 (3-C); 43.27 (15-C); 35.80 
(14-C); 35.76 (6-C); 26.93 (16-C); 22.71 (4O-Ac-C); 21.93 (17-C); 20.97 (10O-Ac-C); 14.92 (18-C); 9.70 (19-C). 
ESI-MS (acetonitrile): calcd for C47H51NO14 853.33, found 854.34 [M+H]+ 
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Figure S1. Structure and annotation of PTX. 
 
 
Figure S2. 1H-NMR (300 MHz, CDCl3) spectrum of PTX. 
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Figure S3. 13C-NMR (75 MHz, CDCl3) spectrum of PTX. 
 
 
Figure S4. 1H,1H-COSY spectrum of PTX. 
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Figure S5. 1H,13C-HSQC spectrum of PTX. 
 
 
Figure S6. 1H,13C-HMBC spectrum of PTX. 
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Figure S7. ESI-MS (acetonitrile) spectrum of PTX. 
 
6.2 PTX RAFT CTA 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 8.14 (dt, J = 8.6, 1.5 Hz, 2H, o-2O-ArH); 7.81 – 7.70 (m, 2H, o-3’NH-ArH); 7.61 (tt, J 
= 7.4, 1.5 Hz, 1H, p-2O-ArH); 7.53 – 7.30 (m, 10H, 3’-ArH and 2O-ArH and 3’NH-ArH); 6.84 (d, J = 9.2 Hz, 1H, 3’-NH-); 
6.29 (s, 1H, 10-H); 6.28 (t, J = 9.2 Hz, 1H, 13-H); 5.96 (ddd, J = 9.2, 9.2, 2.7 Hz, 1H, 3’-H); 5.69 (d, J = 7.1 Hz, 1H, 2-H); 5.45 
(dd, J = 12.9, 2.6 Hz, 1H, 2’-H); 5.11 – 4.87 (m, 2H, 5-H and -CH- (PABTC)); 4.44 (ddd, J = 11.0, 6.7, 4.4 Hz, 1H, 7-H); 4.26 
(dd, J = 45.7, 8.3 Hz, 2H, 20-HH); 3.81 (d, J = 7.0 Hz, 1H, 3-H); 3.45 – 3.15 (m, 2H, -S-CH2- (PABTC)); 2.61 – 2.51 (m, 1H, 6-
HH); 2.47 (s, 1H, 7’-OH); 2.44 (s, 3H, 4O-Ac-H); 2.43 – 2.34 (m, 1H, 14-HH); 2.22 (s, 3H, 10O-Ac-H); 2.22 – 2.17 (m, 1H, 6-
HH); 2.17 (s, 1H, 1-OH); 1.94 (d, J = 1.4 Hz, 3H, 18-H3); 1.93 – 1.82 (m, 1H, 14-HH); 1.68 (s, 3H, 19-H3); 1.66 – 1.61 (m, 2H, -
S-CH2-CH2- (PABTC)); 1.58 (dd, J = 20.2, 7.5 Hz, 3H, -CH-CH3 (PABTC)); 1.40 (dh, J = 7.6, 3.2 Hz, 2H, -S-CH2-CH2-CH2- 
(PABTC)); 1.23 (s, 3H, 16-H3); 1.13 (s, 3H, 17-H3); 0.91 (t, J = 7.3, 3H, -S-CH2-CH2-CH2-CH3 (PABTC)). 
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13C-NMR (100 MHz, CDCl3): δ [ppm] = [>220.0 (S-CS-S)]; 209.96 (9-CO); 171.38 (10-O-CO); 170.54 (d, -CO- (PABTC)); 
169.89 (4-O-CO); 167.55 (d, 1’-CO); 167.18 (2-O-CO); 167.12 (d, 3’-NH-CO); 142.87 (12-C); 133.82 (12-C); 136.95(d), 133.71, 
132.95(d), 132.15(d), 130.37, 129.31, 129.19, 128.89, 128.86, 128.60, 127.30 and 126.72(d) (2O-ArH, 3’-NH-ArH and 3’-
ArH); 84.59 (5-C); 81.21 (4-C); 79.29 (1-C); 76.59 (20-C); 75.69 (10-C); 75.24 (2-C); 75.07 (d, 2’-C); 72.27 (7-C); 72.07 (d, 
13-C); 58.66 (8-C); 52.85 (3’-C); 46.59 (d, -CH- (PABTC)); 45.69 (3-C); 43.33 (15-C); 37.38 (-S-CH2- (PABTC)); 35.70 (14-
C); 35.65 (6-C); 29.96 (d, -S-CH2-CH2- (PABTC)); 26.97 (16-C); 22.86 (4O-Ac-C); 22.30 (17-C); 22.19 (S-CH2-CH2-CH2- 
(PABTC)); 20.96 (10O-Ac-C); 16.04 (d, -CH-CH3 (PABTC)); 14.98 (18-C); 13.70 (d, -S-CH2-CH2-CH2-CH3 (PABTC)); 9.74 (19-
C). 
ESI-MS (acetonitrile): m/z = calcd for C55H63NO15S3 1073.33, found 1074.34 [M+H]+ 
 
 
Figure S8. TLC before (left) and 10 minutes after adding DIC (right) to PABTC:PTX reaction mixture (eluent: 1:1 hexane:ethyl 
acetate v/v). 
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Figure S9. Structure and annotation of PTX-PABTC. 
 
 
Figure S10. 1H-NMR (400 MHz, CDCl3) spectrum of PTX-PABTC. 
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Figure S11. 13C-APT-NMR (100 MHz, CDCl3) spectrum of PTX-PABTC. 
 
 
Figure S12. 1H,1H-COSY spectrum of PTX-PABTC. 
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Figure S13. 1H,13C-HSQC spectrum of PTX-PABTC. 
 
Figure S14. 1H,13C-HMBC spectrum of PTX-PABTC. 
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Figure S15. ESI-MS (acetonitrile) spectrum of PTX-PABTC. 
 
6.3 PTX-polyDMA 
SEC(DMAc, PMMA-St.): Mn = 2648, PDI = 1.09 (PTX-polyDMA15) and Mn = 4356, PDI = 1.07 (PTX-polyDMA30). 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.14 (d, J = 7.6 Hz, 2H, o-2O-ArH); 7.84 (d, J = 7.8 Hz, 2H, o-3’NH-ArH); 7.75 – 
7.21 (m, 11H, 3’-ArH and 2O-ArH and 3’NH-ArH); 6.45 (s, 1H, 10-H); 6.08 (t, J = 9.5 Hz, 1H, 13-H); 5.97 – 5.69 (m , 1H, 3’-
H); 5.64 (m, 1H, 2-H); 5.42 (m, 1H, 2’-H); 5.31 – 5.15 (m, 1H, -CH- (PABTC)); 5.08 – 4.93 (m, 1H, 5-H); 4.34 (dd, J = 10.5, 
6.5, 1H, 7-H); 4.18 (m, 2H, 20-HH); 3.86 – 3.70 (m, 1H, 3-H); 3.42 (td, J = 7.7, 2.4 Hz, 2H, -S-CH2- (PABTC)); 3.25 – 1.08 
(m, 173H [9x16=144H for polyDMA (DP16) and 22H for PTX and 7H for PABTC] for targeted DP15 and 308H 
[9x31=279H for polyDMA (DP31) and 22H for PTX and 7H for PABTC] for targeted DP30); 0.95 (td, J = 7.3, 1.6 Hz, 3H, -
S-CH2-CH2-CH2-CH3 (PABTC)). 
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Calculation of the degree of polymerization for PTX-polyDMA15, respectively PTX-polyDMA30, was performed by 
integration of 3.3 -1.0 ppm (9 monomer protons overlap with 33 protons of the PTX-PABTC): 
? polyDMA30: DP = (307.47 – 33) / 9 = 30.50 
? polyDMA15: DP = (173.03 – 33) / 9 = 15.56 
 
 
Figure S16. Structure and annotation of PTX-polyDMA. 
 
 
Figure S17. 1H-NMR (300 MHz, MeOH-d4) spectrum of PTX-polyDMA15. 
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Figure S18. 1H-NMR (300 MHz, MeOH-d4) spectrum of PTX-polyDMA30. 
 
6.4 polyDMA 
SEC(DMAc, PMMA-St.): Mn = 3477, PDI = 1.09 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 5.30 – 5.14 (m, 1H, -CH- (PABTC)); 3.47 – 3.34 (m, 2H, -S-CH2- (PABTC)); 3.22 – 
1.23 (m, 268H [9x29=261H for polyDMA (DP29) and 7H for PABTC] for targeted DP30); 0.95 (td, J = 7.3, 1.8 Hz, 3H, -S-
CH2-CH2-CH2-CH3 (PABTC)). 
 
 
Figure S19. Structure of polyDMA. 
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Figure S20. 1H-NMR (300 MHz, MeOH-d4) spectrum of polyDMA30. 
 
6.5 rhodamine post-functionalization 
 
 
Figure S21. UV-VIS spectra confirming successful aminolysis of the trithiocarbonate RAFT end group. 
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Figure S22. Reversed phase TLC of free Rho dye (left) and PTX-polyDMA30-Rho (right) (eluent: 1:1 H20:acetonitrile v/v, 1 % TFA). 
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Figure S23. Size distribution measured by DLS of PTX-polyDMA30 before and after labeling with rhodamine-maleimide. 
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abstract 
Acid-sensitive PTX-polymer conjugates were designed by applying a grafting-from-drug RAFT approach. 
PTX was either linked through a cyclic or a linear, acid-sensitive acetal moiety. Relative to direct esterification of 
PTX, which occurred regioselectively at the C2’ OH-group, direct acetalization was observed at either the C2’ or the C7 
OH-group of PTX. This yielded 2 regio-isomers of acetal-based PTX-functionalized RAFT CTA. Subsequent 
polymerization with DMA resulted in amphiphilic highly-defined, acetal-based PTX-polymer conjugates with nearly 
identical features in terms of polymer definition and micellar self-assembly behavior, but with distinct PTX release 
kinetics and absence of burst release. This was further reflected by their in vitro biological performance, giving 
insights into the difference of release mechanism between ester- and cyclic and linear acetal-based PTX-polymer 
conjugates.   
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1 introduction 
Taxanes (i.e. paclitaxel (PTX) and docetaxel (DTX)) are highly valuable anti-cancer drugs due to their 
broad-spectrum activity.[1,2] However, the widespread use of these drugs in clinic remains elusive. During discovery 
and early development, it was found that both drugs exhibited very low water-solubility. In order to commercialize 
these drugs, formulation into a 1:1 ethanol:surfactant cosolvent mixture is required. Cremophor EL is used for the 
first commercial formulation of PTX (i.e. Taxol), whilst polysorbate 80 is exploited in the DTX formulation Taxotere. 
However, severe hypersensitivity reactions are attributed to these surfactants.[3–7] This urged the development of 
formulations based on more benign excipients, leading to the FDA-approval of Abraxane (an albumin-stabilized 
PTX formulation) in 2005, and Genexol-PM (PTX, stabilized by poly(ethylene glycol)-b-poly(d,l-lactic acid); PEG-b-
pDLLA) in South Korea 2 years later. The biocompatibility of both carriers significantly increased the therapeutic 
index, hence higher doses could be administered leading to a more effective chemotherapy.[8] 
However, as the aforementioned formulations are based on physical drug entrapment, intravenous 
administration still holds the risk of systemic release and distribution of drug and hence does not prevent the 
intrinsic side-effects of taxanes (i.e. neutropenia, neuropathy) from occurring. Besides physical drug entrapment by 
strong hydrophobic interaction, chemical conjugation is one of the most versatile strategies for more selective 
drug release.[9,10] Typically, the drug is chemically conjugated to the (polymeric) carrier vehicle through a stimuli-
responsive linker. The latter can then be cleaved either by a specific enzyme (e.g. by cathepsin B lysosomal 
enzymes)[11] or by a subtle change in the chemical environment, as exploited by pH-sensitive (e.g. endosomal 
hydrolysis of acetals/ketals/hydrazone moieties) and redox-sensitive (e.g. cleavage of disulfides in response to 
hypoxic tumour microenvironment) carrier systems.[12–14] Polymer-drug conjugates with the highest progress in 
clinical trials (e.g. Opaxio; PTX conjugated to 48 kDa poly(L-glutamic acid)) are typically prepared by post-
functionalization of the polymer backbone with the drug.[15] However, such strategy has inherent reproducibility 
challenges and requires tedious purification to remove excess unconjugated drug which could cause burst release 
upon intravenous administration. 
A recently uprising trend in polymer-drug conjugate design is direct polymerization from a drug 
molecule.[16,17] This technique is termed the ‘grafting-from-drug’ or ‘drug-initiated’ approach.[18] The promise of this 
method has also been demonstrated for taxane-polymer conjugates. For example, direct ring-opening 
polymerization (ROP) of lactic acid (LA) conjugated to PTX and DTX resulted in defined, hydrophobic PTX/DTX-PLA 
conjugates which could subsequently be formulated into nanoparticles.[16,17] Recently, our group has developed a 
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grafting-from-drug reversible addition-fragmentation chain transfer (RAFT) polymerization approach for acquiring 
defined, amphiphilic PTX-polymer prodrug conjugates with high drug loading and aqueous compatibility.[19] The 
latter was obtained by functionalizing a RAFT chain transfer agent (CTA) with PTX by direct esterification. This 
ester-bond was effectively cleaved in vitro as the IC50 matched the ones of Abraxane and Genexol-PM. These results 
motivated us to further explore this technique to develop acid-sensitive, acetal-based PTX-polymer conjugates 
which could hold the potential to more selectively release drug in response to the acidic environment in tumor 
tissue or upon endocytosis and storage in intracellular vesicles. Literature reports that cyclic and linear acetal 
moieties can exert significantly different, acidic hydrolysis rates (i.e. up to several orders of magnitude), wherein 
linear acetals are known to degrade faster than their cyclic counterparts.[20] Hence, two acetal moieties were 
considered, one based on a cyclic, tetrahydropyran-based acetal (in this paper abbreviated as THP) and the other 
based on a linear, di(ethylene glycol)-based acetal (in this paper abbreviated as DEGA). 
 
Scheme 1. Reaction scheme for the acid-catalyzed acetalization of paclitaxel (PTX) with a dihydropyran (DHP) or a di(ethylene 
glycol) vinyl ether (DEGVE) derivative of PABTC, yielding a PTX RAFT CTA, functionalized through a cyclic or linear acetal bond 
(i.e. THP or DEGA), respectively. Note that acetalization occurs either at the C2’ or at the C7 OH-group of PTX. Whilst the regio-
isomers of the THP-based PTX RAFT CTA could be separated, the regio-isomeric mixture of the DEGA-based PTX RAFT CTA was 
used as such for polymerization of N,N-dimethylacrylamide (DMA). Key abbreviations: THP, tetrahydropyran-based cyclic 
acetal; DEGA, di(ethylene glycol)-based linear acetal; C2’/C7, regio-isomeric mixture, modified either through the C2’ or the C7 
OH-group of PTX. 
  
PTX-C2'THP-PABTC/PTX-C7THP-PABTC
DEGVE-PABTC
PTX-C2'/C7DEGA-pDMA
PTX-C2'/C7DEGA-PABTC
PTXCSA
CH2Cl2, RT
AIBN
DMF, 70 °C
2'
7
CSA
CH2Cl2, RT
AIBN
DMF, 70 °C
PTX
PTX PTX C2'/C7C2'/C7
C2'/C7
m
m
PTX C2'/C7
DHP-PABTC
PTX-C2'THP-pDMA/PTX-C7THP-pDMA
paclitaxel-initiated polymer conjugates with acid-sensitive behavior 
 
135 
2 results and discussion 
Scheme 1 depicts the strategy applied for the syntheses of cyclic and linear acetal-based PTX-polymer 
conjugates. First, a RAFT CTA (i.e. 2-(butylthiocarbonothioylthio)propanoic acid (PABTC)) was modified, either with a 
dihydropyran (DHP) or a di(ethylene glycol) vinyl ether (DEGVE) moiety, yielding DHP-PABTC and DEGVE-PABTC, 
respectively. Both structures were confirmed by nuclear magnetic resonance (NMR) spectroscopy and electron 
spray ionization-mass spectroscopy (ESI-MS) (Figure S1 - S4). DHP-PABTC and DEGVE-PABTC were subsequently used 
for direct, acid-catalyzed acetalization of PTX through a cyclic or linear acetal, respectively. In contrast to the 
regioselective esterification of PTX at the C2’ hydroxyl(OH)-group we observed previously,[19] in the present study 
we found that acetalization occurred at two sites (i.e. either at the C2’ or at the C7 OH-group). 
This resulted in 2 regio-isomers of PTX-THP-functionalized CTA, which could be separated by silica gel 
chromatography. Detailed NMR analysis (Figure S5 - S14) indeed confirmed the absence of the C2’ OH-group (at 2.51 
ppm in the 1H-NMR spectrum) and the presence of the C7 OH-group (at 2.46 ppm) for PTX-C2’THP-PABTC regio-
isomer, whilst the opposite was observed for PTX-C7THP-PABTC regio-isomer. As expected, both isomers produced 
the identical product ion on ESI-MS (Figure S15). Synthesis of PTX-DEGA-PABTC resulted in a reaction mixture from 
which one fraction could be purified by silica gel chromatography. However, NMR characterization (Figure S16 - 
S20) confirmed the presence of the two regio-isomeric species, as in the 13C-NMR spectrum, the anomeric carbon of 
the acetal moiety was observed at 99.72 ppm and 100.52 ppm for the PTX-C2’DEGA-PABTC and PTX-C7DEGA-PABTC 
isomer, respectively. Direct injection ESI-MS revealed ions related to the desired product (Figure S21). These ions 
were also detected by liquid chromatography diode array detection mass spectrometry (LC-DAD/MS), showing two 
fractions eluting closely after one another (Figure S22), further confirming that the obtained PTX-DEGA-PABTC is a 
regio-isomeric mixture. Both isomers could not be separated on a preparative scale, but LC analysis (Figure S22) 
yielded a 82/18 ratio of the respective isomers. 
Both isomers of PTX-THP-PABTC and the regio-isomeric mixture of PTX-DEGA-PABTC were used for RAFT 
polymerization of N,N-dimethylacrylamide (DMA). pDMA is a hydrophilic polymer exhibiting excellent in vivo 
biocompatibility and significantly lower antibody-mediated accelerated blood clearance (ABC) compared to the 
widespread polyethylene glycol (PEG) and polyoxazolines (POx).[21] In analogy to our previous endeavors using 
ester-based PTX-polymer conjugates (abbreviated as PTX-pDMA), a degree of polymerization (DP) of 30 was aimed 
to balance between solubility and high drug loading. For both the cyclic (PTX-THP-pDMA) and the linear acetal-
based conjugates (PTX-DEGA-pDMA), similar molecular weight (MW) and narrow dispersity were measured by size 
chapter 6 
 
136 
exclusion chromatography (SEC, Figure 1A) in addition to a high α– and ω-end group fidelity measured by NMR 
(Figure S23 and S24). These findings underline the value, even at high monomer conversion, of the grafting-from-
drug RAFT approach for the synthesis of well-defined polymer-drug conjugates. The high similarity between our 
earlier reported ester-based and present acetal-based conjugates in terms of total MW, polymer chain length and 
PTX loading capacity (Table 1), is highly favorable and allows an adequate, head-to-head comparison of both 
generations in vitro. As pDMA has good aqueous solubility, its conjugation with PTX yields an amphiphilic polymer 
due to the hydrophobicity of the PTX terminal end and therefore likely self-assembles in water into micellar 
structures. 
We investigated the self-assembly behavior of the acetal-based conjugates in aqueous medium (i.e. 
phosphate buffered saline (PBS)) and compared their behavior to our previously synthesized ester-based 
conjugates. All conjugates could easily be dissolved in PBS up to elevated concentrations (at least 30 mg/mL). Both 
PTX-THP-pDMA and PTX-DEGA-pDMA self-assembled into micellar nanoparticles with similar size as the ester-
based conjugates, as observed by dynamic light scattering (DLS, Figure 1B and Table 2). No difference in particle size 
was observed between the PTX-C2’THP-pDMA and PTX-C7THP-pDMA isomers. The critical aggregation concentration 
(CAC) of the acetal-based conjugates were similar and in good concordance with the first-generation conjugates 
(Figure 1C and Table 2). Finally, all conjugates showed high colloidal stability in PBS for several days at 37 °C (Figure 
1D). 
 
Table 1. Compositional data of the synthesized polymers. 
  
polymer [DMA]0/ 
[CTA] 
conversion 
DMA (%)
a
 
DPconv,b DPendgroup,c Mn (Da)
d
 Ð
d
 PTX 
loading capacity 
(%)
e
 
PTX-pDMA30 30 99 30 31 4356 1.07 21 
PTX-C2’THP-pDMA30 30 94 28 30 3975 1.08 21 
PTX-C7THP-pDMA30 30 95 28 30 4226 1.09 21 
*PTX-C2’/C7DEGA-pDMA30 30 97 29 32 4999 1.08 21 
a
 Determined by 
1
H-NMR spectroscopy. 
b
 Determined by 
1
H-NMR spectroscopy based on monomer conversion. 
c
 Determined 
by 
1
H-NMR spectroscopy based on endgroup analysis. 
d
 Analyzed by SEC in DMAc, calibrated with PMMA standards. 
e
 
Calculated based on conversion by 
1
H-NMR spectroscopy: MWPTX/MWPTX-polymer x 100 %. * regio-isomeric mixture of PTX-
polymer conjugate, modified either through the C2’ or the C7 OH-group of PTX. 
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Figure 1. SEC elugrams (A), intensity size distribution (B), CAC (C) and colloidal stability (D) of PTX-polymer conjugates. B,D: n = 
3, measured by DLS in PBS (30 mg/mL). C: n = 2; measured in PBS by pyrene assay. Data points and error bars in (C) and (D) 
represent mean value and standard deviation (SD), respectively. * regio-isomeric mixture of PTX-polymer conjugate, modified 
either through the C2’ or the C7 OH-group of PTX. 
 
Table 2. Supramolecular and cytotoxicity features of PTX-polymer conjugates. 
polymer Z-Ave (nm)a PDIa CAC (μg/mL)b IC50 (μM)c 
PTX-pDMA30 27.3 ± 0.5 0.119 ± 0.026 102 ± 12 37 x 10-3 
PTX-C2’THP-pDMA30 17.6 ± 0.5 0.102 ± 0.018 113 ± 2 95 
PTX-C7THP-pDMA30 15.0 ± 1.1 0.071 ± 0.020 109 ± 6 95 
*PTX-C2’/C7DEGA-pDMA30 14.8 ± 1.0 0.051 ± 0.001 100 ± 1 51 x 10-1 
a Numeric values for Z-Average hydrodynamic diameter and PDI of PTX-polymer conjugates, measured in PBS (30 
mg/mL) at 37 °C by DLS (n = 3). b CAC in PBS at 20 °C, measured by pyrene assay (n = 2). c Relative IC50-values calculated 
by non-linear regression analysis of MTT data presented in Figure 3. IC50-values of Abraxane and Genexol-PM were 45 x 
10-3 and 46 x 10-3 μM, respectively. * regio-isomeric mixture of PTX-polymer conjugate, modified either through the C2’ 
or the C7 OH-group of PTX. 
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Subsequently we investigated the hydrolysis behavior of the PTX-polymer conjugates at different pH-
values (i.e. pH 7.4 to mimic the conditions in the circulation and extracellular fluids, pH 5 to mimic the acidic 
environment in intracellular vesicles and pH 4 to test an even more acidic environment) and in presence of serum 
(i.e. PBS supplemented with 10 % fetal bovine serum (FBS)). For this purpose, conjugates were incubated for fixed 
periods of time in the respective media, followed by ultra performance liquid chromatography (UPLC) analysis. 
Only limited (i.e. < 5 %) PTX release was observed at pH 7.4 in 96 hours for the ester-based conjugates, most 
probably through a base-catalyzed process, whilst the acetal-based conjugates remained fully stable within the 
timeframe of the experiment at this pH-value (Figure 2A). Additionally, the presence of serum did not substantially 
accelerate the PTX release rate for the ester- nor for the acetal-based conjugates, as for the latter the zero 
baseline also persisted in presence of FBS (Figure 2B). Next, the conjugates were incubated at endosomal pH (i.e. 
pH 5). Whilst release was observed for the linear acetal-based conjugate (i.e. 6 % in 96 hours), no release of PTX 
was observed for the cyclic acetal- and ester-based conjugates within similar time frame (Figure 2C). The latter 
confirms a higher stability of cyclic acetals compared to their linear counterparts and suggests that after swift 
endosomal uptake of the conjugates, which was reconfirmed by confocal microscopy for the cyclic acetal-based 
conjugates (Figure S26) as previously demonstrated for the for the ester-based conjugates,[19] the ester-based 
conjugates most likely did not release PTX through an acid-catalyzed process, but predominantly through an 
enzymatic pathway instead. The acetal-based conjugates were also incubated at pH 4 to verify the influence of pH 
on acetal hydrolysis rate. Indeed, PTX-THP-pDMA showed higher, but still limited release at pH 4, whilst 
substantially higher PTX release was observed for the linear acetal-based conjugates (Figure 2D). This further 
suggests that the release of PTX from the acetal-based conjugates is primarily triggered chemically instead of 
enzymatically, more specifically by means of acid-catalyzed hydrolysis. 
Finally, the biological performance of the acetal-based conjugates was evaluated in vitro on human 
ovarian SKOV-3 cells by MTT assay after 72 hours of co-incubation. Prior to these experiments we verified that none 
of the conjugates showed a tendency towards aggregate formation in presence of serum (Figure S25). As depicted 
in Figure 3, pDMA did not exert any intrinsic cytotoxic effect. Both the acetal-based conjugates induced a decrease 
in cell viability up to the same extent as the ester-based conjugates and two commercial PTX formulations based 
on physical entrapment, albeit significantly higher concentrations are required. These data are in accordance with 
the in vitro release studies, which demonstrated that the extent of PTX release is incomplete at pH 5 after 72 hours 
of incubation. Additionally, the higher release rate observed for PTX-DEGA-pDMA compared to PTX-THP-pDMA 
indeed results in a higher IC50-value of the latter (Table 2). Finally, the MTT results further propose a difference in 
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release mechanism between ester- and acetal-based PTX-polymer conjugates (i.e. enzyme- and acid-catalyzed, 
respectively). Both mechanisms can be of interest in developing advanced polymer-drug conjugates with adequate, 
selective drug release and limited systemic burst release. For acquiring PTX-polymer conjugates with faster release 
kinetics at pH 5, highly pH-sensitive acetal-/ketal- moieties are to be considered. The acetal-/ketal-chemistry, 
developed by Fréchet and co-workers, could provide valuable insights for achieving the latter.[22,23] 
 
 
Figure 2. Drug release kinetics at 37 °C of PTX-polymer conjugates (10 mg/mL) in 100 mM citrate buffer (pH 4; A and pH 5; B), 
phosphate buffer (pH 7.4; C) and PBS supplemented with 10 % FBS (D), determined by UPLC (n = 2). Data points represent 
mean value. * regio-isomeric mixture of PTX-polymer conjugate, modified either through the C2’ or the C7 OH-group of PTX. 
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Figure 3. In vitro cytotoxicity of PTX-polymer conjugates versus commercial PTX nanoformulations Abraxane and Genexol-PM 
(n = 6), co-incubated with SKOV-3 cells for 72 hours. Data points and error bars represent mean value and SD, respectively. 
* regio-isomeric mixture of PTX-polymer conjugate, modified either through the C2’ or the C7 OH-group of PTX 
 
3 conclusions 
In conclusion, the grafting-from-drug RAFT approach allowed the preparation of well-defined acetal-
based PTX-polymer conjugates with nearly identical features in terms of polymer composition and amphiphilic 
properties, but with distinct PTX release properties. The findings of this paper clearly highlight the broad chemical 
versatility and robustness of the polymerization technique and show that, due to the high definition of the 
obtained polymers, RAFT should be considered as a key player in future rational design of advanced polymer-drug 
conjugates. Whereas the in vivo behavior of these systems remains to be elucidated, ester-based systems show the 
advantage of a potentially higher activity on a short term scale. However, the specific acid-triggered PTX release, 
exhibited by acetal-based systems in combination with their resilience to enzymatic cleavage might be beneficial 
as well. 
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4 experimental 
4.1 materials 
All chemicals were purchased from Sigma Aldrich and were used as received unless mentioned otherwise. 
The RAFT CTA 2-(butylthiocarbonothioylthio)propanoic acid (PABTC) was synthesized according to a literature 
procedure.[24] TLC plates were purchased from Macherey Nagel. PTX was purchased from LC Laboratories. PTX-
pDMA30 (ester-based PTX-polymer prodrug conjugate) was synthesized as previously reported.[19] Dulbecco’s 
phosphate buffered saline (PBS), Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), L-
glutamine, sodium pyruvate, penicillin and streptomycin were obtained from Thermo Fisher Scientific. SKOV-3 cells 
were supplied by ATCC. 
 
4.2 analysis 
NMR spectra were recorded on a Bruker 300 MHz FT-NMR spectrometer. Chemical shifts (δ) are given in 
ppm relative to TMS. Samples were prepared in given deuterated solvents and their signals referenced to residual 
non-deuterated signals of the solvent. 
Electron spray ionization-mass spectroscopy (ESI-MS) measurements were performed on a Waters 
(Milford, Mass, USA) LCT Premier XE time-of-flight (TOF) mass spectrometer equipped with an ESI interface. 
Samples were infused in an acetonitrile:formic acid (1000:1) mixture at 0.1 mL/min. 
Liquid chromatography diode array detection mass spectrometry (LC-DAD/MS) was carried out on a Waters 
Alliance 2695 XE separation Module equipped with a Phenomenex Luna reversed-phase C18 (2) column (100 A, 100 x 
2.00 mm, 3 μm), coupled to a 996 diode array detector and a Waters LCT Premier XE TOF mass spectrometer. A 
gradient system of ammonium bicarbonate in H2O (10 mM)/acetonitrile was used at a flow rate of 0.4 mL/min. The 
mobile phase was 50/50 (v/v) for 0 to 1 min. Next, acetonitrile fraction was increased from 50/50 (v/v) to 0/100 
(v/v) from 1 to 10 min, maintained from 10 to 12 min and subsequently decreased back to 50/50 from 12 to 15 min. 
Size exclusion chromatography (SEC) was carried out on an Agilent 1260 system, equipped with a 1260 
ISO-pump, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). Measurements were 
performed in N,N-dimethylacetamide (DMAc) containing 50 mM LiCl at 50 °C, using a flow rate of 0.593 mL/min. A 
guard column and two PL gel 5 μm mixed-D columns were used in series, calibrated with poly(methyl 
methacrylate) (PMMA) standards obtained from PSS (Mainz, Germany). 
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Dynamic light scattering (DLS). DLS measurements were carried out on a Zetasizer Nano S (Malvern) with a 
HeNe laser (λ = 633 nm) at a scattering angle of 173°. 
Fluorescence excitation spectra were collected at room temperature on a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) equipped with a Varian Cary Temperature Controller. 
Ultra performance liquid chromatography (UPLC) analysis was performed using a Waters Acquity system. 
Eluent acetonitrile/water = 45/55 (v/v) with 0.1 % formic acid. An ACQUITY UPLC BEH C18 column was used and the 
detection wavelength was 227 nm. At a flow of 1 ml/min the retention time was 0.97 minutes. Total runtime 1.5 
minutes. Two microliters of sample (i.e. supernatant) was injected and the PTX concentration in the different 
samples was calculated using a calibration curve of PTX standards prepared in acetonitrile in a concentration range 
of 2 - 250 μg/mL. The system was controlled, and calculations were done with the Empower3 software. 
 
4.3 synthesis DHP-PABTC 
In a 500 mL round-bottom unineck flask, PABTC (18.90 mmol, 4.500 g), 4-(dimethylamino)pyridine (DMAP) 
(1.89 mmol, 0.231 g) and (±) 3,4-dihydro-2H-pyran-2-methanol (DHP) (20.80 mmol, 2.374 g) were dissolved in 189 
mL anhydrous dichloromethane (CH2Cl2) and cooled on ice. Next, N,N′-diisopropylcarbodiimide (DIC) (20.80 mmol, 
2.625 g) was added dropwise and the mixture was stirred for 1 hour at room temperature and monitored by TLC. 
Subsequently, the reaction mixture was filtered and concentrated in vacuo. The crude product was purified by silica 
gel chromatography (eluent CH2Cl2). After concentration and subsequent drying under high vacuum, the obtained 
yellow oil (17.74 mmol, 5.926 g, 94 %) was analyzed by NMR-spectroscopy and ESI-MS. 
 
4.4 synthesis DEGVE-PABTC 
In a 500 mL round-bottom unineck flask, PABTC (18.90 mmol, 4.500 g), DMAP (1.89 mmol, 0.231 g) and di(ethylene 
glycol) vinyl ether (DEGVE) (20.80 mmol, 2.749 g) were dissolved in 189 mL anhydrous CH2Cl2 and cooled on ice. 
Next, DIC (20.80 mmol, 2.625 g) was added dropwise and the mixture was stirred for 1 hour at room temperature 
and monitored by TLC. Subsequently, the reaction mixture was filtered and concentrated in vacuo. The crude 
product was purified by silica gel chromatography (eluent CH2Cl2). After concentration and subsequent drying 
under high vacuum, the obtained yellow oil (15.78 mmol, 5.553 g, 83 %) was analyzed by NMR-spectroscopy and 
ESI-MS.  
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4.5 synthesis PTX-THP-PABTC 
Following procedure was conducted for acquiring PABTC, functionalized with PTX through a 
tetrahydropyran-based cyclic acetal (THP). Paclitaxel (PTX) (2.93 mmol, 2.500 g) and camphor-10-sulfonic acid 
(CSA) (0.322 mmol, 0.075 g) were weighed into two separate 50 mL round-bottom twin neck flasks and dried 
overnight under high vacuum over phosphorus pentoxide (P2O5). PTX and CSA were dissolved in 21 mL and 7.5 mL of 
anhydrous CH2Cl2, respectively. DHP-PABTC (3.220 mmol, 1.077 g) was added dropwise to the PTX solution. Finally, 
reaction was initiated by dropwise addition of the CSA solution. Reaction was carried out for 3 hours at room 
temperature and monitored by TLC. Next, reaction was quenched with 90 μL of triethylamine (TEA) (0.644 mmol) 
and concentrated in vacuo. Two purified fractions were isolated form the crude product by silica gel 
chromatography (eluent 3:1 to 2:1 hexane:ethyl acetate v/v with 1 % TEA). After concentration and subsequent 
drying under high vacuum, the two obtained yellow solids (0.65 mmol, 0.771 g, 44 % PTX-C2’THP-PABTC (assuming a 
maximum yield of 0.5 PTX eq. for both regio-isomers); 0.56 mmol, 0.666 g, 38 % PTX-C7THP-PABTC) were analyzed 
by NMR-spectroscopy and ESI-MS. 
 
4.6 synthesis PTX-DEGA-PABTC 
Following procedure was conducted for acquiring PABTC, functionalized with PTX through a di(ethylene 
glycol)-based linear acetal (DEGA). PTX (1.17 mmol, 1.000 g) and CSA (0.117 mmol, 0.027 g) were weighed into two 
separate 50 mL round-bottom twin neck flasks and dried overnight under high vacuum over P2O5. PTX and CSA were 
dissolved in 8.6 mL and 2.7 mL of anhydrous CH2Cl2, respectively. DEGVE-PABTC (1.287 mmol, 0.453 g) was added 
dropwise to the PTX solution. Finally, reaction was initiated by dropwise addition of the CSA solution. Reaction was 
carried out for 3 hours at room temperature and monitored by TLC. Next, reaction was quenched with 33 μL of TEA 
(0.234 mmol) and concentrated in vacuo. The crude product was purified by silica gel chromatography (eluent 5:1 
toluene:ethyl acetate v/v with 1 % TEA). After concentration and subsequent drying under high vacuum, the 
obtained yellow solid (0.42 mmol, 0.510 g, 36 %) was analyzed by NMR-spectroscopy, ESI-MS and LC-MS. NMR 
spectroscopy was done in DMSO-d6 due to acetal instability in the slightly acidic CDCl3. 
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4.7 RAFT polymerization 
4.7.1 synthesis PTX-THP-pDMA30 
PTX-THP-PABTC (C2’ or C7 purified regio-isomer) (0.295 mmol, 0.350 g), 2,2′-azobis(2-methylpropionitrile) 
(AIBN) (0.059 mmol, 0.010 g) and N,N-dimethylacrylamide (DMA) (8.843 mmol, 0.877 g; for targeted degree of 
polymerization (DP) of 30) were dissolved in a Schlenk tube in anhydrous N,N-dimethylformamide (DMF) to obtain 
a monomer concentration of 2 M and a CTA:initiator molar ratio of 5:1. The solutions were subjected to 5 freeze-
pump-thaw cycles before polymerization was initiated at 70 °C for 3 hours under vacuum. Monomer conversion 
was determined by 1H-NMR spectroscopy. Polymers were collected by triple precipitation from cold (4 °C) diethyl 
ether and the obtained light yellow solids were subsequently dried under high vacuum (PTX-C2’THP-pDMA30 (0.259 
mmol, 1.030 g, 88 %) and PTX-C7THP-pDMA30 (0.257 mmol, 1.031 g, 87 %)). 
 
4.7.2 synthesis PTX-DEGA-pDMA30 
PTX- C2’/C7DEGA-PABTC (regio-isomeric mixture, modified either through the C2’ or the C7 OH-group of PTX) 
(0.166 mmol, 0.200 g), AIBN (0.033 mmol, 0.005 g) and DMA (4.975 mmol, 0.493 g; for targeted DP of 30) were 
dissolved in a Schlenk tube in anhydrous DMF to obtain a monomer concentration of 2 M and a CTA:initiator molar 
ratio of 5:1. The solutions was subjected to 5 freeze-pump-thaw cycles before polymerization was initiated at 70 °C 
for 3 hours under vacuum. Monomer conversion was determined by 1H-NMR spectroscopy. Polymer was collected by 
triple precipitation from cold (4 °C) diethyl ether and the obtained light yellow solid was subsequently dried under 
high vacuum (0.134 mmol, 0.546 g, 80 %). 
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4.8 critical aggregation concentration (CAC) 
The CAC of the polymeric PTX conjugates was determined by fluorescence spectroscopy using pyrene as a 
fluorescent probe. First, a dilution series of the polymeric prodrugs was prepared in duplicate in PBS with 
concentrations ranging from 10-2 to 103 μg/mL. Secondly, a 3.6 mg/mL (1.8 x 10-2 M) stock solution of pyrene in 
acetone was prepared and kept on ice to prevent evaporation of the acetone. Next, 10 μL of this solution was 
diluted to 1 mL acetone and kept on ice. To 2.5 mL of each conjugate dilution, 8.3 μL of the latter pyrene solution 
was added under stirring leading to a pyrene concentration of 6.0 x 10-7 M. The CAC was quantified by fluorescence 
spectrophotometry at room temperature based on the change in excitation intensity ratio at 338 and 333 nm with 
varying concentration. 
 
4.9 PTX release kinetics in aqueous buffers and diluted serum 
PTX-pDMA30, PTX-C2’THP-pDMA30, PTX-C7THP-pDMA30 and PTX-C2’/C7DEGA-pDMA30 were formulated (10 
mg/mL) in 100 mM citrate buffer (pH 4 and pH 5) and 100 mM phosphate buffer (pH 7.4), and incubated at 37 °C for 
96 hours (pH 4) or 336 hours (pH 5 and pH 7.4). After 0, 24, 48, 96, 168, 240 and 336 hours of incubation, samples 
of 100 μL were taken. All samples were diluted into 900 μL of acetonitrile. The diluted samples were subsequently 
centrifuged (20 000 g, 10 minutes, 5 °C). Finally, the supernatants were analyzed by UPLC. 
In a separate experiment, PTX-pDMA30, PTX-C2’THP-pDMA30, PTX-C7THP-pDMA30 and PTX-C2’/C7DEGA-pDMA30 
were formulated (10 mg/mL) in PBS, supplemented with 10 % FBS, and incubated at 37 °C. After 0, 5, 24 and 72 
hours of incubation, samples of 100 μL were taken. Samples were diluted into 900 μL of acetonitrile and 
thoroughly vortexed for 1 minute. Next, the diluted samples were centrifuged (20 000 g, 10 minutes, 5 °C) and 
supernatants were analyzed by UPLC. 
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4.10 cell culture 
SKOV-3 human ovarian cancer cells were cultured in DMEM, supplemented with 10 % FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate and antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin). Cells were 
incubated at 37 °C in a controlled, sterile environment of 95 % relative humidity and 5 % CO2. 
 
4.11 in vitro cytotoxicity 
In vitro cytotoxicity was assessed by MTT assay. Formulations of PTX-C2’THP-pDMA30, PTX-C7THP-pDMA30 
and PTX-C2’/C7DEGA-pDMA30 were diluted in PBS with concentrations ranging from 5.85 x 10-5 to 5.85 x 102 μM, along 
with two control nanoparticle PTX formulations Abraxane (Celgene) and Genexol-PM (Samyang 
Biopharmaceuticals). MTT stock solution was prepared by dissolving 100 mg MTT in 20 mL of PBS and subsequent 
membrane filtration (0.220 μm). Before use, the MTT stock solution was 5-fold diluted with culture medium. 
Briefly, SKOV-3 cells were seeded into 96-well plates (10 000 cells per well, suspended in 200 μL of 
culture medium) and incubated overnight. Next, 50 μL of sample, DMSO (positive control = 0 % viability) or PBS 
(negative control = 100 % viability) was added to the cells, followed by 72 hours of incubation. Subsequently, the 
medium was aspirated and the cells were washed with 250 μL of PBS. After aspiration, 100 μL of MTT working 
solution was added and the cells were incubated for 2.5 hours. Finally, the MTT working solution was aspirated and 
the formed purple formazan crystals were dissolved in 50 μL of DMSO. Absorbance was determined at 590 nm 
using an EnVision Multilabel plate reader. The absorbance of the positive control was used as blank and therefore 
subtracted from all values. 
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6 supporting info 
6.1 DHP-PABTC 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 6.35 (dd, J = 10.5, 1.7 Hz, 1H), 4.84 (qd, J = 12.3, 1.3 Hz, 1H), 4.69 (ddddd, J = 10.2, 
4.7 Hz, 2.7 Hz, 1.2 Hz, 0.7 Hz, 1H), 4.23 (dd, J = 9, 1.5 Hz, 2H), 4.03 (m, 1H), 3.35 (t, J = 12 Hz, 2H), 2.05 (m, 2H), 1.83 (m, 
1H), 1.71 (m, 1H), 1.66 (m, 2H), 1.61 (d, J = 12.3 Hz, 3H), 1.42 (sextet, J = 12.2 Hz, 2H), 0.92 (t, J = 12.2 Hz, 3H). 
ESI-MS (acetonitrile): m/z = calcd for C14H22O3S3 334.07, found 335.07 [M+H]+ 
 
Figure S1. 1H-NMR (300 MHz, CDCl3) spectrum of DHP-PABTC.  
 
6.2 DEGVE-PABTC 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 6.49 (dd, J = 14.3, 6.8 Hz, 1H), 4.84 (q, J = 7.4 Hz, 1H), 4.30 (t, J = 4.8 Hz, 2H), 4.19 
(dd, J = 14.3, 2.2 Hz, 1H), 4.02 (dd, J = 6.8, 2.2 Hz, 1H), 3.86 – 3.79 (m, 2H), 3.76 – 3.68 (m, 4H), 3.35 (t, J = 7.4 Hz, 2H), 
1.73 – 1.63 (m, 2H), 1.60 (d, J = 7.4 Hz, 3H), 1.43 (h, J = 7.3 Hz, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
ESI-MS (acetonitrile): m/z = calcd for C14H24O4S3 352.08, found 353.09 [M+H]+ 
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Figure S2. ESI-MS (acetonitrile) spectrum of DHP-PABTC. 
 
Figure S3. 1H-NMR (300 MHz, CDCl3) spectrum of DEGVE-PABTC.   
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Figure S4. ESI-MS (acetonitrile) spectrum of DEGVE-PABTC.
 
6.3 PTX-THP-PABTC 
PTX-C2’THP-PABTC: 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 8.14 (d, J = 6.9 Hz, 2H), 7.74 (d, J = 7.0 Hz, 1H), 7.60 (t, J = 7.3 Hz, 1H), 7.55 – 7.27 
(m, 10H), 7.07 (dd, J = 9.0, 2.1 Hz, 1H), 6.30 (t, J = 9.1 Hz, 1H), 6.28 (s, 1H), 5.87 (dt, J = 8.8, 1.7 Hz, 1H), 5.68 (d, J = 7.1 Hz, 
1H), 4.98 (d, J = 9.0 Hz, 1H), 4.91 (s, 1H), 4.90 – 4.82 (m, 1H), 4.76 (d, J = 2.9 Hz, 1H), 4.51 – 4.36 (m, 2H), 4.26 (dd, J = 
36.4, 8.7 Hz, 2H), 3.90 – 3.76 (m, 2H), 3.67 (ddd, J = 11.7, 8.4, 4.1 Hz, 1H), 3.42 – 3.31 (m, 2H), 2.59 (d, J = 1.5 Hz, 3H), 
2.59 – 2.53 (m, 1H), 2.57 – 2.46 (m, 1H), 2.46 (d, J = 4.1 Hz, 1H), 2.38 (dd, J = 15.3, 9.5 Hz, 1H), 2.23 (s, 3H), 2.17 (s, 1H), 
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2.15 – 2.06 (m, 1H), 1.97 – 1.90 (m, 1H), 1.89 (d, J = 1.4 Hz, 3H), 1.90 – 1.78 (m, 1H), 1.74 – 1.70 (m, 1H), 1.72 – 1.65 (m, 
3H), 1.68 – 1.64 (m, 2H), 1.62 (dd, J = 7.4, 1.8 Hz, 3H), 1.62 – 1.50 (m, 3H), 1.50 – 1.35 (m, 2H), 1.24 (s, 3H), 1.23 – 1.21 (m, 
1H), 1.13 (s, 3H), 0.93 (td, J = 7.3, 1.9 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 219.27, 203.87, 171.38, 171.37, 171.07, 171.00, 170.36, 170.35, 170.23, 167.24, 167.12, 
142.45, 142.42, 138.34, 134.06, 133.82, 133.14, 133.11, 132.02, 130.38, 129.24, 128.92, 128.89, 128.84, 128.17, 127.23, 
126.63, 96.12, 96.01, 84.63, 81.17, 79.44, 79.42, 76.61, 75.90, 75.83, 75.68, 75.24, 72.27, 71.63, 67.79, 67.71, 66.98, 66.93, 
58.67, 58.66, 54.63, 48.10, 47.90, 45.62, 43.38, 37.16, 37.15, 35.88, 35.70, 30.08, 30.05, 29.82, 29.10, 26.97, 23.12, 
23.08, 22.45, 22.20, 20.98, 17.35, 17.19, 15.20, 15.16, 13.73 and 13.72, 9.77. 
ESI-MS (acetonitrile): m/z = calcd for C61H73NO17S3 1187.40, found 1188.41 [M+H]+ 
PTX-C7THP-PABTC: 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 8.13 (d, J = 7.1 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.61 (t, J = 7.3 Hz, 1H), 7.52 – 7.34 
(m, 10H), 7.02 (dd, J = 8.7, 4.2 Hz, 1H), 6.33 – 6.21 (m, 2H), 5.74 (dd, J = 8.8, 2.6 Hz, 1H), 5.68 (d, J = 7.1 Hz, 1H), 4.97 (d, 
J = 8.6 Hz, 1H), 4.81 (qd, J = 7.3, 2.3 Hz, 1H), 4.61 (dd, J = 3.2, 2.3 Hz, 1H), 4.52 (s, 1H), 4.50 – 4.37 (m, 1H), 4.26 (dd, J = 
33.8, 8.5 Hz, 2H), 4.17 – 4.11 (m, 1H), 4.11 – 3.92 (m, 2H), 3.80 (d, J = 7.0 Hz, 1H), 3.33 (td, J = 7.4, 1.5 Hz, 2H), 2.61 – 2.54 
(m, 1H), 2.51 (d, J = 4.1 Hz, 1H), 2.48 (d, J = 1.5 Hz, 3H), 2.39 – 2.29 (m, 1H), 2.24 (s, 3H), 2.23 (s, 1H), 2.13 (dd, J = 15.3, 
8.8 Hz, 1H), 1.96 – 1.89 (m, 1H), 1.89 – 1.87 (m, 3H), 1.88 – 1.78 (m, 1H), 1.80 – 1.71 (m, 1H), 1.71 – 1.65 (m, 3H), 1.66 – 1.62 
(m, 2H), 1.63 – 1.58 (m, 3H), 1.56 (dd, J = 7.4, 1.6 Hz, 3H), 1.48 – 1.35 (m, 2H), 1.26 (s, 3H), 1.25 – 1.18 (m, 1H), 1.14 (s, 3H), 
0.92 (td, J = 7.4, 0.8 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 219.27, 203.95, 171.47, 171.43, 171.26, 171.08, 170.31, 170.11, 170.28, 167.20, 167.03, 
142.71, 142.70, 138.10, 134.16, 133.82, 132.95, 132.98, 131.99, 130.35, 129.33, 129.09, 128.88, 128.86, 128.37, 127.20, 
126.73, 100.40, 100.26, 84.62, 81.20, 79.40, 77.36, 76.60, 75.70, 75.25, 72.27, 71.32, 68.17, 68.01, 67.78, 67.69, 58.64, 
55.11, 47.99, 47.91, 45.63, 43.38, 37.08, 37.06, 35.93, 35.64, 30.06, 29.84, 29.80, 29.50, 26.97, 23.01, 22.40, 22.18, 
21.04, 17.48, 17.01, 16.91, 14.94, 13.73, 9.77. 
ESI-MS (acetonitrile): m/z = calcd for C61H73NO17S3 1187.40, found 1188.42 [M+H]+ 
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Figure S5. 1H-NMR (300 MHz, CDCl3) spectrum of PTX-C2’THP-PABTC. 
 
 
Figure S6. 13C-NMR (75 MHz, CDCl3) spectrum of PTX-C2’THP-PABTC. 
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Figure S7. 1H,1H-COSY spectrum of PTX-C2’THP-PABTC. 
 
Figure S8. 1H,13C-HSQC spectrum of PTX-C2’THP-PABTC. 
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Figure S9. 1H,13C-HMBC spectrum of PTX-C2’THP-PABTC. 
 
 
Figure S10. 1H-NMR (300 MHz, CDCl3) spectrum of PTX-C7’THP-PABTC. 
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Figure S11. 13C-NMR (75 MHz, CDCl3) spectrum of PTX-C7’THP-PABTC. 
 
Figure S12. 1H,1H-COSY spectrum of PTX-C7’THP-PABTC.  
chapter 6 
 
156 
 
Figure S13. 1H,13C-HSQC spectrum of PTX-C7’THP-PABTC. 
 
Figure S14. 1H,13C-HMBC spectrum of PTX-C7’THP-PABTC. 
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Figure S15. ESI-MS (acetonitrile) spectrum of PTX-C2’THP-PABTC (A) and PTX-C7THP-PABTC (B). 
 
6.4 PTX-DEGA-PABTC 
1H-NMR (300 MHz, DMSO-d6): the spectrum shows resonances splits into bands of up to four separate peaks, as 
expected for the four possible isomers, which were for the sake of simplicity evaluated together referring to the 
similar proton: δ [ppm] = 8.91 (q, J = 8.4, 6.7 Hz, 1H), 7.98 (d, J = 7.1 Hz, 2H), 7.91 – 7.79 (m, 2H), 7.73 (t, J = 7.3 Hz, 1H), 
7.67 – 7.12 (m, 10H), 6.30 (s, 1H), 5.97 – 5.75 (m, 1H), 5.50 (t, J = 9.0 Hz, 1H), 5.42 (d, J = 7.3 Hz, 1H), 4.92 (d, J = 7.1 Hz, 
1H), 4.89 – 4.82 (m, 1H), 4.80 – 4.68 (m, 1H), 4.65 (s, 1H), 4.64 – 4.51 (m, 1H), 4.22 – 4.14 (m, 2H), 4.11 (dd, J = 7.0, 4.0 
Hz, 1H), 4.06 – 3.94 (m, 2H), 3.69 – 3.60 (m, 2H), 3.59 – 3.52 (m, 2H), 3.51 – 3.40 (m, 3H), 3.37 (t, J = 7.3 Hz, 2H), 2.43 
– 2.31 (m, 1H), 2.30 (s, 3H), 2.10 (s, 3H), 1.97 – 1.82 (m, 1H), 1.82 – 1.72 (m, 3H), 1.73 – 1.61 (m, 1H), 1.64 – 1.55 (m, 3H), 
1.51 (s, 3H), 1.49 (d, J = 1.8 Hz, 3H), 1.35 (h, J = 7.4 Hz, 2H), 1.27 – 1.16 (m, 3H), 1.03 (s, 3H), 1.00 (s, 3H), 0.87 (t, J = 7.3 
Hz, 3H). 
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13C-APT-NMR (75 MHz, DMSO-d6): δ [ppm] = 219.17, 202.36, 170.98, 170.81, 170.16, 169.90, 169.85, 168.72, 166.26, 
165.17, 139.13 and 137.93, 134.44 and 133.31, 133.46, 131.34, 129.55, 128.88, 128.66, 128.40, 128.34, 128.28, 128.19, 
127.98, 127.93, 127.38, 100.52 (PTX-C7DEGA-PABTC) or 99.72 (PTX-C2’DEGA-PABTC), 83.66, 80.32, 76.69, 75.87, 75.39, 
74.71, 74.47, 70.48, 70.08, 69.62, 68.07, 65.21, 64.70, 57.45, 55.11, 47.66, 46.07, 42.93, 36.56, 36.27, 34.65, 29.53, 
26.24, 22.76, 21.38, 21.23, 20.65, 19.66, 16.42, 14.18, 13.39, 9.74. 
ESI-MS (acetonitrile): m/z = calcd for C61H75NO18S3 1205.41, found 1206.43 [M+H]+ 
 
Figure S16. 1H-NMR (300 MHz, DMSO-d6) spectrum of PTX-C2’/C7DEGA-PABTC. 
 
Figure S17. 13C-APT-NMR (75 MHz, DMSO-d6) spectrum of PTX-C2’/C7DEGA-PABTC.   
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Figure S18. 1H,1H-COSY spectrum of PTX-C2’/C7DEGA-PABTC. 
 
Figure S19. 1H,13C-HSQC spectrum of PTX-C2’/C7DEGA-PABTC.   
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Figure S20. 1H,13C-HMBC spectrum of PTX-C2’/C7DEGA-PABTC. 
 
6.5 PTX-THP-pDMA30 
SEC(DMAc, PMMA-St.): Mn = 3975, PDI = 1.08 (PTX-C2’THP-pDMA30) and Mn = 4226, PDI = 1.09 (PTX-C7THP-pDMA30). 
 
6.6 PTX-DEGA-pDMA30 
SEC(DMAc, PMMA-St.): Mn = 4999, PDI = 1.08 (PTX-C2’/C7DEGA-pDMA30). 
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Figure S21. ESI-MS (acetonitrile) spectrum of PTX-C2’/C7DEGA-PABTC. 
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Figure S22. LC-DAD/MS of PTX-C2’/C7DEGA-PABTC: UV-chromatogram (A; retention times with corresponding λmax are shown) and 
total ion chromatogram (TIC) (B; retention times with corresponding molecular ion are shown). 
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Figure S23. 1H-NMR (300 MHz, MeOH-d4) spectrum of PTX-C2’THP-pDMA30 (A) and PTX-C7THP-pDMA30 (B). 
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Figure S24. 1H-NMR (300 MHz, MeOH-d4) spectrum of PTX-C2’/C7DEGA-pDMA30. 
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Figure S25. Size distribution measured by dynamic light scattering (DLS) of conjugates mixed with 10% of serum. *regio-
isomeric mixture of PTX-polymer conjugate, modified either through the C2’ or the C7 OH-group of PTX. 
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Figure S26. Confocal microscopy images of SKOV-3 human ovarian cancer cells pulsed with rhodamine-labelled PTX-C2’THP-
pDMA conjugates. In the left large panel, cells were counterstained with Hoechst (nuclei - blue) and phalloidin (green – 
actin/membrane). The right panels display counterstaining with LysoTracker and highlight the localization of the conjugates 
in intracellular acidic vesicles. 
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abstract 
Based on the developed grafting-from-drug approach, this chapter describes the synthesis of active 
targeted docetaxel-polymer prodrug conjugates, through a combination of grafting-from-drug RAFT 
polymerization and post-modification with a small molecule targeting ligand for prostate specific membrane 
antigen (PSMA). Docetaxel (DTX) was ligated to a RAFT CTA by regioselective esterification at the C2’ OH-group of 
DTX. Subsequent RAFT polymerization with DMA yielded well-defined, amphiphilic, micellar DTX-polymer prodrug 
conjugates with similar high drug loading, aqueous compatibility, colloidal stability and small particle size as 
compared to the previously reported first- and second-generation PTX-polymer conjugates. Fluorescently labeled 
analogues were prepared by incorporating a minimal fraction of rhodamine-labeled monomer during the 
polymerization step. Additionally, a maleimide-modified derivative of the PSMA targeting ligand S,S-2-(3-(5-amino-
1-carboxypentyl)-ureido)-pentanedioic acid (ACUPA) was synthesized and used for ligation to the other polymer 
chain end after aminolysis of the thiocarbonate moiety. Finally, FACS analysis provides a first indication of 
receptor-specific interaction between the polymer conjugates and PSMA-positive LNCaP cells as compared to non-
ACUPA functionalized control polymer conjugates.   
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1 introduction 
Despite their broad-spectrum activity as anti-cancer drugs, widespread use of taxanes (i.e. paclitaxel (PTX) 
and docetaxel (DTX)) in chemotherapy remains problematic due to toxic side-effects.[1,2] The latter can be evoked 
intrinsically by the drugs and/or by allergenic excipients (e.g. Cremophor EL in Taxol (PTX) and polysorbate 80 in 
Taxotere (DTX)).[3–7] Second-generation taxane formulations (i.e. Abraxane and Genexol-PM (PTX)) based on 
biocompatible surfactants significantly reduced toxicity (i.e. hypersensitivity reactions), increased the therapeutic 
index and thus the efficacy of taxanes.[8–13] However, intrinsic side-effects (e.g. nausea, neuropathy, neutropenia) 
remain present due to systemic drug distribution throughout the body. Hence, selective accumulation (i.e. at the 
(metastatic) tumor site) is imperative in the development of the next generation taxane formulations. 
Nanomedicine pushed the boundaries in targeted drug delivery since the discovery of the enhanced 
permeability and retention effect (EPR)[14,15]. The latter involves ‘leaky’, highly fenestrated neoplastic endothelia 
through which nanomedicines can swiftly pass into the tumor microenvironment where they can reside due to an 
impaired drainage by neighboring lymphatic vessels. The latter phenomenon is termed ‘passive’ targeting as it is 
merely based on physical phenomena. Unfortunately, due to the vast heterogeneity of cancer disease, EPR cannot 
always be relied upon.[16,17] Metastatic tumor tissue is often poorly vascularized and the intrinsic slower tumor 
growth in humans as compared to preclinical models often implies the formation of regular, dense vascular 
endothelium.[18,19] More efficient and selective treatment would thus require additional, active targeting strategies. 
Active targeting involves the interaction between a ligand and a receptor/antigen on the surface of the 
targeted cell prior to receptor-mediated endocytosis.[20] This allows for more selective delivery of drugs to tissues, 
overexpressing the target receptor/antigen. Additionally, active uptake also suppresses multiple drug resistance 
(MDR) mechanisms such as P-glycoprotein (P-gp) efflux.[21] Due to their superior selectivity and affinity towards 
any type of antigen, the benchmark in this field was set by monoclonal antibody-drug conjugates (ADCs).[22–24] 
However, ADC-based chemotherapy is not without limitations. First, monoclonal antibodies (mAbs) cannot always 
thoroughly penetrate into the tumor tissue due to their high molecular weight (MW) and size.[25] Secondly, ADCs can 
prematurely bind to detached, soluble receptor/antigen in tumor tissue fluid, thereby losing their targeting 
capabilities.[26] Finally, the extremely high ADC manufacturing cost (i.e. mAb production, drug conjugation and 
purification) questions whether the use of ADCs is feasible on a global scale and hence whether or not 
economically more favorable platforms for active targeting should be explored more thoroughly.[27]  
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An emerging field in targeted drug delivery comprises small molecule-drug conjugates (SMDCs).[25,28] The 
basic design of the latter is similar to ADCs, with the great distinction that the mAb is substituted by a small-
molecule ligand with high affinity ligand towards the target receptor. Not only is this a great tool for reducing 
costs as the latter does not require a biotechnological production process, the smaller MW and size of SMDCs could 
also allow for a more thorough tumor penetration and reduce off-site toxicity due to swift renal clearance of dose 
which has not reached the site of interest. Several SMDCs are currently evaluated in phase I/II trials as 
chemotherapeutic or imaging agent, showing promising clinical outlook.[28] For the majority of these systems, the 
drug or imaging agent is attached to the small-molecule targeting ligand by a low MW, hydrophilic oligopeptide 
spacer[29–32] and often requires multistep, solid phase peptide synthesis (SPPS) procedures.[33,34] 
This chapter investigates the chemical feasibility of our previously described grafting-from-drug approach 
to apply the same basic design principles of SMDCs and further simplify the synthesis of the spacer by substituting 
the oligopeptide with a low MW, hydrophilic polymer chain.[35] As proof of concept, we aimed at developing a ‘small 
molecule-polymer-drug conjugate’ for prostate cancer. With DTX (i.e. Taxotere) regularly used for treatment of 
hormone-refractory prostate cancer,[36] our goal was to design a DTX-polymer prodrug conjugate, functionalized 
with a targeting ligand for prostate specific membrane antigen (PSMA), a membrane receptor often overexpressed 
by prostate cancer cells and neovascular endothelium of solid tumors.[37–39] Out of the several small-molecule 
ligands with high affinity for PSMA which have been developed,[28,40] we selected the same ligand which was used 
for the BIND-014 technology (i.e. S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-pentanedioic acid (ACUPA)).[41] 
 
2 results and discussion 
The developed synthesis strategy is depicted in Scheme 1. DTX (Figure S1 – S3) was regioselectively 
esterified at the C2’ hydroxyl (OH)-group with a reversible addition-fragmentation chain transfer (RAFT) chain 
transfer agent (CTA;. 2-(butylthiocarbonothioylthio)propanoic acid (PABTC)), yielding DTX-PABTC. The structure of 
the latter was confirmed by nuclear magnetic resonance (NMR) spectroscopy (Figure S4 – S8) and electron spray 
ionization-mass spectroscopy (ESI-MS; Figure S9). This DTX-functionalized RAFT CTA was used for subsequent 
polymerization of N,N-dimethylacrylamide (DMA). A degree of polymerization (DP) of 15 and 30 was aimed to 
investigate the influence of hydrophilic polymer chain length on DTX-pDMA aqueous compatibility and to allow 
comparison with the previously reported PTX-pDMA conjugates. The difference in chain length was confirmed by 
DOSY NMR (Figure 1A) and size exclusion chromatography (SEC; Figure 1D). In analogy to the PTX-pDMA15 conjugates 
active targeted docetaxel-polymer prodrug conjugates 
 
171 
(Chapter 5), DTX-pDMA15 was neither soluble nor dispersible in aqueous buffer. Both DTX-pDMA15 (Figure S10 and 
S12A) and DTX-pDMA30 (Figure S11 and S12B) were characterized by 1H-NMR spectroscopy and showed high α,ω-
endgroup fidelity. Narrow polymer dispersities were observed by SEC for both conjugates, even at high monomer 
conversions (Table 1). As revealed by dynamic light scattering (DLS), DTX-pDMA30 self-assembled into micellar 
nanostructures with colloidal stability (Figure 1B), size (i.e. Z-average = 12.5 ± 0.1 nm; n = 3) and dispersity (i.e. 
0.064 ± 0.004; n = 3) in concordance to the first- and second-generation PTX-pDMA30 conjugates (Chapter 5 and 
Chapter 6). Fluorescently labeled DTX-pDMA30 analogue conjugates (i.e. DTX-pDMARho30) were prepared by 
incorporating a small fraction of rhodamine-labeled monomer during the polymerization step. The latter had little 
influence on the polymer characteristics measured by NMR (Figure S13 and S14) and SEC (Table 1 and Figure S24). 
Likely due to the bulky nature of the rhodamine-labeled monomer, a modest increase in particle size was observed 
by DLS (i.e. Z-average = 23.6 ± 0.1 nm; n = 3), while a narrow dispersity (i.e. 0.094 ± 0.003; n = 3) was maintained 
(Figure 1C), indicating the rhodamine-labeled DTX-pDMARho30 conjugates are suitable for in vitro evaluation. 
 
Table 1. Compositional data of the synthesized polymers. 
polymer [DMA]0/ 
[CTA] 
conversion 
DMA 
 
(%)
a
 
DPconv,b DPendgroup,c Mn (Da)
d
 Ð
d
 DTX 
loading capacity (%)
e
 
DTX-pDMA15 15 88 13 17 2668 1.08 34 
DTX-pDMA30 30 97 29 32 4491 1.09 20 
DTX-pDMARho30 30 97 29 31 4365 1.09 20 
DTX-pDMA30-ACUPA 30
f 97f 29f 30 4876 1.12 19 
DTX-pDMA30-HA 30
f 97f 29f 31 5319 1.09 20 
DTX-pDMARho30-ACUPA 30
f 97f 29f 31 4997 1.13 19 
DTX-pDMARho30-HA 30
f 97f 29f 31 5222 1.09 20 
a
 Determined by 
1
H-NMR spectroscopy. 
b
 Determined by 
1
H-NMR spectroscopy based on monomer conversion. 
c
 Determined by 
1
H-NMR spectroscopy based on endgroup analysis. 
d
 Analyzed by SEC in DMAc, calibrated with PMMA standards. 
e
 Calculated 
based on conversion by 
1
H-NMR spectroscopy: MWDTX/MWDTX-conjugate x 100 %. 
f Post-polymerization functionalized polymers with 
conversion/DP equal to corresponding unfunctionalized DTX-conjugates.
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To allow for the preparation of active targeted DTX-pDMA30 and DTX-pDMARho30, the PSMA-targeting ligand 
ACUPA was synthesized and modified with a maleimide moiety as depicted in Scheme S1. First, 4-maleimidebutyric 
acid was activated with pentafluorophenol (PFP) as confirmed by NMR spectroscopy (Figure S15). Next, 
carboxybenzyl- (Cbz) and tert-butyl ester-protected ACUPA was synthesized (Figure S16 and S17). After Cbz-
deprotection (Figure S18), the latter was used for subsequent reaction with maleimidobutyryl-PFP. Coupling was 
confirmed by NMR spectroscopy (Figure S19). Finally, tert-butyl ester-deprotection with trifluoroacetic acid (TFA) 
revealed maleimidobutyryl-ACUPA, as confirmed by NMR spectroscopy (Figure S20 – S22) and ESI-MS (Figure S23). 
 
Scheme 1. Reaction scheme illustrating regioselective esterification of at the C2’ OH-group of DTX with a RAFT CTA (PABTC), 
followed by polymerization of N,N-dimethylacrylamide (DMA) and post-polymerization functionalization of the 
trithiocarbonate endgroup with a maleimide-modified derivative of a PSMA targeting ligand (ACUPA). 
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Figure 1. DOSY NMR spectra (A) and SEC elugrams (D) of DTX-pDMA conjugates. (B) Colloidal stability of DTX-pDMA30 and size 
distribution (C,E) of DTX-pDMA conjugates (30 mg/mL in PBS) measured by DLS (n = 3). 
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In the final synthesis step, maleimidobutyryl-ACUPA was used for post-polymerization functionalization of 
both DTX-pDMA30 and DTX-pDMARho30 by sequential one-pot aminolysis/thiol−maleimide endgroup modification. For 
the preparation of non-targeted control conjugate, 6-maleimidohexanoic acid (MHA) was used instead. Removal of 
the RAFT trithiocarbonate endgroup (i.e. Z-group; Figure S25) and the structures of both PSMA-targeted DTX-
pDMA30-ACUPA (Figure S26) and non-targeted DTX-pDMA30-HA (Figure S27) were confirmed by NMR spectroscopy. In 
addition, DOSY (Figure 1A and Figure S28) and SEC (Figure 1D) showed a subtle change in diffusional rate and 
increase in MW, respectively, whilst low polymer dispersity was maintained. Functionalization of DTX-pDMARho30 
with maleimidobutyryl-ACUPA or MHA SEC led to similar results as observed by SEC (Figure S24). Interestingly, DLS 
showed a significant and similar shift in particle size from supra to sub 10 nm range for both rhodamine-labeled 
and unlabeled DTX-pDMA30-ACUPA and DTX-pDMA30-HA, compared to their non-functionalized counterparts (Figure 
1E). This can be attributed to the higher hydrophilic nature of the ω-endgroup due to the monocarboxylate (HA) and 
tricarboxylate (ACUPA) moieties compared to the butyl moiety before post-modification, inducing a switch from a 
self-assembled to a more water-soluble state of the DTX-polymer conjugates. Both DTX-pDMA30Rho-ACUPA and DTX-
pDMA30Rho-HA contained equal rhodamine-labeling as confirmed by UV-VIS spectroscopy (Figure S29), and hence are 
suitable for accurate head-to-head comparison in vitro. 
 
 
Figure 2. Histograms and mean fluorescence intensity values of LNCaP cells, co-incubated for 2 hours with 0.04, 0.2 and 1 
mg/mL of targeted DTX-pDMA30Rho-ACUPA (red) or control DTX-pDMA30Rho-HA (blue), measured by FACS (n = 3). 
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Finally, in vitro cellular uptake was evaluated by flow cytometry (FACS) by co-incubation of DTX-pDMA30Rho-
ACUPA or DTX-pDMA30Rho-HA with LNCaP cells. The latter is a human prostate cancer cell line, known for 
overexpressing the PSMA receptor at their surface. Both conjugates were incubated for 2 hours at 3 different 
concentrations prior to FACS analysis. As illustrated in Figure 2, significantly higher fluorescence values were 
observed at all concentrations tested for LNCaP cells co-incubated with DTX-pDMA30Rho-ACUPA. As the degree of 
rhodamine-labeling is equal for both conjugates (cfr. supra), these data suggest that DTX-pDMA30Rho-ACUPA has 
stronger interaction with LNCaP cells as compared to DTX-pDMA30Rho-HA, most likely evoked by the high affinity of 
ACUPA towards PSMA. 
 
3 conclusions 
As the previous chapters emphasized on first- and second-generation PTX-polymer conjugates, this 
chapter comprehensively demonstrates that a similar high degree of polymer definition and physicochemical 
features can be attained when the grafting-from-drug strategy is applied to DTX, further confirming the overall 
robustness and chemical versatility of the approach. Additionally, the combination with established maleimide 
coupling chemistry enabled synthesis of functionalized DTX-polymer conjugates for active PSMA-targeting. FACS 
evaluation of cellular uptake suggests a higher degree of interaction between targeted DTX-polymer conjugate 
and PSMA-positive LNCaP cells as compared to control conjugate. This not only encourages more elaborate in vitro 
evaluation, but also urges to extend beyond ‘grafting-from-taxane’ by exploring alternative APIs and maleimide-
modified targeting ligands. 
 
4 experimental 
4.1 materials 
All chemicals were purchased from Sigma Aldrich unless mentioned otherwise. The RAFT CTA 2-
(butylthiocarbonothioylthio)propanoic acid (PABTC) was synthesized according to literature.[42] TLC plates were 
purchased from Macherey Nagel. Docetaxel (DTX) was purchased from LC Laboratories. Acryloxyethyl 
thiocarbamoyl rhodamine B (ARho) and 4-maleimidobutyric acid were obtained from Polysciences Inc. and TCI, 
respectively. N-ε-Cbz-L-Lysine tert-butyl ester hydrochloride (H-Lys(Z)-Ot-Bu HCl) was purchased from Merck 
Millipore. L-Glutamic acid di-tert-butyl ester hydrochloride (H-Glu(Ot-Bu)-Ot-Bu HCl), 4',6-diamidino-2-
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phenylindole (DAPI) solution (1 mg/mL) in H2O, Dulbecco’s phosphate buffered saline (PBS), cell dissociation buffer 
(enzyme-free), Roswell Park Memorial Institute (RPMI) 1640 GlutaMAX medium, fetal bovine serum (FBS), L-
glutamine, sodium pyruvate, penicillin and streptomycin were obtained from Thermo Fisher Scientific. LNCaP cells 
were supplied by ATCC. 
 
4.2 analysis 
NMR spectra were recorded on a Bruker 300 and 400 MHz FT-NMR spectrometer. Chemical shifts (δ) are 
given in ppm relative to TMS. Samples were prepared in given deuterated solvents and their signals referenced to 
residual non-deuterated signals of the solvent.  
Electron spray ionization-mass spectroscopy (ESI-MS) measurements were performed on a Waters 
(Milford, Mass, USA) LCT Premier XE time-of-flight (TOF) mass spectrometer equipped with an ESI interface. 
Samples were infused in an acetonitrile:formic acid (1000:1) mixture at 0.1 mL/min. 
Size exclusion chromatography (SEC) was carried out on an Agilent 1260 system, equipped with a 1260 
ISO-pump, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). Measurements were 
performed in N,N-dimethylacetamide (DMAc) containing 50 mM LiCl at 50 °C, using a flow rate of 0.593 mL/min. A 
guard column and two PL gel 5 μm mixed-D columns were used in series, calibrated with poly(methyl 
methacrylate) (PMMA) standards obtained from PSS (Mainz, Germany).  
Dynamic light scattering (DLS). DLS measurements were carried out on a Zetasizer Nano S (Malvern) with a 
HeNe laser (λ = 633 nm) at a scattering angle of 173°. 
 
4.3 synthesis DTX-PABTC 
In a 50 mL round-bottom unineck flask, PABTC (2.040 mmol, 0.486 g), 4-(dimethylamino)pyridine (DMAP) 
(0.204 mmol, 0.024 g) and docetaxel (DTX) (1.85 mmol, 1.500 g) were dissolved in 30 mL anhydrous 
dichloromethane (CH2Cl2). Next, N,N′-diisopropylcarbodiimide (DIC) (2.04 mmol, 0.258 g) was added dropwise and 
the mixture was stirred for 3 hours at room temperature and monitored by TLC. Subsequently, the reaction mixture 
was filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (eluent 6:4 
hexane:ethyl acetate v/v). After concentration and subsequent drying under high vacuum, the obtained yellow solid 
(0.90 mmol, 0.922 g, 49 %) was analyzed by NMR spectroscopy and ESI-MS. 
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4.4 synthesis DTX-pDMA 
DTX-PABTC (0.146 mmol, 0.150 g), 2,2′-azobis(2-methylpropionitrile) (AIBN) (0.029 mmol, 0.004 g) and 
N,N-dimethylacrylamide (DMA) (4.377 mmol, 0.433 g or 2.188 mmol, 0.216 g; for targeted degree of polymerization 
(DP) of 30 and 15, respectively) were dissolved in a Schlenk tube in anhydrous N,N-dimethylformamide (DMF) to 
obtain a monomer concentration of 2 M and a CTA:initiator molar ratio of 5:1. The solutions were subjected to 5 
freeze-pump-thaw cycles before polymerization was initiated at 70 °C for 3.5 hours under vacuum. Monomer 
conversion was determined by 1H-NMR spectroscopy. Polymers were collected by triple precipitation from cold (4 
°C) diethyl ether and the obtained light yellow solids were subsequently dried under high vacuum (DTX-pDMA15 
(0.068 mmol, 0.158 g, 47 %) and DTX-pDMA30 (0.141 mmol, 0.553 g, 96 %)). 
 
4.5 synthesis DTX-pDMARho 
DTX-PABTC (0.097 mmol, 0.100 g), AIBN (0.019 mmol, 0.003 g) and monomers (i.e. DMA (2.912 mmol, 0.288 
g) and acryloxyethyl thiocarbamoyl rhodamine B (ARho) (0.005 mmol; 0.003 g); for targeted DP of 30) were 
dissolved in a Schlenk tube in anhydrous DMF to obtain a monomer concentration of 2 M and a CTA:initiator molar 
ratio of 5:1. The solution was subjected to 5 freeze-pump-thaw cycles before polymerization was initiated at 70 °C 
for 3.5 hours under vacuum. Monomer conversion was determined by 1H-NMR spectroscopy. Polymer was collected 
by triple precipitation from cold (4 °C) diethyl ether and the obtained purple solid was subsequently dried under 
high vacuum (0.087 mmol, 0.343 g, 90 %). 
 
4.6 synthesis PSMA targeting ligand 
The trithiocarbonate endgroup of the polymers can be converted into a thiol. Hence, we aimed at 
designing a maleimide-derivative of the PSMA targeting ligand S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-
pentanedioic acid (ACUPA) to allow post-polymerization functionalization (Scheme S1). The synthesis will be fully 
described in the following paragraphs. 
 
4.6.1 synthesis maleimidobutyryl-PFP 
In a 250 mL round-bottom unineck flask, 4-maleimidobutyric acid (5.459 mmol, 1.000 g), and 
pentafluorophenol (PFP) (6.005 mmol, 1.105 g) were dissolved in 60 mL anhydrous CH2Cl2 and put on ice. Next, DIC 
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(6.005 mmol, 0.757 g) was added dropwise and the mixture was stirred for 1.5 hours at room temperature and 
monitored by TLC. Subsequently, the reaction mixture was filtered and concentrated in vacuo. The crude product 
was purified by silica gel chromatography (eluent CH2Cl2). After concentration and subsequent drying under high 
vacuum, the obtained white solid (4.994 mmol, 1.743 g, 91 %) was analyzed by NMR spectroscopy. 
 
4.6.2 synthesis tert-butyl ester ACUPA 
Tert-butyl ester ACUPA as synthesized as previously described.[43] L-Glutamic acid di-tert-butyl ester 
hydrochloride (H-Glu(Ot-Bu)-Ot-Bu HCl) (16.903 mmol, 5.000 g) and triethylamine (TEA) (55.442 mmol, 5.610 g) 
were dissolved in 150 mL anhydrous CH2Cl2 and the resulting solution was cooled to -78 °C. Triphosgene (5.747 
mmol, 1.705 g) in 20 mL anhydrous CH2Cl2 was added dropwise via syringe to the reaction mixture. Upon complete 
addition, the reaction was allowed to warm to room temperature and stir for 30 minutes. N-ε-Cbz-L-Lysine tert-
butyl ester hydrochloride (H-Lys(Z)-Ot-Bu HCl) (10.141 mmol, 3.781 g) was added, followed by TEA (10.141 mmol, 
1.026 g). The reaction was allowed to stir at room temperature overnight. The reaction mixture was then washed 
with H2O (2 x 150 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel 
chromatography (eluent 1.5:1 hexane:ethyl acetate v/v). After concentration and subsequent drying under high 
vacuum, the obtained colorless oil (9.236 mmol, 5.736 g, 91 %) was analyzed by NMR spectroscopy. 
Next, in a 500 mL round-bottom unineck flask, the obtained product (9.236 mmol, 5.736 g) was dissolved 
in 100 mL dioxane and flushed with N2. To the latter, dry 10% Pd/C (573 mg, 10 % by mass) was quickly added and 
the flask was again flushed with N2. Reaction mixture was gently bubbled with H2 for several hours, allowed to stir 
overnight under H2-atmosphere and monitored by TLC until deemed complete. The mixture was first flushed with 
N2, then filtered over a plug of celite and concentrated in vacuo. Subsequent drying under high vacuum yielded a 
viscous colorless oil (9.184 mmol, 4.473 g, 99 %). The latter was analyzed by NMR spectroscopy and the obtained 
tert-butyl ester ACUPA used in the next step without further purification. 
 
4.6.3 synthesis maleimidobutyryl-ACUPA 
In a 50 mL round-bottom unineck flask, maleimidobutyryl-PFP (2.578 mmol, 0.900 g), was dissolved in 12 
mL anhydrous CH2Cl2. Next, tert-butyl ester ACUPA (Cbz-deprotected, 1.719 mmol, 0.837 g) and TEA (5.157 mmol, 
0.521 g), dissolved in 8 mL anhydrous CH2Cl2, was added dropwise and the mixture was stirred for 2 hours at room 
temperature and monitored by TLC. Subsequently, the reaction mixture concentrated in vacuo and the crude was 
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purified by silica gel chromatography (eluent ethyl acetate). Concentration and subsequent drying under high 
vacuum yielded a white solid (1.467 mmol, 0.957 g, 85 %) and the tert-butyl ester maleimidobutyryl-ACUPA was 
analyzed by NMR spectroscopy and used as such in the final step (vide infra). 
Finally, tert-butyl ester maleimidobutyryl-ACUPA (1.467 mmol, 0.957 g) was dissolved in 10 mL anhydrous 
CH2Cl2. A total of 10 mL trifluoroacetic acid (TFA) was added dropwise and reaction was stirred for 2 hours at room 
temperature. Next, 10 mL toluene was added and the mixture was concentrated in vacuo. After subsequent drying 
under high vacuum, the obtained viscous colorless oil (1.453 mmol, 0.703 g, 99 %) was analyzed by NMR 
spectroscopy and ESI-MS. 
 
4.7 post-polymerization functionalization 
Post-polymerization modification was conducted using a reported protocol on sequential one-pot 
aminolysis/thiol−maleimide endgroup modification.[44] DTX-pDMA30 or DTX-pDMARho30 (0.020 mmol, 0.080 g) and 
trimethyl phosphite (TMP) (0.100 mmol, 0.012 g) were dissolved in a Schlenk tube in 0.645 mL acetonitrile. The 
solution was subjected to 3 freeze-pump-thaw cycles before propylamine (0.060 mmol, 0.003 g), dissolved in 0.2 
mL acetonitrile (flushed with N2) was added dropwise and allowed to react for 6 hours at room temperature. Next, 
maleimide ligand (maleimidobutyryl-ACUPA; 0.100 mmol, 0.048 g or 6-maleimidohexanoic acid (MHA) (0.100 
mmol, 0.021 g); for obtaining DTX-pDMA conjugates post-functionalized with PSMA targeted ACUPA- and control 
HA-ligand, respectively) was dissolved in a Schlenk tube in 0.454 mL dimethyl sulfoxide (DMSO). The solution was 
subjected to 3 freeze-pump-thaw cycles before being added to the reaction mixture. After overnight reaction at 
room temperature, excess of TMP and propylamine were discarded by triple precipitation from cold (4 °C) diethyl 
ether. To remove excess of maleimide ligand, the obtained white (DTX-pDMA30-ACUPA and DTX-pDMA30-HA) and 
purple (DTX-pDMARho30-ACUPA and DTX-pDMARho30-HA) solids were dialyzed against 1:1 acetonitrile:H2O v/v for 48 
hours days, followed by dialysis against H2O for 24 hours. The purified solutions were subsequently freeze-dried 
and yielded white (DTX-pDMA30-ACUPA (0.013 mmol, 0.059 g, 69 %); DTX-pDMA30-HA (0.015 mmol, 0.062 g, 77 %)) 
and purple (DTX-pDMARho30-ACUPA (0.014 mmol, 0.060 g, 70 %); DTX-pDMARho30-HA (0.015 mmol, 0.059 g, 77 %)) 
powders which were analyzed by SEC and NMR spectroscopy. For allowing adequate evaluation of in vitro uptake, 
UV-VIS spectroscopy was used to ascertain equal rhodamine labeling of DTX-pDMARho30-ACUPA and DTX-pDMARho30-
HA. 
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4.8 in vitro cellular uptake 
4.8.1 cell culture 
LNCaP human cancer cells were cultured in RPMI 1640 GlutaMAX, supplemented with 10 % FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate and antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin). Cells were 
incubated at 37 °C in a controlled, sterile environment of 95 % relative humidity and 5 % CO2. 
 
4.8.2 FACS 
LNCaP cells were seeded into 24-well titer plates (150 000 cells per well, suspended in 1 mL of culture 
medium) and allowed to attach overnight. Next 1.3, 6.7 or 34.5 μL of 30 mg/mL DTX-pDMARho30-ACUPA or DTX-
pDMARho30-HA in PBS was added to the cells, followed by 2 hours of incubation at 37 °C. After incubation, wells were 
aspirated, washed with 0.5 mL PBS and detached by 0.4 mL enzyme-free cell dissociation buffer. Cell suspensions 
were centrifuged (350 g, 7 min, 4 °C). Finally, supernatant was aspirated and the cell pellets were suspended into 
200 μL of PBS and kept on ice to maintain cell integrity. Live/dead staining was performed by adding 0.5 μL of DAPI 
solution to each cell suspension before measurement. The experiment was conducted in triplicate. FACS was 
performed on a BD LSR Fortessa (BD Biosciences). Data were processed by FlowJo software. 
  
active targeted docetaxel-polymer prodrug conjugates 
 
181 
5 references 
[1] D. G. I. Kingston, D. J. Newman, Curr. Opin. Drug Discov. Devel. 2007, 10, 130–144. 
[2] J. Crown, M. O’Leary, Lancet 2000, 355, 1176–1178. 
[3] L. B. Norris, Z. P. Qureshi, P. B. Bookstaver, D. W. Raisch, O. Sartor, H. Chen, F. Chen, C. L. Bennett, Community Oncol. 2010, 
7, 425–428. 
[4] A. J. ten Tije, J. Verweij, W. J. Loos, A. Sparreboom, Clin. Pharmacokinet. 2003, 42, 665–685. 
[5] Z. Weiszhar, J. Czucz, C. Revesz, L. Rosivall, J. Szebeni, Z. Rozsnyay, Eur. J. Pharm. Sci. 2012, 45, 492–498. 
[6] H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Eur. J. Cancer 2001, 37, 1590–1598. 
[7] K. S. Lee, H. C. Chung, S. A. Im, Y. H. Park, C. S. Kim, S.-B. Kim, S. Y. Rha, M. Y. Lee, J. Ro, Breast Cancer Res. Treat. 2008, 
108, 241–250. 
[8] T.-Y. Kim, Clin. Cancer Res. 2004, 10, 3708–3716. 
[9] N. V Rajeshkumar, S. Yabuuchi, S. G. Pai, Z. Tong, S. Hou, S. Bateman, D. W. Pierce, C. Heise, D. D. Von Hoff, A. Maitra, et al., 
Br. J. Cancer 2016, 115, 442–453. 
[10] H. Shao, H. Tang, O. E. Salavaggione, C. Yu, B. Hylander, W. Tan, E. Repasky, A. A. Adjei, G. K. Dy, J. Thorac. Oncol. 2011, 6, 
998–1005. 
[11] E. Miele, G. P. Spinelli, F. Tomao, S. Tomao, Int. J. Nanomedicine 2009, 4, 99–105. 
[12] N. K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R. L. Theriault, E. Rivera, B. Esmaeli, S. E. Ring, A. Bedikian, G. N. 
Hortobagyi, et al., Clin. Cancer Res. 2002, 8, 1038–1044. 
[13] A. Lluch, I. Alvarez, M. Munoz, M. A. Segui, I. Tusquets, L. Garcia-Estevez, Crit. Rev. Oncol. Hematol. 2014, 89, 62–72. 
[14] H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, J. Control. Release 2000, 65, 271–284. 
[15] V. Torchilin, Adv. Drug Deliv. Rev. 2011, 63, 131–135. 
[16] R. K. Jain, T. Stylianopoulos, Nat. Rev. Clin. Oncol. 2010, 7, 653–664. 
[17] J. I. Hare, T. Lammers, M. B. Ashford, S. Puri, G. Storm, S. T. Barry, Adv. Drug Deliv. Rev. 2016, DOI 
10.1016/j.addr.2016.04.025. 
[18] A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks, D. G. Anderson, Nat. Rev. Cancer 
2012, 12, 39–50. 
[19] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Control. Release 2015, 200, 138–157. 
[20] I. Canton, G. Battaglia, Chem. Soc. Rev. 2012, 41, 2718–2739. 
[21] M. M. Gottesman, T. Fojo, S. E. Bates, Nat. Rev. Cancer 2002, 2, 48–58. 
[22] S. Panowski, S. Bhakta, H. Raab, P. Polakis, J. R. Junutula, in MAbs, Taylor & Francis, 2014, pp. 34–45. 
[23] R. V Chari, M. L. Miller, W. C. Widdison, Angew. Chem. Int. Ed. Engl. 2014, 53, 3796–3827. 
[24] P. Polakis, Pharmacol. Rev. 2016, 68, 3–19. 
[25] N. Krall, J. Scheuermann, D. Neri, Angew. Chem. Int. Ed. Engl. 2013, 52, 1384–1402. 
[26] G. Casi, D. Neri, J. Med. Chem. 2015, 58, 8751–8761. 
[27] C. Peters, S. Brown, Biosci. Rep. 2015, 35, 1–20. 
[28] M. Srinivasarao, C. V Galliford, P. S. Low, Nat. Rev. Drug Discov. 2015, 14, 203–219. 
[29] C. P. Leamon, J. A. Reddy, P. J. Klein, I. R. Vlahov, R. Dorton, A. Bloomfield, M. Nelson, E. Westrick, N. Parker, K. Bruna, J. 
Pharmacol. Exp. Ther. 2011, 336, 336–343. 
[30] R. Kurzrock, N. Gabrail, C. Chandhasin, S. Moulder, C. Smith, A. Brenner, K. Sankhala, A. Mita, K. Elian, D. Bouchard, et al., 
Mol. Cancer Ther. 2012, 11, 308–316. 
[31] E. Kähkönen, I. Jambor, J. Kemppainen, K. Lehtiö, T. J. Grönroos, A. Kuisma, P. Luoto, H. J. Sipilä, T. Tolvanen, K. Alanen, 
Clin. Cancer Res. 2013, 19, 5434–5443. 
[32] A. J. Beer, M. Schwaiger, J. Nucl. Med. 2011, 52, 335–337. 
[33] S. A. Kularatne, K. Wang, H.-K. R. Santhapuram, P. S. Low, Mol. Pharm. 2009, 6, 780–789. 
[34] J. Roy, T. X. Nguyen, A. K. Kanduluru, C. Venkatesh, W. Lv, P. V. N. Reddy, P. S. Low, M. Cushman, J. Med. Chem. 2015, 58, 
3094–3103. 
  
chapter 7 
 
182 
[35] B. Louage, L. Nuhn, M. D. Risseeuw, N. Vanparijs, R. De Coen, I. Karalic, S. Van Calenbergh, B. G. De Geest, Angew. Chem. 
Int. Ed. Engl. 2016, 55, 11791–11796. 
[36] P. A. Watson, V. K. Arora, C. L. Sawyers, Nat. Rev. Cancer 2015, 15, 701–711. 
[37] M. C. Haffner, J. Laimer, A. Chaux, G. Schäfer, P. Obrist, A. Brunner, I. E. Kronberger, K. Laimer, B. Gurel, J.-B. Koller, Mod. 
Pathol. 2012, 25, 1079–1085. 
[38] D. Shen, F. Xie, W. B. Edwards, PLoS One 2013, 8, e68339. 
[39] V. Bagalkot, O. C. Farokhzad, R. Langer, S. Jon, Angew. Chem. Int. Ed. Engl. 2006, 45, 8149–8152. 
[40] S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, 
M. G. Pomper, Cancer Res. 2009, 69, 6932–6940. 
[41] J. Hrkach, D. Von Hoff, M. M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, et al ., 
Sci. Transl. Med. 2012, 4, 128–139. 
[42] C. J. Ferguson, R. J. Hughes, D. Nguyen, B. T. T. Pham, R. G. Gilbert, A. K. Serelis, C. H. Such, B. S. Hawkett, Macromolecules 
2005, 38, 2191–2204. 
[43] R. P. Murelli, A. X. Zhang, J. Michel, W. L. Jorgensen, D. A. Spiegel, J. Am. Chem. Soc. 2009, 131, 17090–17092. 
[44] B. A. Abel, C. L. McCormick, Macromolecules 2016, 49, 6193–6202. 
 
  
active targeted docetaxel-polymer prodrug conjugates 
 
183 
6 supporting info 
6.1 docetaxel 
DTX was purchased from LC Laboratories and its purity was confirmed by 1H-NMR spectroscopy and 
compared to paclitaxel. 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 8.10 (A, d, J = 7.3 Hz, 2H), 7.61 (B, tt, J = 6.9, 1.3 Hz, 1H), 7.49 (C, t, J = 7.6 Hz, 2H), 
7.42 – 7.34 (D, m, 4H), 7.34 – 7.28 (E, m, 1H), 6.21 (F, t, J = 8.9 Hz, 1H), 5.67 (G, d, J = 7.1 Hz, 1H), 5.47 (H, d, J = 9.4 Hz, 
1H), 5.29 – 5.22 (I, m, 1H), 5.21 (J, s, 1H), 4.94 (K, dd, J = 9.6, 2.2 Hz, 1H), 4.61 (L, s, 1H), 4.30 (M, d, J = 8.5 Hz, 1H), 4.23 (O, 
dd, J = 11.1, 6.6 Hz, 1H), 4.18 (N, dd, J = 8.4, 1.0 Hz, 1H), 3.90 (P, d, J = 6.9 Hz, 1H), 2.57 (Q, ddd, J = 14.4, 9.7, 6.6 Hz, 1H), 
2.37 (R, s, 3H), 2.26 (S, d, J = 9.0 Hz, 2H), 1.90 – 1.79 (X, m, 4H), 1.74 (W, s, 3H), 1.34 (V, s, 9H), 1.23 (U, s, 3H), 1.12 (T, s, 
3H). 
 
 
Figure S1. Structure (annotated) of docetaxel (DTX). 
  
O
HO
HO
O
O
O
O
OO
OH
H
NO
O
OH O
A+B+C
D+E
F
G
H
J
K
M+N
O
P
Q+X
R
S
X
W
U+T
V
V
V
I
L
chapter 7 
 
184 
 
Figure S2. 1H-NMR (400 MHz, CDCl3) spectrum of DTX. 
 
Figure S3. Overlay 1H-NMR spectra of PTX and DTX.
  
DTX 
PTX 
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6.2 DTX-PABTC 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 8.12 (A, dt, J = 8.2, 1.1 Hz, 2H), 7.65 – 7.56 (B, m, 1H), 7.50 (C, td, J = 7.5, 1.2 Hz, 
2H), 7.44 – 7.24 (D, m, 5H), 6.27 (E, t, J = 9.0 Hz, 1H), 5.68 (F, d, J = 7.1 Hz, 1H), 5.56 – 5.43 (G, m, 1H), 5.40 – 5.26 (H, m, 
2H), 5.21 (I, s, 1H), 5.03 – 4.92 (J, m, 1H), 4.83 (K, dq, J = 11.8, 7.4 Hz, 1H), 4.32 (L, d, J = 8.5 Hz, 1H), 4.26 (N, ddd, J = 11.1, 
6.5, 2.3 Hz, 1H), 4.19 (M, d, J = 8.5 Hz, 1H), 3.93 (O, d, J = 7.0 Hz, 1H), 3.41 – 3.25 (P, m, 2H), 2.65 – 2.52 (Q, m, 1H), 2.43 
(R, s, 3H), 2.38 – 2.25 (S, m, 1H), 2.22 – 2.08 (T, m, 1H), 1.93 (U, s, 3H), 1.84 (V, ddd, J = 14.1, 11.2, 2.2 Hz, 1H), 1.75 (W, s, 
3H), 1.71 – 1.63 (X, m, 2H), 1.61 (Y, s, 3H), 1.51 – 1.36 (Z, m, 2H), 1.34 (A1, s, 9H), 1.23 (B1, s, 3H), 1.12 (C1, s, 3H), 0.94 (D1, t, 
J = 7.3 Hz, 3H). 
13C-APT-NMR (101 MHz, CDCl3): δ [ppm] =[>220.0 (S-CS-S)], 211.72 (A), 170.59 (F, d, J = 43.7 Hz), 169.83 (E), 167.58 (D, 
d, J = 35.2 Hz), 167.22 (C), 155.24 (B), 139.22 (G), 137.27 (H), 135.66 (N), 133.78 (I), 130.34 (J), 129.34 (K), 129.01 (L), 
128.85 (M), 128.31 (M), 126.57 (O), 84.31 (Q), 81.09 (R), 80.57 (S), 79.07 (T), 76.70 (U), 75.37 (W, d, J = 7.3 Hz), 75.14 (X), 
74.63 (V), 72.16 (Y), 72.04 (Z, d, J = 6.3 Hz), 57.68 (A1), 54.12 (B1), 47.19 (C1, d, J = 29.9 Hz), 46.54 (D1), 43.24 (E1), 37.24 
(P1, d, J = 3.4 Hz), 37.06 (Q1), 35.69 (R1), 29.99 (F1, d, J = 3.0 Hz), 28.30 (G1), 26.47 (H1), 22.80 (J1), 22.22 (I1, d, J = 2.3 
Hz), 21.06 (K1), 16.26 (L1, d, J = 28.4 Hz), 14.36 (M1), 13.73 (N1), 10.09 (O1). 
ESI-MS (acetonitrile): m/z = calcd for C51H65NO15S3 1027.35, found 1028.36 [M+H]+ 
 
6.3 DTX-pDMA 
SEC(DMAc, PMMA-St.): Mn = 2668, PDI = 1.08 (DTX-pDMA15) and Mn = 4491, PDI = 1.09 (DTX-pDMA30). 
DTX-pDMA15: 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.11 (t, J = 6.4Hz, 2H), 7.68 – 7.55 (m, 3H), 7.50 – 7.14 (m, 5H), 6.09 (br, 1H), 
5.63 (br, 1H), 5.45 – 5.10 (m, 3H), 5.21 (br, 1H), 5.05 – 4.92 (m, 1H), 4.31 – 4.10 (m, 3H), 3.87 (br, 1H), 3.46 – 3.37 (m, 
2H), 3.26 – 1.02 (m, 35H DTX-PABTC + 9H x 17(DP) = 188H), 0.95 (td, J = 7.4, 1.7 Hz, 3H). 
DTX-pDMA30: 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.11 (t, J = 6.4Hz, 2H), 7.68 – 7.55 (m, 3H), 7.50 – 7.14 (m, 5H), 6.09 (br, 1H), 
5.63 (br, 1H), 5.45 – 5.10 (m, 3H), 5.21 (br, 1H), 5.05 – 4.92 (m, 1H), 4.31 – 4.10 (m, 3H), 3.87 (br, 1H), 3.46 – 3.37 (m, 
2H), 3.26 – 1.02 (m, 35H DTX-PABTC + 9H x 32(DP) = 323H), 0.95 (td, J = 7.4, 1.7 Hz, 3H). 
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Figure S4. 1H-NMR (400 MHz, CDCl3) spectrum of DTX-PABTC (annotated). 
 
Figure S5. 13C-APT-NMR (101 MHz, CDCl3) spectrum of DTX-PABTC (annotated).  
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Figure S6. 1H,1H-COSY spectrum of DTX-PABTC. 
 
Figure S7. 1H,13C-HSQC spectrum of DTX-PABTC.  
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Figure S8. 1H,13C-HMBC spectrum of DTX-PABTC. 
 
6.4 DTX-pDMARho  
SEC(DMAc, PMMA-St.): Mn = 4365, PDI = 1.09 (DTX-pDMARho30). 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.11 (t, J = 6.4Hz, 2H), 7.68 – 7.55 (m, 3H), 7.50 – 7.14 (m, 5H), 6.09 (br, 1H), 
5.63 (br, 1H), 5.45 – 5.10 (m, 3H), 5.21 (br, 1H), 5.05 – 4.92 (m, 1H), 4.31 – 4.10 (m, 3H), 3.87 (br, 1H), 3.46 – 3.37 (m, 
2H), 3.26 – 1.02 (m, 35H DTX-PABTC + 9H x 31(DP) = 314H), 0.95 (td, J = 7.4, 1.7 Hz, 3H). 
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6.5 maleimidobutyryl-PFP 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 6.73 (s, 2H), 3.66 (t, J = 6.7 Hz, 2H), 2.71 (t, J = 7.4 Hz, 2H), 2.07 (p, J = 7.0 Hz, 2H). 
19F-NMR (282 MHz, CDCl3): δ [ppm] = -152.66 (d, J = 17.0 Hz, 2F), -157.95 (t, J = 21.6 Hz, 1F), -161.91 – -162.66 (m, 2F). 
 
 
Scheme S1. Reaction scheme illustrating synthesis of maleimidobutyryl-PFP (A), the tert-butyl ester PSMA targeting ligand 
ACUPA (B) and subsequent coupling of the latter two, followed by tert-butyl ester-deprotection (C).  
  
4-maleimidobutyric acid
A
H-Glu(Ot-Bu)-Ot-Bu HCl
PFP maleimidobutyryl-PFP
tert-butyl ester ACUPA
maleimidobutyryl-ACUPA
B
C
i. triphosgene, CH2Cl2, RT
ii. + H-Lys(Z)-Ot-Bu HCl
iii. 10% Pd/C, H2, dioxane
DIC
CH2Cl2, RT
i. TEA, CH2Cl2, RT
ii. TFA, CH2Cl2, RT
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6.6 tert-butyl ester ACUPA 
Before Cbz-deprotection: 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.44 – 7.26 (m, 5H), 5.44 – 5.14 (m, 3H), 5.13 – 4.99 (m, 2H), 4.41 – 4.25 (m, 2H), 
3.28 – 3.05 (m, 2H), 2.41 – 2.17 (m, 2H), 2.13 – 1.97 (m, 1H), 1.89 – 1.66 (m, 2H), 1.67 – 1.55 (m, 1H), 1.55 – 1.47 (m, 2H), 
1.44 (s, 18H), 1.42 (s, 9H), 1.38 – 1.29 (m, 2H). 
13C-APT-NMR (75 MHz, CDCl3): δ [ppm] = 172.57, 172.50, 172.49, 157.05, 156.73, 136.82, 128.57, 128.16, 128.10, 82.24, 
81.83, 80.63, 66.66, 53.41, 53.09, 40.81, 32.77, 31.72, 29.49, 28.22, 28.14, 28.01, 22.42. 
After Cbz-deprotection: 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 5.18 (dd, J = 8.0, 2.2 Hz, 2H), 4.32 (td, J = 8.1, 5.0 Hz, 2H), 2.68 (t, J = 6.7 Hz, 2H), 
2.42 – 2.19 (m, 2H), 2.06 (dddd, J = 13.9, 9.0, 6.7, 4.9 Hz, 1H), 1.92 – 1.68 (m, 4H), 1.68 – 1.53 (m, 1H), 1.45 (s, 18H), 1.42 
(s, 9H), 1.38 – 1.26 (m, 2H). 
 
Figure S9. ESI-MS (acetonitrile) spectrum of DTX-PABTC. 
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Figure S10. 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMA15. 
 
 
Figure S11. 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMA30. 
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Figure S12. α,ω-endgroup fidelity confirmed by 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMA15 (A) and DTX-pDMA30 (B). 
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Figure S13. 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMARho30. 
Figure S14. α,ω-endgroup fidelity confirmed by 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMARho30. 
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Figure S15. 1H-NMR (A; 300 MHz, CDCl3) and 19F-NMR spectrum (B; 282 MHz, CDCl3) of maleimidobutyryl-PFP. 
  
BL70_PROTON_17Aug2016_01.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
N
o
rm
a
liz
e
d
 I
n
te
n
si
ty
2.022.002.011.75
A (2H)
D (2H)
B (2H)
C (2H)
CDCl3
BL69_FLUORINE_09Aug2016_01.esp
-135 -140 -145 -150 -155 -160 -165 -170 -175 -180
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
si
ty
E
E
E
E
E EA
A
B
C
D
A 
B 
active targeted docetaxel-polymer prodrug conjugates 
 
195 
 
Figure S16. 1H-NMR (300 MHz, CDCl3) spectrum of tert-butyl ester ACUPA (Cbz-protected). 
 
Figure S17. 13C-APT-NMR (75 MHz, CDCl3) spectrum of tert-butyl ester ACUPA (Cbz-protected). 
  
NH
O O
NHO
O
O
O
O
N
H
O
O
chapter 7 
 
196 
 
Figure S18. 1H-NMR (300 MHz, CDCl3) spectrum of tert-butyl ester ACUPA (Cbz-deprotected). 
 
6.7 maleimidobutyryl-ACUPA 
Before tert-butyl ester-deprotection: 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 6.72 (s, 2H), 6.31 (t, J = 5.4 Hz, 1H), 5.39 (s, 2H), 4.32 (dd, J = 4.6, 1.7 Hz, 1H), 4.30 
(d, J = 5.0 Hz, 1H), 3.57 (t, J = 6.5 Hz, 2H), 3.32 (dq, J = 13.0, 6.5 Hz, 1H), 3.13 (dq, J = 12.2, 5.9 Hz, 1H), 2.45 – 2.22 (m, 
2H), 2.18 (t, J = 7.0 Hz, 2H), 2.13 – 2.02 (m, 1H), 1.95 (dt, J = 11.2, 6.8 Hz, 2H), 1.89 – 1.71 (m, 2H), 1.70 – 1.58 (m, 1H), 1.56 
– 1.46 (m, 2H), 1.45 (s, 9H), 1.44 (s, 9H), 1.43 (s, 9H), 1.39 – 1.29 (m, 2H). 
After tert-butyl ester-deprotection: 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 10.25 (br, 3H), 7.74 (t, J = 5.6 Hz, 1H), 6.99 (s, 2H), 6.30 (s, 2H), 4.09 (s, 1H), 
4.03 (s, 1H), 3.38 (t, J = 6.9 Hz, 2H), 2.97 (q, J = 6.6 Hz, 2H), 2.28 – 2.14 (m, 2H), 2.02 (t, J = 7.5 Hz, 2H), 1.91 (dddd, J = 
13.9, 9.0, 7.0, 5.2 Hz, 1H), 1.78 – 1.56 (m, 4H), 1.50 (dq, J = 14.4, 7.4 Hz, 1H), 1.43 – 1.30 (m, 2H), 1.26 (q, J = 7.9 Hz, 2H). 
13C-APT-NMR (101 MHz, DMSO-d6): δ [ppm] = 174.55, 174.19, 173.74, 171.06, 171.01, 157.31, 134.46, 52.27, 51.67, 38.37, 
36.91, 32.61, 31.82, 29.92, 28.85, 27.54, 24.17, 22.65. 
ESI-MS (acetonitrile): m/z = calcd for C20H28N4O10 484.180, found 485.186 [M+H]+   
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Figure S19. 1H-NMR (300 MHz, CDCl3) spectrum of tert-butyl ester maleimidobutyryl-ACUPA. 
 
6.8 post-polymerization functionalization 
SEC(DMAc, PMMA-St.): 
Mn = 4876, PDI = 1.12 (DTX-pDMA30-ACUPA) and Mn = 5319, PDI = 1.09 (DTX-pDMA30-HA) 
Mn = 4997, PDI = 1.13 (DTX-pDMARho30-ACUPA) and Mn = 5222, PDI = 1.09 (DTX-pDMARho30-HA) 
 DTX-pDMA30-ACUPA 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.11 (t, J = 6.4Hz, 2H), 7.68 – 7.55 (m, 3H), 7.50 – 7.14 (m, 5H), 6.09 (br, 1H), 
5.63 (br, 1H), 5.45 – 5.10 (m, 3H), 5.21 (br, 1H), 5.05 – 4.92 (m, 1H), 4.50 – 3.42 (m, 4H(DTX) + 4H(ACUPA) = 8H), 3.26 – 
0.80 (m, 31H DTX + 19H ACUPA + 9H x 30(DP) = 320H). 
 DTX-pDMA30-HA 
1H-NMR (300 MHz, MeOH-d4): δ [ppm] = 8.11 (t, J = 6.4Hz, 2H), 7.68 – 7.55 (m, 3H), 7.50 – 7.14 (m, 5H), 6.09 (br, 1H), 
5.63 (br, 1H), 5.45 – 5.10 (m, 3H), 5.21 (br, 1H), 5.05 – 4.92 (m, 1H), 4.50 – 3.42 (m, 4H(DTX) + 2H(HA) = 6H), 3.26 – 
0.80 (m, 31H DTX + 9H HA + 9H x 31(DP) = 319H). 
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Figure S20. 1H-NMR (A; 400 MHz, DMSO-d6) and 13C-APT-NMR spectrum (B; 101 MHz, DMSO-d6) of maleimidobutyryl-ACUPA 
(tert-butyl ester-deprotected). 
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Figure S21. 1H,1H-COSY spectrum of maleimidobutyryl-ACUPA (tert-butyl ester-deprotected). 
 
Figure S22. 1H,13C-HSQC spectrum of maleimidobutyryl-ACUPA (tert-butyl ester-deprotected).  
chapter 7 
 
200 
 
Figure S23. ESI-MS (acetonitrile) spectrum of maleimidobutyryl-ACUPA (tert-butyl ester-deprotected). 
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Figure S24. SEC elugrams of DTX-pDMARho30, DTX-pDMARho30-ACUPA and DTX-pDMARho30-HA, compared to DTX-pDMA30.  
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Figure S25. Absence of RAFT CTA Z-group confirmed by 1H-NMR (300 MHz, MeOH-d4) for DTX-pDMA30-ACUPA and DTX-pDMA30-
HA. 
 
Figure S26. 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMA30-ACUPA.   
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Figure S27. 1H-NMR (300 MHz, MeOH-d4) spectrum of DTX-pDMA30-HA. 
 
Figure S28. DOSY NMR spectra of HA, DTX-PABTC, DTX-pDMA15, DTX-pDMA30 and DTX-pDMA30-HA.   
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Figure S29. UV-VIS spectra of DTX-pDMARho30-ACUPA and DTX-pDMARho30-HA, both at 4 mg/mL, confirming equal rhodamine 
labeling. 
 

  
205 
 
 
PART IV 
RELEVANCE, SUMMARY AND 
GENERAL CONCLUSIONS 
  
  
 
 
207 
chapter 8 
 
broader international context 
 
Benoit Louage,a Olivier De Wever,b Wim E. Hennink,c Bruno G De Geesta 
 
a Laboratory of Pharmaceutical Technology, Department of Pharmaceutics,  
Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium 
b Department of Radiation Oncology and Experimental Cancer Research,  
Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium 
c Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences,  
Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands 
 
Journal of Controlled Release 2017 
  
chapter 8 
 
 
208 
1 approved technologies beyond Taxol and Taxotere 
1.1 Abraxane 
In 2005, the first and so far only alternative PTX formulation was FDA-approved for treatment of 
metastatic breast cancer. It is devoid of ethanol and toxic Cremophor EL and contains human serum albumin (HSA) 
instead. PTX exhibits high systemic protein binding. Albumin is the most abundant plasma protein and known to 
function as carrier molecule for lipophilic drugs based on physical, hydrophobic interaction.[1–4] The formulation can 
be prepared by dissolving 2 - 3 % of HSA in water, adding 2 to 4 % (v/v) of chloroform and finally adding PTX in a 
quantity between 5 - 20 % by weight relative to the weight of the albumin present in solution. The latter mixture is 
subjected to high pressure homogenization (i.e. between 9000 and 40 000 psi) yielding a nanoemulsion which is 
frozen and lyophilized. The obtained powder can be reconstituted in saline (i.e. 0.9 % NaCl), subsequently diluted in 
physiological solution and administered through intravenous infusion.[5,6] Reconstitution generates 130 nm 
particles. Upon dilution into the bloodstream, the only modest hydrophobic interaction causes the particles to 
rapidly disassemble into single PTX-albumin complexes.[7] 
Phase I studies showed absence of cremophor-related toxicities which resulted in a relatively higher 
maximum tolerated dose (MTD; i.e. 300 mg/m2 for Abraxane versus 200 - 250 mg/m2 for Taxol)[8] and greater 
efficacy in phase II and III trials.[4,9–12] After FDA-approval, additional retrospective in vitro and in vivo studies 
showed higher tumor accumulation of Abraxane compared to Taxol at equal dose. The latter could be correlated to 
binding of the PTX-albumin complexes to endothelial gp60-receptors and subsequent transcytosis.[13] Once entered 
in the tumor interstitium, the complex can bind the secreted protein acidic and rich in cysteine (SPARC) which could 
in turn facilitate the delivery of PTX into tumor cells. Even though SPARC is not a tumor specific protein, high 
expression has been associated with malignant transformation.[14–17] Despite the preclinical evidence, further 
clinical research should be conducted to confirm whether these mechanisms also hold true in humans. It has been 
suggested that elevated expression of SPARC could be a positive biomarker for Abraxane efficacy, although this 
might apply only for specific tumor types.[18–22] This advanced formulation is generally not considered a 
nanomedicine. Abraxane exhibits similar short PTX half-lives as compared to Taxol, hence EPR-mediated delivery is 
unlikely to occur.[23] The success of the platform most probably lies in its ability to significantly lower the toxicity of 
PTX by avoiding Cremophor EL its formulation, allowing higher dosing and hence improving therapeutic effect. 
Recently, 2 more indications have been added for treatment with Abraxane: advanced NSCLC and late-stage 
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pancreatic cancer.[24] Based on the same technology, the company (i.e. Celgene) has developed an albumin-based 
formulation of DTX (ABI-008) which currently undergoes phase I/II trials. 
 
1.2 Genexol-PM 
Genexol-PM was approved in South Korea in 2007 for treatment of metastatic breast cancer. The 
solubilizing agent in this formulation is an amphiphilic block copolymer, comprised of monomethoxy 
poly(ethylene-glycol)-b-poly(lactic acid) (PEG-PLA; Figure 1A) which is obtained by ring-opening polymerization 
(ROP).[25,26] The formulation can be prepared by solvent diffusion. Briefly, PTX and block copolymer are dissolved in 
acetonitrile and stirred. After solvent evaporation, the obtained gel matrix is dispersed in water to acquire a clear 
micellar solution with physically entrapped PTX. The latter is filtered (0.22 μm) and subsequently lyophilized.[27] The 
obtained powder is reconstituted in saline solution and diluted in 5 % dextrose before administration by 
intravenous infusion.[28] Similar to Abraxane, Genexol-PM showed much lower toxicity in phase I studies compared 
to Taxol (MTD was more than doubled) which allowed high dose administration.[29] However, no differences in 
plasma AUC were observed at equal PTX dose.[28] This suggests the micelles rapidly disassemble after 
administration and/or the drug diffuses out of the particles and strongly interacts with abundant plasma proteins 
such as albumin. Again, the main asset of this formulation is the ability to solubilize PTX without Cremophor EL, not 
necessarily through acting as a nanomedicine. Genexol-PM has now also been approved in South Korea for 
treatment of NSCLC and ovarian cancer. No FDA-approval has yet been granted for the formulation in the US, but 
several clinical trials are currently ongoing. 
 
2 advanced taxane nanomedicines 
The clinical success of the aforementioned Cremophor EL-free formulations re-highlighted the great 
potential of taxanes. However, the rationale of these formulations was merely to solubilize these hydrophobic 
compounds. Even though Cremophor EL-related toxicity was avoided, high systemic drug exposure evoked by these 
formulations still leads to intrinsic taxane side-effects including myalgia, neutropenia and neuropathy.[8,28] Based 
on the assets mentioned before, there is a great opportunity in the field of nanomedicine for further broadening 
the therapeutic index of taxanes. A summary of all taxane formulations in clinical trials is presented in Table 1. In 
the following paragraphs, a selection of novel, pioneering technologies will be discussed to scope the current 
trends in advanced taxane delivery.   
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2.1 physical encapsulation 
As previously mentioned, PTX-encapsulated in albumin nanoparticles (i.e. Abraxane) and polymeric 
micelles (i.e. Genexol-PM) are likely to dissociate and/or swiftly release PTX once injected in the bloodstream.[23] To 
truly be defined as nanomedicines, drug-encapsulated formulations have to ensure strong mutual hydrophobic 
interactions between amphiphiles intrinsically, as well as between amphiphile and drug, in order to avoid particle 
dissociation and premature drug release, respectively.[30] 
Kataoka and co-workers designed a micellar PTX formulation based on PEG-poly(aspartate) (i.e. NK105) in 
which half of the aspartate moieties are functionalized with 4-phenyl-1-butanol (PEG-p(Asp-Bz); Figure 1B) to yield 
an amphiphilic block copolymer which forms micellar structures in aqueous environment and exerts strong 
interaction with PTX.[31] The block copolymer is synthesized by ring-opening polymerization of β-benzyl L-aspartate 
N-carboxy anhydride, initiated by the terminal primary amine group of a α-methoxy-ω-aminopoly(ethylene glycol) 
macroinitiator.[32] After polymerization, the polymer can be dialyzed, filtered and lyophilized. Micelles are formed 
upon reconstitution in water. Next, PTX is dissolved in organic solvent (e.g. ethanol) and subsequently added to the 
micellar dispersion, allowing physical entrapment of the drug into the hydrophobic core of the micelles. The 
obtained formulation can be lyophilized, reconstituted in suitable iso-osmotic medium and administered through 
intravenous infusion.[33] Preclinical studies showed 90-fold higher plasma AUC and 25-fold higher tumor AUC of PTX 
compared to the Taxol formulation.[34,35] Phase I studies showed a significant drop in systemic neurotoxicity and 
clinical efficacy was proven in a phase II study.[36] These results indicate that NK105 truly acts as a nanocarrier, 
avoiding premature systemic burst release of PTX and facilitating drug targeting via the EPR effect. NK105 has 
recently finalized a phase III trial in the US for the treatment of metastatic breast cancer. Unfortunately, the 
primary endpoint of the study (i.e. in terms of progression free survival (PFS)) did not meet the prespecified 
statistical criteria.[37] This can put in question whether merely passively targeted nanomedicines could be used as a 
standard chemotherapeutic treatment modality. The latter will be further discussed in section 5. 
A related block copolymer system has recently been reported by Hennink and co-workers in which the 
hydrophobic block consists of N-(2-hydroxypropyl)methacrylamide (HPMA) bearing aromatic benzoyl groups (PEG-
p(HPMAm-Bz); Figure 1C).[38] The formulation was evaluated in a subcutaneous xenograft mouse model and showed 
prolonged blood circulation kinetics, effective retention of PTX within the micellar core, low toxicity, high EPR-
mediated tumor accumulation and efficient tumor regression.[30] 
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Systems based on physical encapsulation are also being explored for active targeting by surface 
decoration with high-affinity ligands. So far, BIND-014 is the first and only active targeted polymeric taxane 
nanoformulation which has reached clinical trials.[39] This system, developed by the Langer and co-workers, 
comprises encapsulation of DTX into nanoparticles, composed of PEG-PLA and poly(ethylene glycol)-b-poly(lactic-
co-glycolic acid) (PEG-PLGA) block copolymers of which a fraction is functionalized with a small molecule high-
affinity ligand for prostate specific membrane antigen (PSMA) (i.e. S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-
pentanedioic acid (ACUPA); Figure 1D).[40] Preclinical development showed superior efficacy of the PSMA-targeted 
DTX nanoformulation compared to the corresponding non-targeted DTX-loaded nanoparticles. BIND-014 was in 
clinical phase I for treatment of advanced cancer and phase II for metastatic prostate cancer and NSCLC. However, 
disappointing results have recently put clinical translation of BIND-014 on hold.[41] This case study highlights the 
necessity for future nanomedicine development to use preclinical models providing a better predictive value 
towards clinical outcome and to exploit concurrent screening to enable careful patient selection for targeted 
nanomedicine therapy. This will be further discussed in section 5. 
 
 
Figure 1. Molecular structures of polymeric systems used for physical encapsulation of PTX and DTX. (A) PEG-PLA, (B) PEG-
p(Asp-Bz), (C) PEG-p(HPMAm-Bz), (D) BIND-014 which is composed of both PEG-PLA (D1) and PEG-PLGA (D2), and PEG-PLA 
(D3) / PEG-PLGA (D4) functionalized with the ACUPA targeting moiety at the hydrophilic PEG chain end. 
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2.2 chemical conjugation 
At present, the nanomedicines with the highest approval rate are drug conjugates. These therapeutics 
comprise active agents, covalently attached to targeted antibodies, peptides or water-soluble polymers. 
Conjugating PTX to a hydrophilic polymeric carrier encompasses multiple advantages. First of all, it allows for the 
preparation of PTX derivatives with substantially higher aqueous solubility.[1] Second, uncontrolled, systemic 
passive diffusion of drug out of the nanocarrier vehicle is limited as chemical bonds have to be cleaved first. This is 
a highly attractive asset for polymer-drug conjugates to compete with the numerous liposomal and polymeric 
micelle and nanoparticle formulations in clinical trials (Table 1). Third, when the polymeric carrier is of high 
molecular weight (HMW) and/or the polymer-drug conjugate self-assembles into a nanoparticle, renal excretion is 
limited and thus passive targeting is feasible. Finally, conform to the Ringsdorf model, additional ligands can be 
attached to the carrier vehicle for active targeting.[42] 
The approval of Oncaspar (pegylated asparaginase) in 1994 demonstrated that PEG is a highly attractive 
carrier molecule for bio-conjugation.[43] Not surprisingly, only a few years after Taxol was marketed, the first linear 
PEG-PTX conjugates were reported by Greenwald and colleagues.[44] A series of conjugates (PEG MW of 5 or 40 kDa) 
were synthesized by conjugating PEG derivatives with a terminal carboxylic acid group to PTX using carbodiimide 
chemistry (Figure 2A). Even though both low molecular weight (LMW) and HMW PTX-conjugates showed promising 
in vitro efficacy, the best in vivo activity was obtained with HMW PTX-conjugates.[45] The latter showed an increased 
PTX half-life due to slow renal filtration. Thus, the observed in vivo activity most probably resulted from EPR-
mediated tumor targeting, although reports have not been very clear. In 2001, Enzon Pharmaceuticals tested these 
PTX-conjugates in a phase I clinical trial, but decided to discontinue further development in 2003.[46] A possible 
reason could be the high molecular weight and limited possibility to functionalize linear PEG which does not allow 
high drug loading and impedes administration to patients. Nektar Therapeutics therefore developed a 4-armed 
PEG structure to which 4 DTX molecules were conjugated.[47] Improved activity and pharmacokinetics were 
observed in rats and dogs. This conjugate (i.e. NKTR-105) is undergoing phase I/II for treatment of several solid 
tumors. Other hydrophilic hyperbranched structures are now also being explored for chemical conjugation of DTX. 
Two of them have now entered phase I clinical trials. One is based on cyclodextrins (i.e. CRLX301), the other 
involves dendrimer technology (i.e. DEP DTX/DTX-SPL8783).[48–50] 
Amongst the PTX-polymer conjugates which are currently being investigated, most progress has been 
made by PTX poliglumex (also known as Opaxio, Xyotax, CT-2103). This is a biodegradable, HMW (i.e. 48 kDa) 
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conjugate of poly(L-glutamic acid) to which PTX is conjugated by esterification of its C2’ hydroxyl group with the 
carboxylic acid side groups of the polymer (Figure 2B).[51] As the C2’ hydroxyl group is crucial for binding tubulin,[52] 
this water-soluble nanoformulation is in fact a PTX prodrug. Preclinical evaluation showed considerably prolonged 
plasma half-life, higher MTD, tumor exposure and anti-tumor efficacy compared to Taxol.[53] It has also been 
proposed that release of PTX predominantly occurs after cellular uptake and is mediated by lysosomal enzymes 
(e.g. cathepsin B).[54,55] These features demonstrate the prodrug and passive targeting capabilities of the 
formulation. Although a phase III trial for first line chemotherapy of advanced NSCLC was somewhat disappointing, 
the formulation (in combination with platinum drugs) shows promising results in a clinical phase I/II trial for 
treatment of ovarian cancer and as radiosensitizers for treatment of several cancers.[56–58] 
Another conjugated system with high profile preclinical results is the CriPec platform. This core-
crosslinked polymeric micelle technology is based on methoxy poly(ethylene glycol)-b-poly(N-(2-hydroxypropyl) 
methacrylamide-lactate) (PEG-p(HPMAm-Lacn); Figure 2C) block copolymers, developed by Hennink and co-
workers.[59] These polymers can self-assemble upon heating due to their lower critical solution temperature (LCST) 
behavior. In the CriPec platform, a fraction of the lactate side chains is reacted with methacrylic anhydride. Next, 
using a fast heating solvent displacement method, a methacrylated DTX-derivative is loaded into the block 
copolymer micelles.[60] The micellar dispersion is then transferred to a buffer containing potassium persulfate in 
which the polymeric micelles are crosslinked (i.e. by mutual reaction between the pending block copolymer 
methacrylate moieties) and covalently loaded with DTX (i.e. by reaction between the methacrylate moieties of both 
the DTX-derivative and those of the block polymer).[61] Loading capacities up to around 10 % can be achieved. The 
robustness of this polymer synthesis and drug formulation strategy enables to tailor the micelles in terms of size, 
nanocarrier degradation and drug release kinetics.[62] This can offer opportunities in customizing DTX-formulations 
in function of patient-specific tumor characteristics (e.g. smaller particle sizes for tumors with more narrowly 
fenestrated endothelium, faster release kinetics for tumors exerting higher clearance rates[49]) which could be 
assessed by imaging nanodiagnostics (e.g. iron oxide nanoparticles; section 5). A phase I study is currently 
recruiting patients with solid tumors for determining the highest safe dose.[63] 
No active targeted taxane-polymer conjugates are currently in clinical trials. However, the first active 
targeted polymeric nanoformulation ever reported was a polymer-drug conjugate, moreover a p(HPMA)-
doxorubicin conjugate (PK2, Pfizer Inc.). This platform involves attachment of doxorubicin to the pending hydroxyl 
groups of p(HPMA), using a tetrapeptide Gly-Phe-Leu-Gly spacer.[64] The latter was designed by Kopeček and co-
workers and can be cleaved specifically by lysosomal enzymes (i.e. cathepsin B).[65,66] Additionally, the backbone 
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was functionalized with galactosamine. The latter is a ligand with affinity towards lectins, present on the surface 
of mammalian liver cells. A phase II trial showed modest improved hepatic targeting for PK2, compared to the 
conjugate lacking the galactose residues (PK1).[67] No further clinical results have been published for this system. 
Table 1 gives a summary of all the aforementioned innovative taxane formulations which are currently undergoing 
clinical evaluation. 
 
Figure 2. Molecular structures of polymeric systems used for chemical conjugation of PTX and DTX. (A) PEG-PTX, (B) poly(L-
glutamic acid)-PTX, (C) Cripec, where DTX is modified with a methacrylate moiety (C1) through a hydrolysable spacer and 
encapsulated in core-crosslinked amphiphilic block copolymer micelles through copolymerization with methacrylate moieties 
on the side chain of the hydrophobic block of PEG-p(HPMAm-Lacn) (C2). 
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Table 1. Summary of advanced taxane formulations in clinical trials.[24,42,46,49,50,68–80] 
product composition ligand (target) indication clinical status 
LEP-ETU PTX liposome / breast cancer, lung cancer, 
ovarian cancer 
phase II 
EndoTAG-1 PTX liposome / breast cancer, pancreatic 
cancer 
phase II 
PNU-91934 PTX liposome / oesophageal cancer phase II 
LE-DT DTX liposome / advanced solid tumors phase II 
ATI-1123 DTX liposome / advanced solid tumors phase I 
Abraxane (ABI-007) PTX albumin-bound 
formulation 
/ breast cancer, pancreatic 
cancer, NSCLC 
approved (US, 
2005) 
ABI-008 DTX albumin-bound 
formulation 
/ metastatic breast cancer, 
hormone-refractory 
prostate cancer 
phase I/II 
Genexol-PM (IG-001) PTX PEG-PLA polymeric micelle / breast cancer, lung cancer, 
ovarian cancer 
phase II/III, 
approved 
(South Korea, 
2007) 
Paxceed PTX PEG-PLA polymeric micelle / rheumatoid arthritis phase II 
Paclical PTX retinoid XR-17 polymeric 
micelle 
/ ovarian cancer phase 
III/orphan drug 
(US, 2009) 
NK105 PTX PEG-p(Asp-Bz) polymeric 
micelle 
/ gastric cancer, breast 
cancer 
phase II/III 
Nanoxel PTX polymeric micelle / advanced breast cancer phase I 
DTX-PM (Nanoxel-PM) DTX polymeric micelle /  phase I 
Nanotax PTX polymeric nanoparticle / peritoneal neoplasms phase I 
DTX-PNP DTX polymeric nanoparticle / advanced solid 
malignancies 
phase I 
BIND-014 DTX PEG-PLGA/PEG-PLA 
nanoparticle 
small molecule 
ACUPA (PSMA) 
phase I: metastatic cancer 
phase II: metastatic 
castration-resistant 
prostate cancer, NSCLC 
phase I/II 
Taxoprexin DHA-PTX conjugate  / melanoma, liver cancer, 
kidney cancer, 
adenocarcinoma, NSCLC 
phase II/III 
NKTR-105 4-armed PEG-DTX conjugate / solid tumors, ovarian 
cancer 
phase I/II 
CRLX301 cyclodextrin-PEG-DTX 
conjugate 
/ refractory tumors phase I 
DEP DTX (DTX-
SPL8783) 
dendrimer-DTX 
conjugate 
/ advanced cancers phase I 
PTX poliglumex 
(Opaxio, Xyotax,  
CT-2103) 
poly(L-glutamic acid)-PTX 
conjugate 
/ lung cancer, ovarian cancer phase III 
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Table 1 (continued)   
product composition ligand (target) indication clinical status 
Cripec DTX DTX-conjugated  
PEG-p(HPMAm-Lacn)  
core-crosslinked polymeric 
micelle 
/ solid tumors phase I 
GRN1005 (ANG1005) angiopep 2-PTX conjugate low-density 
lipoprotein 
receptor-
related protein 
1 (LRP1) 
breast cancer with brain 
metastases, NSCLC with 
brain metastases 
phase II 
 
3 antibody-drug conjugates 
Although not always considered as nanomedicines, antibody-drug conjugates (ADCs) comprise the current 
state-of-the-art in active targeted drug delivery and are therefore mentioned in this dissertation. ADCs could also 
set the benchmark for novel active targeted taxane nanomedicines as the latter can compete with ADCs with 
regard to drug loading. Monoclonal antibodies (mAbs) bind antigens with meticulous specificity.[81] Therefore, they 
have been extensively investigated over the past 20 years as carrier vehicles for targeted delivery of small 
molecule cytotoxic agents. To obtain an ADC, a cytotoxin is coupled to a mAb via a linker molecule. Even though 
stable linkers have proven to be successful, the latest trends in linker design aim at maintaining stability in the 
bloodstream whilst releasing drug payload at the target site. This release can be triggered either by pH-, redox- or 
enzyme-mediated stimuli.[82] 
The high potential of ADC-technology is reflected by its clinical track record. Over 40 ADCs are currently 
undergoing clinical evaluation and 2 have been FDA-approved.[83] Brentuximab vedotin comprises the chimeric mAb 
cAC10, directed against CD30 and conjugated to monomethyl auristatin E (MMAE) through an cathepsin-cleavable, 
self-immolative dipeptide (i.e. valine-citrulline) linker (Figure 3A). Like taxanes, MMAE is a very potent antimitotic 
agent which interferes with microtubule dynamics, but not through promotion of formation and stabilization of 
microtubules, but by blocking tubulin polymerization.[84] Based on positive results obtained in single-arm 
multicenter clinical trials, an accelerated FDA-approval was granted in 2011 for treatment of relapsed or refractory 
hodgkin lymphoma and anaplastic large-cell lymphoma which are often featured by an overexpression of CD30.[85] 
Trastuzumab emtansine was the first approved ADC for treatment of solid tumors. The drug consists of an anti-
HER2 mAb, conjugated by its lysine residues to the cytotoxic maytansinoid emtansine through a non-cleavable 
thioether linker (Figure 3B). Emtansine (DM1) also inhibits the formation of microtubules, predominantly by binding 
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tubulin.[86] Release occurs after receptor-mediated uptake and lysosomal degradation. Proved safety and 
effectiveness in a phase III trial involving 991 patients led to a full market approval in 2013 for treatment of HER2-
positive metastatic breast cancer patients who previously received trastuzumab and a taxane. Another ADC called 
gemtuzumab ozogamicin was approved in 2000 but has been withdrawn in 2010 after showing lack of benefit 
over conventional therapy and concomitant hepatotoxicity.[87] 
The latter example along with the fact that all the approved ADCs still induce systemic toxicity (e.g. 
neutropenia, nausea, neuropathy, thrombocytopenia) indicate that, despite the strong ADC pipeline, the technology 
still needs further investigation and improvement.[88] Lessons are to be learnt concerning linker design as several 
toxicities have been attributed to specific linkers.[89–92] Next, the ability of mAbs to effectively localize at the target 
site can be considered a point of discussion. Even though mAbs exhibit blood half-lives > 3 days, mAbs might 
extravasate too slow and not efficiently penetrate in tumor tissue, leading to heterogeneous distribution with the 
highest concentration at the periphery.[77,93,94] Additionally, the number of drug molecules which can be conjugated 
to mAbs is limited. The drug-antibody-ratio (DAR) is usually 4 mol/mol.[95,96] As the average molecular weight of the 
used cytotoxins is 1000 Da and the molecular weight of an antibody is approximately 150 000 Da, loading 
capacities are typically even below 5 %. This explains why initially developed ADCs based on regular 
chemotherapeutics, including taxanes, lack therapeutic efficacy and hence novel cytotoxic agents (e.g. MMAE and 
DM1) with substantially higher potency (i.e. up to factor 1000) are required for obtaining sufficient therapeutic 
effect in spite of low drug loading.[97,98] However, this also implies that only a small fraction of premature drug 
release could result in severe systemic toxicity. The final and probably biggest issue from a healthcare point of 
view is that the power of the technology comes at a price. ADCs rank amongst the most expensive medicines on the 
market (e.g. the treatment cost of trastuzumab emtansine is approximately $ 1 400 per dose).[82] This is not only 
due to the high cost of mAb manufacturing, in particular the drug conjugation and the subsequent purification are 
major challenges.[99] In order to allow widespread use in clinic, these costs would have to be lowered in the future. 
A lot of promising efforts are being conducted to address these issues. New linkers are being developed 
based on rational design. The field is currently investigating the use of smaller antibody fragments such as 
diabodies, miniantibodies and small immune proteins (SIPs) which could allow for more efficient distribution into 
tumor tissue.[100] Novel ADCs are developed based on highly potent second-generation taxanes (Figure 3C).[101] The 
latter show promising in vivo activity leading to complete tumor regression in a subcutaneous A431 xenograft 
mouse model.[102] Additionally, mAb decoration with drug-functionalized polymers is being investigated to increase 
cytotoxic payload.[103] For example, Mersana Therapeutics has developed an anti-HER2 ADC (XMT-1522) to which 3 to 
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5 hydrophilic, biodegradable polymer chains were conjugated, each bearing up to 5 auristatin molecules and an 
average payload of 15 molecules per mAb (Figure 3D).[104] XMT-1522 showed very potent activity in vitro against 
several breast, NSCLC, gastric and ovarian cancer cell lines. Complete regression was observed in vivo for both high 
and low HER2-expressing mouse xenograft models.[105] This could also be a viable approach for obtaining 
sufficiently potent taxane-based ADCs. Novel techniques including the use of algae as vector for protein expression 
are being explored to cut production costs.[106] Besides these efforts, as for most biotechnological products, it is not 
likely that the price will dramatically drop in the very near future. This leaves opportunities open for other 
alternative active targeted therapies based on non-biotechnological, synthetic endeavors. 
 
4 small molecule-drug conjugates 
Besides nanomedicines and ADCs, small molecule-drug conjugates (SMDCs) have shown great promise in 
targeted chemotherapy and the latter could provide a complementary platform for the treatment of tumors which 
are less susceptible to EPR-mediated drug delivery. Similar building blocks are exploited for SMDCs as for ADCs (i.e. 
drug, spacer molecule and targeting moiety). The latter however is not a mAb, but a synthetic, small molecule 
targeting ligand. Spacer design is crucial for the construction of SMDCs. The same chemical rationale is used as for 
ADCs, i.e. to achieve specific drug release in the tumor environment based on (self-immolative) acid-, redox- or 
enzyme-sensitive properties. SMDCs preferably encompass a rigid, hydrophilic spacer molecule to avoid 
intramolecular interference between drug and ligand.[107,108] Increasing hydrophilic properties also limits aspecific 
cellular uptake by passive diffusion which is the predominant uptake mechanism of free hydrophobic drugs.[73,109] 
The molecular weight of the spacer molecule can influence the efficacy of SMDCs. For example, it was shown that 
folate-rhodamine conjugates with HMW PEG spacers (i.e. > 5 kDa) do not exhibit fast and adequate tumor 
penetration.[110] On the other hand, SMDCs with LMW spacers (i.e. < 2 kDa) are capable of passively diffusing into the 
tumor tissue more thoroughly and more rapidly than macromolecular carrier molecules.[73,110–112] 
In certain respects, SMDCs have advantages over ADCs. First, the smaller size of SMDCs could allow for 
more effective penetration throughout the tumor mass.[73,96] The latter can be an important asset for treating less 
EPR-sensitive tumors and for passing dense membrane structures such as the blood brain barrier (BBB). Second, 
the stepwise synthesis of SMDCs allows for a more controlled and site-specific drug conjugation.[96] Third, the low 
molecular weight of SMDCs inherently results in a high drug loading capacity. Hence, beyond the conjugation of 
extremely potent drugs (e.g. MMAE and DM1), this technology is also suitable for conjugation of well-established 
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chemotherapeutic drugs including taxanes. Fourth, small hydrophilic molecules exhibit fast renal clearance.[113] 
Though considered a drawback in EPR-mediated drug delivery, this property could pose advantages with regard to 
toxicity. Unless a technology possesses 100 % binding specificity which currently cannot even be achieved by ADCs, 
the longer the blood half-life, generally the higher the risk of side-effects.[96] As SMDCs generally saturate the 
target receptor within 5 – 20 minutes after intravenous injection,[110] fast excretion of the dose fraction which is not 
bound to the target tissue would minimalize systemic side-effects.[114,115] To compensate for the fast renal clearance, 
a higher dosing might be required. Hence, a prodrug approach with tumor-specific, stimuli-responsive drug release 
would be preferred, as this can substantially increase MTD and hence allow administration of higher doses without 
risking high off-site toxicity. 
9 SMDCs are currently in clinical trials of which more than half in phase II or III,[73] including GRN1005. The 
latter is a conjugate, composed of 3 PTX molecules linked to angiopep 2 by ester bonds which are cleaved in 
lysosomal vesicles (Figure 4A).[116] Angiopep 2 is a peptide-based ligand, targeting low-density lipoprotein receptor-
related protein 1 (LRP1), a cell-surface receptor involved in cancer metastasis. GRN1005 is currently undergoing a 
phase II trial for treatment of NSCLC with brain metastases and for breast cancer in combination with trastuzumab 
(Table 1). 
As for nanomedicines, the hydrophobicity of anti-cancer drugs challenges the design and formulation of 
SMDCs. For example, a surfactant (i.e. Solutol HS15) is still required to obtain a clinically applicable formulation of 
GRN1005.[117] These solubility issues could be resolved by designing spacers with sufficient hydrophilicity. Most of 
the spacer molecules currently used for SMDC-technology involve peptide sequences. The latter are typically 
synthesized by multistep solid phase peptide synthesis (SPPS). A more straightforward, alternative approach could 
be the one-step synthesis of a hydrophilic, LMW polymer spacer, directly onto the drug molecule. Polymerization 
strategies have been developed to achieve the latter. For example, degradable LMW PTX-PLA conjugates have been 
synthesized by direct ring-opening polymerization (ROP) of DL-lactide from PTX (Figure 4B).[118] Within our own 
research group, we have recently developed a hybrid system in which a customized, hydrophilic LMW polymer 
spacer (i.e. poly(N,N-dimethylacrylamide) (pDMA)) can be engineered onto PTX using reversible addition-
fragmentation chain transfer (RAFT) polymerization (Figure 4C).[119] Additionally, the obtained highly water-soluble 
PTX-polymer conjugate can be post-modified by established thiol-maleimide coupling at the opposite polymer 
chain end. As the resulting compound meets the structural requirements of SMDCs, we are currently exploring the 
potential of this approach for engineering effective, water-soluble taxane-based SMDCs. Another aspect of SMDC-
technology which might hamper clinical translation is the current limited availability of high-affinity small-
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molecule targeting ligands. This is not an issue in the field of ADCs, as high-affinity mAbs can be raised against 
virtually any target antigen.[120] The search for novel, high-affinity small-molecule ligands towards tumor-specific 
epitopes has indeed proven to be challenging.[121,122] However, this can be facilitated in the future by using predictive 
computational modeling methods[123] and DNA-encoded chemical library technologies which, in contrast to 
conventional high-throughput screening (HTS), allow for extensive parallel evaluation of chemical libraries in one 
reaction tube.[124–126] 
 
5 clinical translation of advanced taxane formulations 
A broad range of taxane nanomedicines have been developed and various preclinical in vivo studies have 
demonstrated that passive and active targeting is a great tool for significantly improving drug delivery. 
Surprisingly, only a few of these systems survived clinical trials.[127] This somewhat low number, along with the 
recent disappointing clinical results of NK105 and BIND-014, obliges the field to question the overall validity of 
targeted nanomedicines in clinical chemotherapy. A recently published meta-analysis on the preclinical 
performance of anti-cancer nanomedicines suggests that the field might have a delivery problem, as only 0.7 % 
(median) of the intravenously injected nanoparticle dose was claimed to accumulate in tumors.[128] This publication 
triggered a major discussion amongst experts.[129,130] 
The majority of (taxane) nanomedicines currently residing in clinical trials rely on passive targeting. Their 
limited clinical translation thus far suggests that EPR-mediated delivery cannot always be taken for granted.[131] 
Several possible limitations with regard to EPR effect have indeed been brought forward amongst experts. Two 
well-reported mechanisms which can counteract the EPR effect include dense stroma and high tumor interstitial 
fluid pressure (IFP).[132,133] These features can impede the tumor-directed flow of nanomedicines. However, 
strategies have been explored to overcome these hurdles, for example by pretreatment or co-formulation with 
anti-stromal drugs and/or vascular endothelial growth factor (receptor) (VEGF(R)) inhibitors, respectively.[134–136] 
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Figure 3. Molecular structures of ADCs: brentuximab vedotin (A), trastuzumab emtansine (B), a novel taxane ADC (C), XMT-1522 
(D). 
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Figure 4. Molecular structures of SMDCs: GRN1005 (A) PTX-PLA (B) and PTX-pDMA (C). 
 
The most likely reason for the limited clinical translation of nanomedicines is the overall intrinsic 
heterogeneity of human cancer disease which is often not accurately reflected by the current, most commonly used 
preclinical models.[137–141] Due to their easy access and fast proliferation rate, in vitro cultured human cancer cell 
lines are frequently used for subcutaneous xenograft mouse models. However, extensively cultured cell lines are 
known to genetically adapt to their in vitro environment.[142] Hence, tumors generated from these cell lines in 
immunodeficient mice often present pathologies in vivo with little resemblance to the corresponding tumors 
occurring in humans. For example, due to the fast proliferation rate, the tumor vasculature is often underdeveloped 
and fenestrated and thus very suitable for EPR-mediated drug delivery. In patients however, the immune system 
can drastically slow down the proliferation rate, thereby generating tumors with normal physiological vasculature. 
This partly explains why nanomedicines perform only moderately in clinical trials, in spite of superior preclinical 
efficacy. Preluding imaging techniques could determine which population would be suitable for EPR-mediated drug 
delivery. Indeed, besides nanomedicines, pharmaceutical companies are equally investing in nanodiagnostics. For 
example, Merrimack Pharmaceuticals has recently used 30 nm iron oxide nanoparticles (Feraheme, AMAG 
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Pharmaceuticals) in a clinical trial to screen patients on EPR effect before administration of their liposomal 
irinotecan formulation Onivyde (MM-398).[41,49,143,144] 
Furthermore, preclinical evaluation of anti-cancer nanomedicines typically occurs in primary tumor 
models. In clinical setting, however, cancer is generally treated differently. Primary tumors are preferentially 
removed by surgical resection and/or radiotherapy.[140] Though occasionally conducted at presurgical stage as 
neoadjuvant therapy, chemotherapy is commonly applied when conditions are too delicate for the latter two 
techniques and for treatment of metastases.[145] Metastatic tissues are less featured by fenestrated endothelia as 
compared to primary solid tumors and very small metastases are often poorly vascularized.[146,147] It is clear that 
these characteristics do not allow for efficient passive targeting. Additional active targeting strategies should also 
be considered for more effective treatment of metastatic cancer disease and preclinical evaluation should be 
performed using more appropriate animal models.[148] 
Research efforts over the past 10 years resulted in development of clinically more relevant models, 
including the use of genetically engineered mouse (GEM) models. GEM mice can be designed to spontaneously 
grow orthotopic and hence anatomically relevant tumors. The latter could allow for better insights in the behavior 
of nanomedicines in a physiologically similar tumor environment as in patients. Furthermore, metastatic GEM 
models could provide an added value in identifying what features of nanomedicines are required for effective 
treatment of metastatic cancer disease. Another important model is the patient-derived xenograft (PDX) 
model.[149,150] By extracting cancer cells directly from patients and live passaging in mice, greater concordance has 
been observed in terms of tumor architecture, histomorphology and global gene expression.[151] It is likely that 
inter-patient variabilities in EPR susceptibility could be detected in PDX models.[152] Expanding the patient 
population for PDX modelling also allows discovery of predictive biomarkers based on genomic and proteomic 
profiling of responders and non-responders.[153] This could allow for a better patient screening, improve the success 
rate of nanomedicines in clinical trials and hence deliver a valuable contribution towards personalized medicine.[154]  
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6 future perspectives 
The progress towards more efficient and safer taxane anti-cancer nanomedicines has so far not been a 
very swift and efficient process in terms of clinical translation. Many recent ups and downs can be acknowledged. 
Does this imply that the assets of nanomedicines have been overestimated? Most probably not, but it would be 
unrealistic to expect a universal effective response in all cancer patients. Different types of nanomedicines all have 
their benefits and drawbacks. It is therefore useless to discuss which one is better than the other, but crucial to 
figure out which or which combination is best for each individual patient. Human cancer disease is highly 
heterogenic and should therefore be taken more into account for future design and evaluation of novel targeted 
anti-cancer nanomedicines. As now more and more relevant animal models (i.e. PDX, GEM) are becoming available, 
it will be highly recommended to expand preclinical testing beyond the well-established cell line-derived 
xenograft models. This will probably deliver superior predictive values and could help in deciding whether or not to 
proceed to evaluation in patients. These approaches will also provide biomarkers with regard to drug response 
which can be used in patient screening for clinical trials. Additionally, companion nanodiagnostics (e.g. imaging 
nanoparticles) will be complementary tools to further screen tumors in patients and evaluate their susceptibility 
to passive and active targeting. By careful selection of suitable patients through personalized nanomedicine, a 
better assessment of the full potential of targeted nanomedicine will be possible.[155] Furthermore, the clinical 
response and hence approval rate of future anti-cancer (nano)medicines can be significantly improved. 
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chapter 9 
 
summary and general conclusions 
 
This PhD dissertation focused on the design of polymer-based carrier systems to enhance both the 
solubility and the delivery of taxane anti-cancer drugs. PART I of the thesis comprises a general introduction to 
scope the need for advanced chemotherapy. Chapter 1 reports on the current treatment modalities for cancer 
applied in clinic. In particular, anti-cancer drug treatment is described along with the issues of conventional 
chemotherapy, to illustrate the need for safer and more efficacious anti-cancer drug delivery. Next, the rationale 
and assets of nanomedicines (i.e. passive and active targeting, bioresponsive drug release) are explained, outlining 
a window of opportunity for the materials chemistry field to come up with alternative formulation strategies for 
improved anti-cancer drug delivery. Chapter 2 provides a concise background on taxane drugs and their first 
approved commercial formulations. Both the discovery and early development of paclitaxel (PTX) and docetaxel 
(DTX) are sketched. Next, an overview is given on the sourcing and manufacturing processes of taxanes. The 
biological mechanism of action is covered. Finally, the physicochemical features of Taxol and Taxotere are 
elucidated, along with their clinical translation and toxicity issues. 
PART II covers the experimental work on the design of two polymeric nanocarrier systems for physical 
drug entrapment. Though PTX was used within the scope of this dissertation, note that both systems could also be 
exploited for physical encapsulation of other hydrophobic drugs. Chapter 3 describes the formulation of PTX-
loaded poly(glycerol sebacate) (PGS) nanoparticles. To obtain the latter, a straightforward formulation procedure 
was developed which involves co-dissolution of PGS and PTX in ethanol (EtOH) and subsequent solvent 
displacement in water (H2O). The biocompatibility of all excipients (i.e. PGS, EtOH and H2O) is a crucial asset for 
biomedical applications. Dynamic light scattering (DLS) confirmed PTX/PGS particles within the 200 nm size range 
with narrow dispersity and high colloidal stability in physiological aqueous medium. Additionally, the critical 
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aggregation concentration (CAC) of the nanoparticles was very low (i.e. < 1 ?g/mL), allowing substantial dilution 
without particle disintegration. Flow cytometry (FACS) and confocal microscopy confirmed the capability of PGS 
nanoparticles of delivering hydrophobic compounds into cancer cells in vitro. Finally, PTX/PGS nanoparticles 
showed equal in vitro biological performance compared to 2 commercial, advanced PTX formulations (i.e. Abraxane 
and Genexol-PM), whilst empty PGS nanoparticles confirmed the expected high cytocompatibility. These promising 
in vitro data propose key incentives for further in vivo evaluation. So far however, only a modest PTX concentration 
(i.e. 0.5 mg/mL) could be obtained in the developed formulation. Future optimization would be required to further 
increase the drug loading capacity of the system, allowing to formulate sufficient doses of PTX into a smaller 
formulation volume. The latter would render the administration (i.e. intravenous, intraperitoneal) of PTX/PGS 
nanoparticles more feasible in clinical setting. 
Chapter 4 reports on the systematic design of amphiphilic, acid-degradable, block copolymer 
nanoparticles, synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization. To obtain a 
bioresponsive, acid-sensitive hydrophobic block, a hydrophobic, ketal-functionalized acrylate monomer (i.e. (2,2-
dimethyl-1,3-dioxolane-4-yl)methyl acrylate (DMDMA)) was copolymerized with a hydrophilic monomer (i.e. 
hydroxyethyl acrylate (HEA)). The DMDMA:HEA molar ratio was varied to obtain 5 different block copolymers with 
increasing amount of DMDMA incorporated in the hydrophobic block. Next, the influence of the hydrophobic block 
design on the physicochemical properties was extensively investigated. A DMDMA content higher than 11 mol % 
results in self-assembly into nanoparticles in aqueous medium. All nanoparticles showed substantial colloidal 
stability in phosphate buffered saline (PBS), with sizes and CAC ranging from 23 to 338 nm and from 241 to 10 
μg/mL, respectively, proportional to the block copolymer DMDMA content. Under acidic conditions, the 
nanoparticles decomposed into soluble unimers of which the decomposition rate was inversely proportional to the 
block copolymer DMDMA content. FACS and confocal microscopy confirmed in vitro the utility of the designed 
nanoparticles as carrier vehicle for the delivery of hydrophobic compounds into cancer cells. The block copolymers 
showed no intrinsic cytotoxicity. When loaded with PTX however, a significant decrease in cell viability was 
observed comparable to that of Abraxane and Genexol-PM. The main objective of this study was to deliver a proof-
of-concept, demonstrating that RAFT polymerization is a valuable technique for designing well-defined, smart drug 
delivery carrier systems. However, this system cannot yet be reckoned suitable for further in vivo evaluation. 
Modifications in polymer design have to be considered to obtain nanoparticles with faster degradation kinetics at 
biologically more relevant pH-values (i.e. 5 – 6.5), to achieve higher drug loading and to ensure maintenance of 
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particle integrity upon substantial dilution in complex biological matrices (e.g. blood). Promising strategies to 
accomplish the latter include cross-linking strategies and chemically attaching the drug to the nanocarrier vehicle. 
Chemical conjugation of drugs to a polymeric carrier is a highly acknowledged technique for designing 
advanced anti-cancer drug formulations. An important advantage of chemical conjugation over physical 
encapsulation is the possibility to more thoroughly restrict premature burst release and hence reduce side-effects. 
PART III encompasses the second experimental section of the thesis, describing the design of taxane-polymer 
conjugates based on a grafting-from-drug RAFT approach. Chapter 5 describes the first-generation of ester-based 
PTX-polymer prodrug conjugates developed by this approach. A RAFT chain transfer agent (CTA) was 
regioselectively conjugated to the C2' hydroxyl group of PTX. The latter is crucial for the biological activity of PTX. 
This drug-functionalized RAFT CTA was subsequently exploited for polymerization of the hydrophilic monomer N,N-
dimethylacrylamide (DMA), yielding well-defined, amphiphilic PTX-polymer prodrug conjugates with high drug 
loading (i.e. 20 wt % PTX) and water-solubility (i.e. ? 30 mg/mL conjugate). When dispersed in PBS, stable micellar 
particles were detected by DLS, 27 nm in size and with narrow dispersity. The relatively high CAC of the 
nanoparticles (i.e. 102 μg/mL) implicates that the conjugate will most likely switch from micellar to water-soluble 
state upon aqueous dilution. Additional modification of the obtained conjugate was demonstrated by ω-end post-
functionalization with a fluorescent tracer molecule. In vitro experiments showed that this conjugate is readily 
taken up into endosomes where native PTX is efficiently cleaved off and subsequently reaches its subcellular 
target (i.e. microtubules), as confirmed by a similar cytotoxicity profile compared to Abraxane and Genexol-PM 
which are based on mere physical encapsulation. These results encourage further evaluation in vivo, especially 
because the high drug loading allows for the administration sufficient PTX doses. Selecting the right mouse model 
will be crucial. Conventional subcutaneous primary tumor models might not illustrate the full potential of this 
system, as the water-soluble, low molecular weight conjugates will most likely not exert significant passive 
targeting, mediated by the enhanced permeability and retention (EPR) effect. A clinically more relevant model (i.e. 
orthotopic/metastatic mouse model) might be more suitable to investigate whether, compared to nanoparticles, 
these small soluble conjugates can more efficiently penetrate tumor tissue, featured by poor vascularization 
and/or by significantly less fenestrated endothelia. For this purpose, it will be vital to collaborate with research 
groups, disposing of the required expertise. 
Chapter 6 reports on second-generation PTX-polymer conjugates based on a similar approach as described 
in Chapter 5. To obtain conjugates with acid-sensitive release properties, the gained expertise on acetal/ketal 
synthesis in Chapter 4 was further exploited. PTX was linked to a RAFT CTA either through a cyclic or through a 
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linear acetal moiety. In contrast to the regioselective esterification of PTX reported in Chapter 5, direct 
acetalization of PTX can occur at 2 sites (i.e. either at the C2’ or at the C7 hydroxyl group), yielding 2 regio-isomers of 
PTX-functionalized RAFT CTA. The isomers based on the cyclic acetal could be separated by silica gel 
chromatography, whilst the isomers based on the linear acetal could be used as regio-isomeric mixture for 
subsequent RAFT polymerization. The properties of the resulting PTX-polymer conjugates were in accordance to 
their first-generation counterparts in terms of polymer definition, drug loading and water-solubility. Both the first- 
and second-generation conjugates did not exert burst release in PBS, whether or not supplemented with 10 % fetal 
bovine serum (FBS). At pH 4 and 5, significant release of PTX was observed for the linear acetal-based PTX-polymer 
conjugate, whilst the cyclic acetal-based and first-generation conjugates showed limited and no release, 
respectively. Viability was decreased in vitro to the same extent as for the first-generation conjugates, however 
higher concentrations were required (i.e. roughly by factor 102 and 103 for the linear and cyclic acetal-based 
conjugates, respectively). These data clearly indicate that the linear acetal-based conjugates are more acid-
sensitive than their cyclic acetal-based counterparts, and that the release of PTX from the first-generation ester-
based conjugates is predominantly occurring through an enzymatically catalyzed process. 
As both the first- and second-generation PTX-polymer conjugates most likely form soluble unimers upon 
aqueous dilution, long circulation kinetics and EPR-mediated passive targeting are not to be expected in vivo. On 
the other hand, swift renal clearance of small hydrophilic molecules can be a great tool to minimize side-effects by 
the fraction of the dose that has not reached its target site. To still obtain efficient accumulation of short half-life 
PTX-conjugates in tumor tissue (less susceptible to EPR effect), active targeting strategies need to be considered. 
Chapter 7 comprises the design of DTX-polymer prodrug conjugates, equipped with an active targeting ligand. 
Using the same approach as described in Chapter 5, a DTX-functionalized RAFT CTA was synthesized and used to 
obtain highly defined DTX-polymer prodrug conjugates. Additionally, S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-
pentanedioic acid (ACUPA) was synthesized. The latter possesses high binding affinity towards prostate specific 
membrane antigen (PSMA), a surface receptor often overexpressed by malignant prostate cells. ACUPA was further 
modified with a maleimide moiety and subsequently used for post-modification of the DTX-polymer prodrug 
conjugates. Successful synthesis of DTX-polymer-ACUPA prodrug conjugates was confirmed by size exclusion 
chromatography (SEC) and nuclear magnetic resonance (NMR) spectroscopy. Fluorescently labeled DTX-polymer-
ACUPA analogues were prepared by incorporating a small fraction of fluorescent monomer during the 
polymerization step. DTX-polymer prodrug conjugates, post-modified with a non-targeting moiety were prepared 
as control. FACS showed that the DTX-polymer-ACUPA prodrug conjugates interact to a higher extent in vitro with 
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PSMA-positive prostate cancer cells compared to the control. Complementary in vitro experiments (i.e. confocal 
microscopy, competitive binding assays, MTT) should further clarify whether DTX-polymer-ACUPA, compared to the 
control, can efficiently deliver higher doses of DTX to PSMA-positive prostate cancer cells by receptor-mediated 
endocytosis and if this translates into higher and more specific cytotoxicity. 
In summary, this PhD thesis has explored various design, synthesis and formulation strategies for 
obtaining advanced, passively or active targeted polymeric taxane formulations. Though solvent displacement is a 
very simple technique that enables formulation of nanoparticles with narrow size dispersity, achieving sufficient 
drug loading proved to be challenging. Throughout the experimental part of this thesis, RAFT has proven its value 
as highly controllable and chemically versatile polymerization technique in designing well-defined, bioresponsive 
drug delivery systems. The grafting-from-drug approach in particular has shown great promise. This 
straightforward synthesis strategy results in polymeric taxane prodrug conjugates with high drug loading and 
limited burst release in vitro. The successful post-modification with an active targeting ligand further highlights 
the opportunities of the approach. The small size of these soluble conjugates could allow for efficient penetration 
into (metastatic) tumor tissue that is less susceptible to passive targeting by EPR. This can be investigated in vivo, 
though by careful selection of an appropriate and clinically relevant mouse model. Future in vitro and in vivo 
experiments will clarify whether this approach enables active targeted drug delivery. Overall, this thesis 
encompasses valuable insights for future rational design of advanced polymeric anti-cancer drug delivery systems 
based on physical encapsulation and chemical conjugation. 
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hoofdstuk 9 
 
samenvatting en algemene conclusies 
 
Deze thesis heeft zich gefocust op het design van polymeer-gebaseerde dragersystemen met als doel 
zowel de oplosbaarheid als de afgifte van taxaan anti-kankergeneesmiddelen te verbeteren. DEEL I van deze thesis 
omvat een algemene inleiding waarbij de behoefte aan geavanceerde chemotherapie in kaart wordt gebracht. 
Hoofdstuk 1 beschrijft de therapieën tegen kanker die heden in de kliniek worden aangewend. De nadruk wordt 
vooral gelegd op conventionele chemotherapie en de problematiek met betrekking tot toxiciteit. Zo wordt ook de 
nood aan een veiligere en efficiëntere afgifte van anti-kankergeneesmiddelen geïllustreerd. Vervolgens worden de 
basisbegrippen en troeven van nanomedicijnen (bijvoorbeeld passieve en actieve ‘targeting’, bioresponsieve 
vrijstelling van geneesmiddelen) uiteengezet en aldus de opportuniteiten van dit onderzoeksveld om alternatieve 
formulatiestrategieën te ontwikkelen voor verbeterde afgifte van anti-kankergeneesmiddelen. In Hoofdstuk 2 
wordt de achtergrond van taxanen geschetst, samen met de eerste formulaties die hiervan op de markt werden 
gebracht. Eerst wordt de ontdekking en vroegtijdige ontwikkeling van paclitaxel (PTX) en docetaxel (DTX) 
beschreven. Vervolgens wordt een overzicht gegeven van de verschillende bronnen, grondstoffen en technieken 
voor de productie van taxanen. Het werkingsmechanisme wordt uitgelegd en ten slotte worden ook de 
fysicochemische eigenschappen van Taxol en Taxotere opgegeven, samen met het gebruik van deze formulaties in 
de kliniek en de gerelateerde neveneffecten. 
DEEL II beschrijft het verrichte experimentele werk omtrent de ontwikkeling van twee polymeer-
gebaseerde, nanoscopische dragersystemen voor fysische encapsulatie van geneesmiddelen. Hoewel in deze thesis 
telkens PTX werd gebruikt, kunnen beide systemen in de toekomst ook nog met andere hydrofobe geneesmiddelen 
getest worden. In Hoofdstuk 3 wordt de formulatie van poly(glycerol sebacate) (PGS) nanopartikels beschreven. 
Hiervoor werd een eenvoudig formulatieprotocol opgesteld op basis van ‘solvent displacement’. PTX en PGS 
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werden samen opgelost in ethanol (EtOH) en vervolgens werd deze oplossing druppelsgewijs en onder roeren 
toegevoegd aan water (H2O). Een belangrijke troef van deze formulatie is de biocompatibiliteit van de gebruikte 
excipiëntia (PGS, EtOH en H20), wat cruciaal is voor systemen die bestemd zijn voor biomedische toepassing. Door 
middel van dynamische lichtverstrooiing (DLS) werden partikels met afmetingen niet groter dan 200 nm 
gedetecteerd, die gekenmerkt worden door een geringe polydispersiteit en hoge colloïdale stabiliteit in 
fysiologisch waterig midden. Bovendien werd een zeer lage kritische aggregatie concentratie (CAC) gemeten (< 1 
μg/mL). Dit wijst erop dat de gevormde partikels niet snel uiteen zullen vallen bij substantiële verdunning. Flow 
cytometrie (FACS) en confocale microscopie hebben aangetoond dat hydrofobe componenten na encapsulatie in 
PGS nanopartikels efficiënt kunnen worden afgegeven aan kankercellen in vitro. Ten slotte werd via MTT assay 
vastgesteld dat PTX/PGS nanopartikels de viabiliteit van kankercellen in dezelfde mate kunnen inperken als 2 
commerciële, geavanceerde PTX formulaties (Abraxane en Genexol-PM). Zoals verwacht werd geen intrinsieke 
cytotoxiciteit vastgesteld voor onbeladen PGS nanopartikels. Deze in vitro data vormen een goed onderbouwde 
basis voor verdere in vivo evaluatie. Echter, tot op heden kon enkel een matige PTX concentratie (0.5 mg/mL) 
verkregen worden in de ontwikkelde formulatie. Het systeem vereist dus nog verdere optimalisatie om de 
geneesmiddelbelading te verhogen. Op die manier kan een klein volume formulatie over een adequate dosis PTX 
beschikken, wat de formulatie toegankelijker maakt voor toediening (intraveneus, intraperitoneaal) aan patiënten. 
Hoofdstuk 4 beschrijft het systematische design van amfifiele, zuur-degradeerbare, blok copolymeer 
nanopartikels, gesynthetiseerd via ‘reversible addition-fragmentation chain transfer’ (RAFT) polymerisatie. Om een 
bioresponsief, zuurgevoelig hydrofoob blok te verkrijgen, werd een hydrofoob, ketal-gefunctionaliseerd acrylaat 
monomeer ((2,2-dimethyl-1,3-dioxolane-4-yl)methyl acrylaat (DMDMA)) gecopolymeriseerd met een hydrofiel 
monomeer (hydroxyethyl acrylaat (HEA)). Door de DMDMA:HEA molaire ratio te variëren, werden 5 verschillende 
blok copolymeren gesynthetiseerd met een toenemende fractie DMDMA in het hydrofobe blok. Vervolgens werd de 
invloed van de samenstelling van het hydrofobe blok op de fysicochemische eigenschappen van het polymeer 
onderzocht. Polymeren met een DMDMA fractie hoger dan 11 mol % vormen spontaan nanopartikels in waterig 
midden. De nanopartikels vertoonden hoge colloïdale stabiliteit in fosfaat gebufferde zoutoplossing (PBS). De 
grootte en de CAC van de partikels varieerde respectievelijk van 23 tot 338 nm en van 241 tot 10 μg/mL, evenredig 
met de molaire fractie DMDMA. Onder zure condities degradeerden de nanopartikels tot wateroplosbare unimeren. 
De degradatiesnelheid was omgekeerd evenredig met de molaire fractie DMDMA. FACS en confocale microscopie 
hebben in vitro aangetoond dat de ontwikkelde nanopartikels kunnen aangewend worden als dragersysteem voor 
efficiënte afgifte van hydrofobe geneesmiddelen aan kankercellen. De blok copolymeren zelf vertoonden geen 
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intrinsieke cytotoxiciteit. Echter, wanneer de nanopartikels werden beladen met PTX, kon de viabiliteit van 
kankercellen in dezelfde mate gereduceerd worden als met Abraxane en Genexol-PM. Het doel van deze studie was 
vooral om na te gaan of RAFT toelaat om gedefinieerde, responsieve dragersystemen voor geneesmiddelafgifte te 
ontwikkelen. In dit opzet werd geslaagd. Echter, in dit stadium is het systeem nog niet geschikt voor verdere in vivo 
evaluatie. Aanpassingen in polymeerdesign moeten worden overwogen om nanopartikels te verkrijgen met een 
snellere degradatiekinetiek bij fysiologisch relevantere pH-waarden (5 – 6.5), met een hogere 
geneesmiddelbelading en met behoud van partikelintegriteit bij substantiële verdunning. Dit zou kunnen worden 
verwezenlijkt door de nanopartikels te crosslinken enerzijds en anderzijds door het geneesmiddel chemisch te 
koppelen aan het dragersysteem. 
Chemische conjugatie van geneesmiddelen aan polymere dragers is een erkende techniek voor de 
ontwikkeling van geavanceerde formulaties voor anti-kankergeneesmiddelen. Door middel van chemische 
conjugatie kan versnelde geneesmiddelvrijstelling in de bloedbaan in grotere mate ingeperkt worden in 
vergelijking met fysische encapsulatie, wat toelaat om ongewenste neveneffecten verder te onderdrukken. DEEL III 
omvat het tweede experimentele luik van deze thesis en beschrijft een nieuwe designstrategie voor de aanmaak 
van taxaan-polymeer conjugaten op basis van een ‘grafting-from-drug’ RAFT approach. In Hoofdstuk 5 wordt de 
synthese en evaluatie van de ‘eerste-generatie’, ester-gebaseerde PTX-polymeer prodrug conjugaten beschreven. 
Een RAFT ‘chain transfer agent’ (CTA) werd regioselectief gekoppeld aan de C2’ hydroxyl groep van PTX. Deze is 
cruciaal voor de biologische activiteit van PTX. De PTX-gefunctionaliseerde RAFT CTA werd vervolgens aangewend 
voor de polymerisatie van het hydrofiele monomeer N,N-dimethylacrylamide (DMA). Gedefinieerde, amfifiele PTX-
polymeer conjugaten werden verkregen met een hoge geneesmiddelbelading (20 wt % PTX) en 
wateroplosbaarheid (? 30 mg/mL conjugaat). Na dispergeren in PBS werden via DLS stabiele micellen 
gedetecteerd, met een grootte van 27 nm en een lage polydispersiteit. De relatief hoge CAC (102 μg/mL) van de 
conjugaten impliceert dat deze micellen bij substantiële verdunning in waterig midden zullen uiteenvallen. 
Aanvullende modificatie werd verricht door ω-eindgroep post-functionalisatie met een fluorescente ‘tracer’ 
molecule. In vitro experimenten hebben aangetoond dat de conjugaten snel door kankercellen worden opgenomen 
via endocytose. Vanuit deze endosomen kan PTX vrijgesteld worden en vervolgens zijn subcellulair doelwit 
(microtubuli) bereiken. De conjugaten vertoonden een gelijkaardig cytotoxiciteitsprofiel in vergelijking met 
systemen, gebaseerd op louter fysische encapsulatie (Abraxane en Genexol-PM). Deze resultaten vormen een 
goede basis voor verdere in vivo evaluatie, vooral omdat de hoge geneesmiddelbelading toelaat om een adequate 
dosis PTX toe te dienen. De keuze van een geschikt in vivo muismodel zal hierbij wel cruciaal zijn. Conventionele 
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muismodellen op basis van een primaire subcutane tumor kunnen mogelijks niet ten volle het potentieel van dit 
systeem vaststellen, omdat deze wateroplosbare conjugaten met laag molecuulgewicht niet in grote mate passief 
zullen accumuleren in tumorweefsel door middel van het ‘enhanced permeability and retention’ (‘EPR’) effect. Een 
klinisch relevanter model (orthotopisch/metastatisch muismodel) is mogelijks geschikter om te onderzoeken of 
deze kleine conjugaten in vergelijking met nanopartikels efficiënter zijn in het doordringen van tumorweefsel, dat 
gekenmerkt wordt door een beperkte doorbloeding en/of door fysiologisch normaal afgelijnd endotheel. Om deze 
proeven te kunnen verrichten zal het essentieel zijn om samen te werken met onderzoeksgroepen die beschikken 
over de nodige expertise. 
Hoofdstuk 6 handelt over de ontwikkeling van ‘tweede-generatie’ PTX-polymeer conjugaten, gebaseerd op 
dezelfde approach zoals beschreven in Hoofdstuk 5. Er werd hiervoor gebruik gemaakt van de opgebouwde 
expertise omtrent acetal/ketal synthese, beschreven in Hoofdstuk 4, om conjugaten te verkrijgen met 
zuurgevoelige vrijstellingseigenschappen. PTX werd gekoppeld aan een RAFT CTA, zowel via een cyclische als via 
een lineaire acetalgroep. In tegenstelling tot de regioselectieve estervorming met PTX, beschreven in Hoofdstuk 5, 
kan rechtstreekse acetalisatie gebeuren op 2 posities van PTX: ofwel op de C2’ of op de C7 hydroxyl groep. Deze 
chemische koppelingsreactie geeft dus aanleiding tot 2 regio-isomeren van PTX-gefunctionaliseerde RAFT CTA. De 
isomeren op basis van het cyclische acetal konden van elkaar gescheiden worden via silica gel chromatografie. De 
isomeren op basis van het lineaire acetal konden als regio-isomeer mengsel worden gebruikt in de 
daaropvolgende polymerisatiestap. De eigenschappen van de verkregen PTX-polymeer conjugaten waren in 
overeenstemming met deze van de ‘eerste-generatie’ conjugaten met betrekking tot polymeerdefinitie, 
geneesmiddelbelading en wateroplosbaarheid. Zowel de ‘eerste-‘ als de ‘tweede-generatie’ conjugaten vertoonden 
geen versnelde vrijstelling in PBS, zowel in aan- als in afwezigheid van 10 % foetaal kalfsserum (FBS). Bij pH 4 en 5 
werd een significante vrijstelling van PTX vastgesteld voor de conjugaten op basis van het lineaire acetal. 
Vrijstelling was beperkt en afwezig bij pH 4 en 5 voor de conjugaten op basis van het cyclische acetal en de ‘eerste-
generatie’ conjugaten, respectievelijk. De celviabiliteit kon in dezelfde mate worden teruggedrongen als met de 
‘eerste-generatie’ conjugaten, echter hogere concentraties waren vereist. Een concentratie, hoger met ongeveer 
factor 102 en 103 was vereist voor de conjugaten op basis van het lineaire en cyclische acetal, respectievelijk. Deze 
data tonen duidelijk aan dat het lineaire acetal zuurgevoeliger is dan het cyclische acetal, en dat de vrijstelling van 
PTX uit de ‘eerste-generatie’ conjugaten, op basis van esterkoppeling, hoogst waarschijnlijk via een enzymatisch 
proces verloopt. 
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Wegens de kleine afmeting en hoge wateroplosbaarheid van deze conjugaten is het onwaarschijnlijk dat 
deze in vivo lang in de bloedbaan zullen circuleren en efficiënt via ‘EPR’ zullen accumuleren in tumorweefsel. 
Echter, vlotte renale klaring van de fractie geneesmiddel die het tumorweefsel niet bereikt, kan een belangrijke 
troef zijn voor reduceren van systemische neveneffecten. Om toch een adequate dosis van deze PTX-conjugaten 
met korte halfwaardetijd ter hoogte van tumorweefsel (minder onderhevig aan ‘EPR’ effect) te kunnen afgeven, 
moeten actieve ‘targeting’ strategieën overwogen worden. Hoofdstuk 7 omvat het design van DTX-polymeer 
prodrug conjugaten, uitgerust met een ligand voor actieve ‘targeting’. Door gebruik te maken van de 
designstrategie beschreven in Hoofdstuk 5, werd een DTX-gefunctionaliseerde RAFT CTA gesynthetiseerd en verder 
gebruikt voor de aanmaak van gedefinieerde DTX-polymeer prodrug conjugaten. Bovendien werd S,S-2-(3-(5-
amino-1-carboxypentyl)-ureido)-pentanedioic acid (ACUPA) gesynthetiseerd. Dit ligand heeft een hoge 
bindingsaffiniteit voor prostaat specifiek membraan antigen (PSMA), een receptor die tot overexpressie wordt 
gebracht door maligne prostaat kankercellen. ACUPA werd verder gemodificeerd met een maleimide eindgroep en 
vervolgens gebruikt voor de post-modificatie van de DTX-polymeer prodrug conjugaten. De synthese van ACUPA-
gefunctionaliseerde DTX-polymeer prodrug conjugaten kon worden bevestigd via ‘size exclusion’ chromatografie 
(SEC) en nucleaire magnetische resonantie (NMR) spectroscopie. Fluorescent gelabelde analogen konden worden 
aangemaakt door een kleine fractie fluorescent monomeer mee te laten reageren tijdens de polymerisatiestap. Als 
controle werden DTX-polymeer prodrug conjugaten aangemaakt, gefunctionaliseerd met een eindgroep die niet 
specifiek bindt met PSMA. FACS heeft aangetoond dat de DTX-polymeer-ACUPA prodrug conjugaten in grotere mate 
interageren in vitro met PSMA-positieve prostaat kankercellen in vergelijking met de controle. Aanvullende in vitro 
experimenten (confocale microscopie, competitieve bindingsexperimenten, MTT) zullen moeten aantonen of DTX-
polymeer-ACUPA, in vergelijking met de controle, al dan niet op efficiënte wijze hogere dosissen DTX kan afgeven 
aan PSMA-positieve prostaat kankercellen via receptor-gemedieerde endocytose en of dit leidt tot hogere en 
selectievere cytotoxiciteit. 
Samengevat werden gedurende deze thesisperiode meerdere design-, synthese- en formulatiestrategieën 
onderzocht en uitgewerkt, met als doel geavanceerde polymere formulaties te ontwikkelen voor zowel passieve 
als actieve ‘targeting’ van taxaan anti-kankergeneesmiddelen. Ondanks de eenvoud van ‘solvent displacement’ en 
de hoge definitie van de partikels die met deze techniek werd verkregen, kon tot nu toe nog geen adequate 
geneesmiddelbelading worden verwezenlijkt. Er werd aangetoond dat RAFT een controleerbare en chemische 
veelzijdige polymerisatietechniek is voor het ontwerpen van gedefinieerde, bioresponsieve dragersystemen voor 
geneesmiddelen. De ‘grafting-from-drug’ approach blijkt veelbelovend te zijn. Deze eenvoudige synthesestrategie 
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geeft aanleiding tot polymere taxaan prodrug conjugaten met hoge geneesmiddelbelading en beperkte versnelde 
vrijstelling in vitro. De succesvolle post-modificatie met een ligand voor actieve ‘targeting’ benadrukt verder de 
veelzijdigheid van deze syntheseroute. De kleine afmeting van deze wateroplosbare conjugaten kan ertoe leiden 
dat deze efficiënter kunnen binnendringen in (metastatisch) tumorweefsel dat minder onderhevig is aan passieve 
‘targeting’ door ‘EPR’. Dit kan worden nagegaan in vivo, op voorwaarde dat hiervoor een geschikt en klinisch 
relevant muismodel wordt gebruikt. Toekomstige in vitro en in vivo experimenten zullen verder moeten uitmaken 
of deze approach ook geneesmiddelen selectiever kan afgeven via actieve ‘targeting’. Kortom, in deze thesis 
werden waardevolle inzichten verschaft die van belang kunnen zijn voor toekomstig rationeel design van 
geavanceerde polymere dragersystemen voor fysische encapsulatie en chemische conjugatie van anti-
kankergeneesmiddelen. 
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